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On the interaction between surgical trauma and the host's response: 
"The cleaner and gentler the act of operation, the less the patient suffers, 
the smoother and quicker his convalescence, the more exquisite his healed 
wound" 
Lord Moynihan of Leeds (1902) 
"Inflammation is the response of vascularised tissues to injury and is 
characterised by the clinical signs first recorded by Aulus Cornelius Celsus: 
'rubor, dolor, calor et tumor'. 
It is the body's mechanism of rallying and amplifying the host's defences 
to combat injury. However, prolonged or extensive inflammation may 
lead to irreversible damage to the host" 
Anne S Hamblin (1991) 
St Thomas' Hospital, London 
"While inflammation and immunity are frequently studied 
independently, in reality the two are inseparable. Most of the cells and 
molecules that defend the body are involved in both inflammation and 
immunity" 
Lloyd Old (1988) 
"Discoverer" of tumour necrosis factor 
Memorial Sloan-Kettering Cancer Center 
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ABSTRACT 
The aim of this thesis was to provide further insight into the sequence of 
events leading to the induction of the integrated host response to injury. 
This work has concentrated primarily on studies of mediators and 
components in the plasma of injured patients. 
Only by studying frequent, serial samples, obtained from a clean and 
uniform model of major injury (20 abdominal aortic surgery patients), was 
interleukin-1 (IL-1) was shown to be detectable in plasma within two 
hours of injury. This preceded a rise in interleukin-6 (IL-6). Tumour 
necrosis factor (TNF) and interferon gamma (IFNy) were not detected in 
this group, but TNF was present within a few hours of injury in a group of 
accidental trauma patients (n=6), usually preceding the peak in IL-6 levels. 
Together, these two findings have provided in vivo clinical evidence in 
keeping with the widely accepted in vitro finding that IL-1 and TNF 
induce the production of IL-6. 
The systemic IL-1 and IL-6 response to surgical trauma was shown to 
increase with the severity of the surgical insult. Moreover an early, 
exaggerated IL-6 response was associated with the subsequent clinical 
development of major complications. 
It has been proposed that following major surgery or injury, bowel-
derived endotoxin induces inflammatory cytokines. This hypothesis was 
tested in eight patients undergoing abdominal aortic aneurysm surgery. 
Systemic and portal blood were serially sampled and assayed for endotoxin 
and its associated cytokines. Endotoxin levels were generally below the 
limit of detection (3.7pg/ml), TNF was not detected and IL-1 levels were 
similar in portal and systemic blood. However there was a significant 
difference (p<0,0001) between systemic and portal IL-6 levels, which 
increased markedly with time. These results implicate the colon as a 
major source of IL-6 and suggest that only a very low endotoxin 
concentration is required to induce cytokine production. Alternatively, 
endotoxin may evoke local production, within the ischaemic colon, of IL-6 
without itself reaching detectable levels in the portal circulation. 
The peripheral blood mononuclear cell (PBMC) is a well documented 
source of IL-1, TNF, IL-6 and IFNy in vitro. Although TNF, IL-1 and IFNy 
were not detected in the plasma of the aneurysm patients, there remained 
the possibility that these cells were secreting cytokines in concentrations 
that were too low to detect with ELISA, but which nevertheless could be 
important when these cells migrated to a site of inflammation. Using an 
uncommon technique, the reverse haemolytic plaque assay, an increase 
was demonstrated in IFNy production by PBMC after injury, which 
persisted for more than a week. Production of IL-6 was not found, 
suggesting that PBMC are not a particularly important source of the high 
plasma levels of IL-6. 
Recent evidence has pointed to glutamine as an important component of 
the host immune response, making it seem plausible that this amino acid 
might indeed be associated with the activity of cytokine mediators of the 
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host response. A remarkable correlation (r= -0.95, p<0.0001) between 
plasma IL-6 and glutamine was observed in six major surgery patients. 
The possibility of a significant physiological interaction between 
glutamine and IL-6 is discussed. 
Thus, the theme running through this thesis begins with injury and 
endotoxin as the initiators of the host response, which is mediated in turn 
by the acute phase cytokines. These are induced in different quantities and 
in different organs, tissues and cells, depending on the initial insult, but a 
sequential pattern of production seems apparent. Consideration has been 
given to the role these cytokines might play in the pathogenesis of an 
inappropriate host response or their use as markers of this response. 
The hypothesis is proposed that IL-6 functions as a circulating, 
quantitative signal of cell damage. 
The present data provide information which may be of value in the 
management of injured patients, namely the quantification of the 
magnitude of injury and the prediction of its outcome. In principle, the 
use of cytokine assays, in particular IL-6, would appear to be a potentially 
useful adjunct to the clinical assessment of critically ill patients. High IL-6 
levels appear to anticipate by at least 12 to 24 hours, clinical evidence of 
complications and assessment of CRP levels. There is the added benefit of 
IL-6 being an isolated measurement, therefore interpretable on its own, 
without the entry of other complex data into the data-base of an outcome 
scoring system. 
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THESIS BACKGROUND AND HYPOTHESIS 
The research background 
Major Injury/ surgery 
Inflammation+ immunosuppression 
~ antibWtics (pmphylactic) 
Infection 
~ antibWtics ( thempeutic) 
Late Death 
Figure i: Chain of events between major injury and late death. 
Despite both careful attention to the principles of antisepsis and improved 
monitoring and therapeutics, sepsis remains a major cause of morbidity 
and mortality in patients after either major surgery or severe trauma. The 
chain of events leading from major injury to late death remains a 
persistent problem as a steadily increasing number of high risk patients 
undergo major surgery or are successfully resuscitated after major injury. 
Antibiotics, both prophylactic and therapeutic, have ameliorated the last 
two steps in the chain (Figure i), but the problem persists. There has been 
no substantial change in overall wound infection rates for over twenty 
years, with the level set at about five percent for all operative cases (Cruse 
PJE et al., 1980). This risk of sepsis occurs in the presence of a well 
documented acute phase response, which includes inflammatory events, 
as well as wide-ranging deficiencies in the immune response of patients 
subjected to trauma or major surgery. Impairment of humoral and cell-
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mediated immunity has been correlated with the increased risk of sepsis 
in these patients (see Chapter 1). 
Why only patient A, who has the same operation as patients B and C, goes 
on to develop sepsis is often not clear. Increasingly, therefore, the focus of 
research is shifting to the first step in the chain (Figure i) in an attempt to 
identify, understand and, finally, modify its mediators. An understanding 
of the underlying causes or "triggers" for these responses remain poorly 
defined, but it has become increasingly clear that they are largely mediated 
by cytokines, which are polypeptides produced by a wide variety of cells 
including macrophages and lymphocytes. The majority of reports on 
cytokine biology have concentrated on patients with either cancer or 
established infection. Less is known about the activity of cytokines in 
patients after surgery or trauma. 
Published trauma studies have concentrated on the in vitro cytokine 
responses of cells isolated from trauma patients. Despite some impressive 
in vitro work, the clinical evaluation of cytokines has been scanty and 
inconsistent. Although cytokines had been variously and variably detected 
in body fluids of patients with a variety of diseases, at the start of this 
thesis there was only a single letter (Nijsten MWN et al., 1987) in the 
English literature of plasma cytokine levels after surgery or trauma. 
Indeed, two major text-books published in 1989 and 1990, reviewing the 
immune consequences of trauma with specific reference to cytokines, 
made virtually no reference to interleukin-6. 
Considerable interest has also arisen in endotoxin and the mediation of its 
systemic effects via tumour necrosis factor and interleukin-1. However the 
detection in the clinical setting of all three of these factors has been 
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contradictory. As will be described in the Chapter 2, interleukin-I went 
from being the most widely detected plasma cytokine in the first half of 
the last decade, to being virtually undetectable in plasma a few years later, 
after the advent of immunoassays and improved bioassays. Tumour 
necrosis factor was reported to predict morbidity and mortality, but these 
studies were usually based on a single measurement of the cytokine (for 
example at admission to an intensive care unit) or perhaps a daily 
measurement. Yet it was known that cytokines have a plasma half-life of 
only minutes. Moreover, in most reports, both the units of measurement 
used and the concentrations reported were widely disparate, partly as a 
consequence of the wide variety of bioassays or immunoassays being used. 
The detection of endotoxin was even more inconsistent, with statements 
such as "endotoxin is a normal constituent of portal blood" contrasting 
with "endotoxin is only detectable in very low concentrations in the portal 
blood of laparotomy patients" (see Chapter 6). 
Finally, there has been renewed interest over the last two or three years in 
the acute phase response, after the realisation that interleukin-6, a 
pleiotrophic cytokine, is primarily responsible for the induction of acute 
phase protein synthesis. Allied to this has been renewed interest in 
glutamine which, while not being an acute phase protein, could perhaps 
be described as a "negative" acute phase amino acid. Recent glutamine 
research has stimulated clinical trials showing that its inclusion in enteral 
and parenteral feeds is of great benefit to both compromised patients and 
their gastrointestinal tract, an organ which is being increasingly shown to 
be of immunological importance. The possibility of a link between this 
amino acid and a polypeptide known to control acute phase protein 
synthesis (interleukin-6), was therefore investigated. 
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The hypothesis 
The sequelae to injury are dictated by the host's response to that injury. 
Cytokines are important mediators of the integrated host response. It was 
hoped that by studying major injury patients, with repeated sampling over 
a longitudinal time course, it would be possible to define more accurately 
any relationship that might exist between circulating cytokines, glutamine 
endotoxin and clinical progress. A better understanding of the kinetics and 
production of these factors was sought through sampling of both portal 
and systemic blood simultaneously. 
The work presented in this thesis started with most of this hypothesis, the 
remainder evolving during the course of the research. It involves a series 
of studies performed in patients undergoing major or minor surgery as 
well as victims of major trauma. These studies were aimed at providing 
insight into the sequence of events leading to the induction of the 
integrated host response to injury. 
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1.1 A BRIEF HISTORY OF TRAUMA & SEPSIS 
Archeological findings of trephined skulls and bones with healed fractures 
provide mute evidence of prehistoric man's efforts to care for the sick and 
injured. Through the ages, trauma and sepsis exacted a terrible toll in 
human suffering and death as a result of misconceptions concerning the 
causes of infection and the effects of injury. While Homer described the 
nature of battle wounds and Hippocrates described healing as a naturally 
occurring response and Celsus described, in the first century, the classic 
features of inflammation, nonetheless little progress was made until the 
18th century (Majno G, 1975). The underlying principles of invasive 
infection and tissue repair were neither understood nor applied to the care 
of wounds. Treatment such as cautery, phlebotomy, purgation and the 
application of filthy poultices all detracted from nature's own healing 
efforts and it is not suprising that a hunted animal, which sought simply 
shelter and rest when wounded, often fared better than the wounded 
hunter himself, especially if he was attended by the finest physicians in the 
town. 
Although Ambrose Pare recognised in the sixteenth century, the value of 
natural healing when he wrote "I dress the wound; God heals it" (Packard 
FR, 1927), more than 200 years passed before John Hunter noted: 
There is a circumstance attending accidental injury which does not belong 
to disease, namely that the injury done, has in all cases a tendency to 
produce both the disposition and means of cure. 
John Hunter 1794 
Thus Hunter recognised that inflammation is not a disease, but is in fact a 
remarkable process evoked within the host, following trauma or sepsis, to 
eliminate necrotic tissue, terminate infection and assist in tissue repair. 
Nonetheless the cause and dissemination of infection remained 
unexplained and 92 percent of soldiers who underwent amputation of the 
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femur in the Crimean war died of "hospital gangrene" (Chenu JC, 1865). In 
the middle of the 19th century Pasteur, and later Koch, established the 
relationship between microorganisms and disease (King L, 1957) and Lister 
introduced, in the face of great ridicule, the concept of antisepsis to surgery 
(Lister J, 1870). The importance of the immunological response to 
infection was highlighted by the observations of Metchnikoff (Metchnikoff 
E, 1905) and Erlich (Bordet J, 1895) at the turn of the century, which 
demonstrated the important roles of phagocytic destruction of bacteria and 
humoral antibodies. 
However, the most dramatic advance in the whole history of medicine 
has probably been the surgical revolution of the last one hundred years, 
made possible by the development of safe anaesthesia, blood transfusion 
and the discovery of sulphonamides and penicillin. 
The pace quickened even further in the post-war decades with the 
development of organ transplantation, resulting in an explosion of 
interest in the field of immunology which has subsequently been carried 
into all specialties. In addition, surgeons continued to push their 
discipline to the limits with ever more extensive and demanding 
operations, which finally made clear the importance of the physiological 
and metabolic host responses and the need to support them, in order to 
enhance survival from major surgery, trauma and infection. 
1.2 THE INTEGRATED HOST RESPONSE - A DEFINITION 
We now know that the beneficial host response which Hunter recognised 
almost 200 years ago, has three main components: (1) the primary local 
response, (2) a non-specific systemic response and (3) a specific antibody 
response (Belfrage S, 1963). These can usefully be redefined as the 
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"Integrated Host Response" to injury consisting of a local and a systemic 
component, namely local inflammation and the systemic acute phase 
response. The latter includes immunological, metabolic, endocrine, 
neurological and haematological changes. 
This particular description of the integrated host response is a distillation 
of several definitions. Many observations on the acute phase response 
have been made over the years and it has been defined in a number of 
ways. Koj and Gordon described the acute phase response as "an early and 
unspecific but highly complex reaction of the animal organism to a variety 
of injuries, such as bacterial or parasitic infection, mechanical or thermal 
trauma, malignant growth or ischaemic necrosis" (Koj A, 1985). They went 
on to say that "It (the acute phase response) includes not only the local 
reaction but also neurological, endocrine and metabolic alterations which 
are expressed as fever, leucocytosis, increased secretion of certain 
hormones (among which cortisol is particularly important), changes zn 
the concentration of some heavy metals in blood and liver, activation of 
the clotting, complement, kinin-forming and fibrinolytic pathways, 
negative nitrogen balance, transfer of amino acids from muscle to liver 
followed by drastic rearrangement of plasma protein synthesis". 
Dinarello, however, included certain immunological changes: "Host 
responses to microbial infections, injury and inflammatory disease 
include dramatic changes in metabolic, haematologic and immunologic 
parameters that are often grouped together and called the acute phase 
response" (Dinarello CA, 1984). 
As a result of the complexity of these definitions some authors have 
concentrated on more specific changes that occur after injury, and 
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Whicher states that "The acute phase response of inflammation comprises 
the increase in serum level of a family of liver derived proteins which 
appear to have important and diverse functions in the inflammatory 
process. This physiological response to injury is accompanied by a number 
of other systemic responses such as fever, leucocytosis and muscle 
proteolysis which are probably all mediated by a cytokine or family of 
cytokines, derived from macrophages and some tissue cells. known as 
interleukin 1" (Whicher JT, 1985). Pepys emphasises the acute phase 
proteins response: "Following most forms of tissue injury, infection or 
inflammation, the concentrations of a number of proteins increase, and 
then return to normal again as healing or recovery occurs" (Pepys MB, 
1981). 
1.3 THE INTEGRATED HOST RESPONSE- MAIN FEATURES 
These changes include elevation of body temperature, tachycardia, 
increased elaboration of pituitary and stress hormones, alterations in 
circulating leukocyte populations, increased hepatic synthesis of various 
proteins, and redistribution of iron and trace minerals within the body 
(Beisel W, 1975). A prolonged acute phase response, resulting from severe 
infection or injury, induces severe adverse effects which were first 
clarified by Cuthbertson in his classical nitrogen balance studies in post-
traumatic patients (Cuthbertson DP, 1930). He demonstrated that the 
catabolic responses following injury are frequently out of proportion to 
any reduction in nitrogen intake. These responses were further refined as 
hypermetabolism, accelerated proteolysis and an erosion of lean body mass 
by Dr Francis Moore at Harvard University (Moore F, 1980). 
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1.4 FEVER 
Fever is probably the oldest and most widely known manifestation of 
illness and the acute phase response. It is mentioned in the bible and 
Homer thought it a punishment from the Gods for bad conduct. In the 
humoral theory of disease purported by Hippocrates, fever was attributed 
to an excess of yellow bile which, like fire, was hot and dry (Atkins E, 1985). 
We now know that fever is regulated by specialised temperature sensitive 
neurones, localised in the anterior hypothalamus. The body's temperature 
"set-point" is increased in response to endogenous pyrogens, such as 
endotoxin and the acute phase cytokines (Chapter 2), whose actions 
involve intracerebral prostaglandins acting on the hypothalamus. 
Antipyretics, such as sodium salicylate, which inhibit prostaglandin 
synthesis from arachadonic acid, can attenuate endotoxin induced fevers 
with a concomitant decrease in cerebrospinal fluid prostaglandin levels 
(Bernheim HA et al., 1979). An increase in body temperature of 1 °C gives 
rise to an increase in resting energy expenditure of about 13 percent. 
1.5 ENDOCRINE CHANGES 
The endocrine response to injury may begin before the injury itself, with 
awareness of approaching danger activating the hypothalamic defence 
area. This results in the secretion of a number of pituitary hormones, 
including adrenocorticotrophic hormone (ACTH), growth hormone and 
vasopressin, as well as the activation of the sympatho-adrenal system 
which also results in increased secretion of cortisol and adrenaline (Fleck 
A, 1978)(Frayn KN, 1986). 
Once injury occurs, different stimuli will reinforce this stress response. 
These stimulators include nociceptive afferents from damaged areas, 
baroreceptors responding to hypotension and hypovolaemia and stimuli 
from osmo- and chemoreceptors responding to changes in blood 
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biochemistry. Hormones increasing after the injury include glucagon, 
insulin, ACTH, cortisol, the catecholamines, growth hormone, thyroxine 
and aldosterone (Kushner I, 1982). 
The metabolic activities of the catecholamines augment cardiovascular 
function and are also calorigenic. Their metabolic responses are mediated 
by the second messenger, intracellular cyclic adenosine monophosphate 
(cAMP), and include hyperglycaemia, glycogenolysis, gluconeogenesis, 
lipolysis and suppression of insulin secretion (Wilmore DW et al., 1974). 
This initial response has been called the "ebb phase" and lasts typically 
around 12-24 hours. The ebb phase merges into a more prolonged period 
of catabolism known as the "flow phase", in which an increase in 
metabolic rate and breakdown of body tissue occurs (Cuthbertson DP, 
1942). 
1.6 TRACE ELEMENTS 
The integrated host response gives rise to reproducible changes in the 
serum concentrations of iron, zinc and copper. The redistribution of iron 
and zinc into the liver is associated with new synthesis of the liver 
proteins ferritin and metallothionein, respectively. The benefits or 
drawbacks of provision of additional supplements of trace metals, remain 
controversial (Mertz W, 1981). 
1.7 THE IMMUNE RESPONSE 
A primary factor in the development of sepsis after major injury is 
depression of the host immune response. The fact that both humoral and 
cellular immunity are depressed after surgery and trauma, was rarely 
given any clinical consideration until it was highlighted in a Lancet 
editorial of October 1974 (Anon, 1974). Yet seven years previously, Riddle 
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and Berenbaum had noted that T lymphocytes, from postoperative 
patients, exhibited depressed proliferation in response to mitogen 
stimulation (Riddle PR et al., 1967). Anaesthesia and glucocorticoid release 
were the favoured explanations and, for the next few years, research in 
this area focused on the effects of anaesthesia. In 1969 Arturson et al 
followed serum immunoglobulins for several weeks in burns patients and 
recorded a fall in all types of immunoglobulin, thought to be related to 
protein loss from the burn wound (Arturson G et al., 1969). In 1974, 
Cooper et al also reported that the humoral response was impaired after 
surgery and noted that anaesthesia contributed very little to this response 
(Cooper AJ et al., 1974). 
The first attempt to study the effect of a standard major surgical procedure 
on the immune response of healthy patients was carried out in 1975 by 
Slade et al who chose as their model, kidney donor patients undergoing 
nephrectomy. All parameters measured (T, Band total lymphocyte counts, 
mitogen blastogenic response, mixed leucocyte activity and antigen skin 
responses) fell as a result of surgery, except serum immunoglobulins 
which were unaltered. All, except skin responses, were near normal by the 
fifth postoperative day (Slade MS et al., 1975). The results of these and 
numerous other studies meant that, by the end of the decade, it was widely 
recognised that PML, macrophage and reticuloendothelial function are 
decreased after burns, mechanical trauma and surgery. 
In a symposium in 1979, designed to draw together the results of the 
previous two decades research in this field, Howard noted that in many 
studies the same interesting observation had been made, namely that 
lymphocyte and neutrophil function differed, depending on whether the 
cells were tested in the patient's own serum or pooled donor serum 
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(Howard RJ, 1979). Invariably decreased responsiveness occured in the 
patient's own plasma but was not always evident in pooled plasma (Park 
SK et al., 1971)(Alexander JW et al., 1968). Furthermore the serum from 
burnt patients inhibited chemotaxis of normal polymorphonuclear 
leucocytes (Fikrig SM et al., 1977). The explanation for this was thought to 
lie in the reduced opsonic activity observed in blood from postoperative 
patients (Saba TM, 1975). However, during the next decade the increasing 
understanding of cytokines and other soluble mediators introduced a 
complexity, far beyond simple opsonic activity, to the control of the 
immune response (see Chapter 2). 
Both specific and non-specific immune defences are impaired after 
trauma, and the remainder of this section aims to provide a synopsis of 
current knowledge. 
1.7.1 Alterations in immune cells 
Leucocytosis: As early as 1920, Cannon noted a consistent early leucocytosis 
after injury (Cannon W, 1919). A peripheral leucocytosis after thermal, 
non-thermal and surgical injury is now well documented, and results 
from an increased release of granulocytes from bone marrow storage 
pools, followed by an increased production of precursors. A mild 
leucocytosis can also be seen in the response to adrenalin released in 
situations of mild stress and it is apparent that there are two pools of 
granulocytes in the vascular compartment. The first is the circulating pool 
and the second is adherent to the vasculature - the "marginated pool". 
Demargination of the white cells from the vessel walls, provoked by 
adrenaline and cortisol, will cause an apparent leucocytosis. The opposite 
effect can be seen in endotoxic shock, where a leucopaenia may be 
observed. Here the bone marrow releases large numbers of neutrophils, 
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but a large number become marginated, resulting in a fall of circulating 
white cells (Athens JW et al., 1961). 
Polymorphonuclear leucocytes: The three phases of polymorphonuclear 
leucocyte (PML) function are chemotaxis, phagocytosis and intracellular 
killing. Chemotaxis has been extensively researched in trauma and burns 
patients and all studies have noted a chemotactic deficit, although onset 
varied between days one and five (Fikrig SM et al., 1977)(Warden GD, 
1981). Furthermore the serum from burned patients inhibited chemotaxis 
of normal PML (Warden GD, 1981). 
While Alexander noted an increased rate of phagocytosis with decreased 
intracellular killing in burned patients (Alexander JW et al., 1968), Balch 
studied patients after severe battle trauma and found decreased 
phagocytosis of bacteria (Balch HH, 1955). While these workers used direct 
bactericidal assays, other measures of microbicidal function have been 
used to assess various parameters of the oxidative reactions causing 
microbial death, including oxygen consumption (Heck EL et al., 1975) and 
chemiluminescence (Howes RM et al., 1976). These and other newer assays 
have served to confirm the findings of the bactericidal assays whilst also 
providing insight into the nature of the microbicidal defect. Therefore, 
although there are a few contrary reports, the overwhelming impression 
is of decreased PML function following burns, mechanical trauma and 
operation (Howard RJ, 1979). 
Lymphocytes themselves are probably most usefully studied after 
fractionation. The development of monoclonal antibodies such as the 
cluster of differentiation (CD) series, allowed more accurate definition of 
the functional subsets. This was greatly facilitated by the availability of 
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automated counting using the fluorescence activated cell sorter (FACS) 
which allows complete objectivity and a large sample size. The total 
number of circulating lymphocytes and of the subpopulations CD3 (pan T 
cell), CD4 (helper T cell), CDS (suppressor/ cytotoxic T cell) and natural 
killer cells have been noted to fall after injury (Lennard TWJ et al., 
1985)(Grob P et al., 1988)(Bauer AR et al., 1978). However, the suppressor 
cell response has been inconsistently reported, with (1) an increased 
response (Hansbrough JF et al., 1984)(Mclrvine AJ et al., 1982), (2) a 
decreased response that did not reach significance (Rodrick Ml et al., 
1986)(0'Mahoney JB et al., 1985) and (3) a significantly decreased response 
(Lennard TWJ et al., 1985)(Faist E et al., 1986), noted. 
O'Mahoney, who had reported a decrease, was also an author of the earlier 
Mclrvine paper which reported an increase. In the later paper he described 
an artifactual finding to explain the contradictory results. In the 1982 study, 
cells stained with monoclonal antibodies were identified by fluorescence 
microscopy and this suggested an increase in CDS cells. Following the 
introduction of flow cytometry, which selected cells by size prior to 
counting them, it became apparent that some of the CDS positive cells 
were not T cells. These were the large granular lymphocytes, monocytes 
and immature PML which were binding to the monoclonal antibodies and 
hence masquerading as T cells. 
Thus, with regard to alterations in lymphocyte subgroups following 
injury, there remains inconsistency in results of the CDS population 
response. On the other hand, the fall in the CD4 population has been a 
consistent finding in all these studies. 
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However the significance of all these studies is now open to question, 
because it depends on the extent to which the phenotypic markers, 
detected by the monoclonal antibodies, reflect the function of the T cells 
which they identify. It is now clear that the correlation between phenotype 
and function is not as close as was originally proposed. In particular, a 
small subset of CD4 positive cells has been found to be of importance in 
the generation of suppressor cells (Thomas Y et al., 1982) and it is now 
clear that both the two main T cell subsets are heterogenous, both in 
phenotype and function (Takada S et al., 1983). 
Monocyte/macrophages: In recent years the macrophage has emerged as a 
key cell in immune dynamics after trauma. Macrophages play a central 
role in cell-mediated immunity, both in antigen recognition as antigen 
presenting cells and also in the effector limb as inflammatory, tumoricidal 
and phagocytic cells. These cells elaborate cytokine mediators including 
tumour necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6), 
as well as complement components, plasminogen activator and tissue 
thromboplastin (Unanue ER et al., 1980). An interesting concept describes 
two general classes of macrophage: "facilitatory" and "inhibitory" (Miller 
SE et al., 1982). The former are characterised by (1) interaction with T 
helper cells, (2) the presence of the immune response antigen (Ia antigen), 
(3) production of cytokines and (4) inhibition by prostaglandin E2 (PGE2) 
and by T suppressor cells. 
Inhibitory macrophages are characterised by (1) interactions with T 
suppressor cells, (2) absence of the Ia antigen and (3) activation by and 
production of PGE2. In particular the production of PGE2 by macrophages 
may represent an important immunosuppressive mechanism because 
these cells are increased after injury (Faist E et al., 1987) and PGE2 is capable 
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of suppressing various immune functions. These include augmentation 
of T suppressor cell proliferation and inhibition of T helper and B cell 
proliferation, as well as the inhibition of cytokine production. Several 
studies have documented the beneficial effects of cyclooxygenase 
inhibitors, which inhibit prostaglandin synthesis, in animal trauma 
models and trauma patients (Hansbrough JF et al., 1986)(Faist E et al., 
1990). 
Originally it was thought trauma, burn injury or intra-abdominal 
infection produced an immediate reduction in the circulating numbers of 
monocytes (Bauer AR et al., 1978), but more recent studies using 
monoclonal antibodies have shown a significant elevation of circulating 
macrophages following injury (Faist E et al., 1988). This group have also 
shown that inhibitory macrophages are dominant after injury resulting in 
immunocompetence. During the post-traumatic course the macrophagic 
PGE2 output was significantly elevated (upto eight
fold on days five to 
seven) compared to controls, a finding that was originally reported in burn 
trauma by Miller (Miller CL, 1981). They also showed a reduction in IL-1 
and interferon gamma (IFNy) production during this time, although 
Rodrick et al have shown increased IL-1 production and marked 
interleukin-2 (IL-2) suppression in non-thermal injuries (Rodrick Ml et 
al., 1986). Macrophage chemotaxis (McCabe WP et al., 1973), phagocytosis 
and respiratory burst activity are also reduced in injured patients (Miller 
CL, 1981). 
These findings all indicate a severe depression of cell-mediated immunity 
leading to a down-regulation of the immune response. 
Mitogen responsiveness: Following the initial description of Riddle and 
Berenbaum of a postoperative depression of the lymphocyte proliferative 
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response to the extract of red beans phaseolis vulgaris - phyto-
haemagglutinin (Riddle PR et al., 1967), mitogens have been widely used 
to study a variety of surgical patients. The assay measures the proliferative 
response (percentage uptake of tritiated thymidine) of an individual's T 
cells when stimulated with the mitogen. The mitogen response reflects 
the interaction of macrophages and T cells during T cell proliferation, a 
response which Constantian showed in 1978 to be mediated by a serum 
polypeptide (it would now be called a cytokine) which activated suppressor 
T cells (Constantian MB, 1978). In addition T cells show decreased mixed 
lymphocyte responses (Sakai H et al., 1974). 
Studies of burns patients have demonstrated a significant correlation 
between mitogen responsiveness and a patient's ability to life-threatening 
sepsis, with all patients succumbing to fatal sepsis demonstrating a virtual 
absence of phytohaemagglutinin response (Miller SE et al., 1982). This and 
other studies have, therefore, verified the early observations of Riddle and 
Berenbaum (Miller CL, 1981)(0'Mahoney JB et al., 1984). 
Natural Killer cells(NK cells): These cells require no antigen presentation 
and are not restricted by their major histocompatibility complex 
(Heberman RB, 1984). Using a monoclonal antibody (Leu-7) and flow 
cytometry, the number of circulating NK cells has been shown to fall after 
major surgery and trauma (Lennard TWJ et al., 1985)(Grob P et al., 1988). 
These cells have been shown to have a wide range of cytotoxic activity 
against a number of tumour cell lines and one of their probable roles in 
the circulation is to act against circulating tumour cells. A fall in number 
of NK cells could therefore be expected to reduce resistance to circulating 
tumour cells. This was supported by a study of hind limb amputation in 
mice, which suppressed NK activity in tumour-free mice. Amputation of 
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non tumour-bearing limbs in tumour-bearing mice also suppressed NK 
activity and led to a significant increase in the number of metastases 
(Pollock RE et al., 1984). 
1.7.2 Alterations in humoral immunity 
Serum immunoglobulin response to injury has received only scattered 
attention, and the few studies done of immunoglobulins A, G and M (IgA, 
IgG and IgM) levels have yielded varying results. Elective surgery and 
trauma have been shown to be associated with reduced levels of IgM and 
IgG respectively (Gauperaa T et al., 1985)(Alexander JW et al., 1979), but 
Bjornson found no effect on IgG following trauma (Bjornson AB et al., 
1978b). However he and others noted reduced IgG levels after burn injury 
(Bjornson AB et al., 1977)(Alexander JW et al., 1979). Arturson et al 
followed serum IgG, IgM, IgE, IgD and IgA for several weeks in burns 
patients and recorded an initial fall in all types of immunoglobulin, 
thought to be related to protein loss from the burn wound (Arturson G et 
al., 1969). Serum IgM returned to normal after one week, IgA, IgG and IgE 
after two weeks and IgD after one month. 
Hershman et al set out to document overall IgA, IgG and IgM levels and 
establish their patterns in severely injured and burns patients, during the 
initial two weeks after injury. They found that all three classes were 
reduced in all patient groups on postoperative day one with IgG affected 
most. Levels in the "uneventful recovery group" returned to mid-normal 
by two weeks. The "infected nonthermal group" showed a supranormal 
IgA, IgG and IgM response by seven days which, in the case of IgG, 
persisted to two weeks. In the "infected burns group" the IgG response was 
the most clearcut, with sharply reduced levels at all times. Humoral 
immunity is also altered, as reflected by reduced serum immunoglobulins 
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after severe trauma (Hershman MJ et al., 1988a). In a study of patients, 
over the first four days following varying grades of surgical trauma as well 
as major mechanical trauma, IgA, IgG and IgM fell in all patient groups, 
reaching their lowest level within 24 hours and staying low until the end 
of the study. The drop was most marked in the major trauma group (Grob 
Pet al., 1988). 
These immunoglobulin changes could, at least partly, be caused by 
compartmental shifts, because B cells sampled after trauma are able to 
produce normal quantities of immunoglobulins, although they cannot be 
stimulated to produce specific antibodies (Nohr CW et al., 1984). 
Moreover, B lymphocyte levels, as determined with monoclonal 
antibodies and flow cytometry, remain relatively normal (Lennard TWJ et 
al., 1985)(Grob Pet al., 1988). The second explanation is a defect of terminal 
B cell maturation, with switching from IgM to IgG production attributable 
to macrophage induced suppression (Ertel Wet al., 1987). 
1.7.3 Complement 
The complement (C') system is a complex, integrated cascade of serum 
proteins that is important in both chemotaxis and opsonisation. It is 
activated along the classical pathway, consisting of Cl, C4 and C2, by 
interaction with antigen-antibody complexes resulting in the activation of 
C3. Activation along the alternative pathway bypasses these early 
components and is initiated directly, after activation of C3 by damaged 
tissues or bacterial polysaccharides. 
A number of investigators have reported profound abnormalities of 
complement levels and functions with burns. In 1966 Arturson noted that 
levels of Cl-4 fell by upto 20 percent after lethal burns (Arturson G et al., 
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1966). Bjornson demonstrated reduction in components of both the classic 
and alternate pathways after thermal injury (Bjornson AB et al., 1978a), 
but two years later the same group reported rather different findings. They 
found that functional activity of the alternative complement pathway and 
the concentration of properdin were decreased during eight weeks post-
burn in septic and non-septic patients. This compared with reduced 
classical pathway activity only in septic patients, and only in the initial 
post-burn period (Bjornson AB et al., 1980). Heideman suggested that burn 
injury might cause a direct activation of complement via the alternative 
pathway either by aggregating serum proteins or by thermal alteration of 
host tissues (Heideman M, 1979). 
Increased levels of C3a and CSa have been reported in burned patients as a 
result of activation of the alternative pathway by anaphylotoxins (Gelfand 
JA et al., 1983). While mean classical pathway titres were 49 percent below 
the normal mean, they found the alternative pathway titre to be reduced 
by more than 90 percent and provided evidence supporting complement 
activation, not simply protein loss, as the cause of this depletion. An early 
fall in C3, C4 and C factor B was seen after surgical injury resulting from 
complement activation, consumption and compartmental shifts, but by 48 
hours levels were recovering (Grob Pet al., 1988). 
During the early 1970s, several studies attempted to utilise changes in 
complement components as indices of the effect of trauma on the host 
defence and as prognostic indicators (Robin M et al., 1975), but the results 




Various studies had suggested that preoperative anergy was associated 
with an increased risk of sepsis and it was claimed that persistent anergy 
would predict development of sepsis (Maclean LD et al., 1975). However 
further research has dampened these hopes and, whereas all studies show 
an association between anergy and sepsis, in many cases it appears that 
sepsis precedes the development of anergic reactions. In addition, 
preoperative testing was found to be no more successful at predicting the 
subsequent development of sepsis than hypoalbuminaemia and less 
successful than clinical judgement in predicting sepsis and mortality 
following surgery for gastrointestinal malignancy (Ottow RT et al., 1984). 
Many studies are open to criticism on the basis of poorly matched study 
groups, for example, a study of skin testing in 46 preoperative patients 
claimed to show that the incidence of death and sepsis was greater in the 
anergic group. However, not only did the results fail to reach significance, 
but the anergic group was significantly older and had a greater incidence of 
malignant disease (Christou NV et al., 1984). In a British study of 166 
patients about to undergo major elective abdominal surgery, 11 percent 
were found to be anergic and of these 21 percent had major septic 
complications compared to 8 percent of the normally reactive group, but 
the difference was not statistically significant. They concluded 
"preoperative delayed hypersensitivity testing is valueless either for 
warning or reassurance about the occurrence of postoperative 
complications" (Ausobsky JR et al., 1982). 
It seems probable therefore, that delayed hypersensitivity skin testing will 
find a role as a research tool, able to identify a group of patients likely to 
have an impairment of the immune system, for example Nohr et al have 
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shown that anergic patients do not produce antibody normally in response 
to tetanus toxoid (Nohr CW et al., 1984). However skin tests do not predict 
the development of sepsis reliably and widespread clinical use seems 
unlikely to be useful. 
1.7.5 Summary 
After severe trauma, delayed type hypersensitivity responses, allograft 
rejection, T cell proliferation in response to mitogens, mixed lymphocyte 
responses and T-dependent antibody responses are all diminished. These 
are all hallmarks of a general T cell defect. In addition defects in 
macrophage and neutrophil function are pronounced, whereas B cell 
activity appears to be relatively unaffected (Table 1.1). 
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Table 1.1 Acquired immune cell abnormalities in patients suffering trauma, 






Function or characteristic 
circulating cell number 
spontaneous migration 
chemotaxis and phagocytosis 
bactericidal activity 
lysosomal enzyme levels 
chemiluminescence 
dye reduction 
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1.8 THE ACUTE PHASE PROTEIN RESPONSE 
For a long time it has been recognised that the concentrations of plasma 
proteins alter after trauma. In 1935 Cuthbertson and Tompsett reported 
that after both surgical and accidental trauma, a fall in the plasma 
concentration of the albumin moiety is observed with a marked rise in the 
globulin fraction (Cuthbertson DP et al., 1935). They also noticed that 
fibrinogen was often raised under these conditions. Five years earlier, 
Tillet and Francis (Tillet WS et al., 1930) had observed that acute phase 
sera from individuals with lobar pneumonia possessed the capacity to 
precipitate a non-protein somatic fraction known as fraction C, derived 
from pneumococci. Once the pneumonia resolved, this reaction was no 
longer demonstrable. MacLeod and A very characterised the reactive 
substance in the acute phase sera as a protein and named it C-reactive 
protein (CRP) (Macleod CM et al., 1941a)(Macleod CM et al., 1941b). CRP 
has been found to be undetectable in normal plasma, but to increase 
dramatically during infection of various types. 
Electrophoresis of plasma after trauma shows a decrease in the albumin 
band and an increase in the alpha-1 and alpha-2 globulin bands 
(Sunderman FW Jr, 1964) thus giving rise to the term acute phase protein. 
Although it was known that many of the acute phase proteins were alpha-
globulins (Hoch-Ligeti C et al., 1953), electrophoretic studies could not 
differentiate between the many plasma proteins contained in the regions. 
The study of individual proteins was made possible by the introduction of 
immunological methods (Mancini G et al., 1965)(Laurell CB, 
1966)(Minchin-Clarke HG et al., 1971), and it became apparent that a 
considerable number of proteins increase during an acute phase response. 
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Koj has reviewed in detail the protein changes after trauma in humans 
and has classified the proteins into five groups on the basis of their change 
in concentration during an acute phase response (Koj A, 1983)(Koj A, 
1985). The first group is the "very strong" or "spectacular" acute phase 
proteins which usually increase in concentration by 20-1000 fold after 
trauma and includes CRP. The second group is the "strong" acute phase 
proteins which usually increase by 2-5 fold after trauma, and includes 
alpha-1-acid glycoprotein and fibrinogen. The third or "weak" group, 
increase by 30-60 percent after trauma and include caeruloplasmin and the 
complement factor C3. The fourth group comprises the "neutral" proteins 
which show no regular changes in concentration after trauma. This group 
includes alpha-2-macroglobulin and the immunoglobulins. The fifth and 
last group consists of "negative" or synthesis inhibited acute phase 
proteins, and includes those whose concentrations usually decrease by 30-
60 percent after trauma. This group includes albumin and transferrin. 
A prefix of "positive" or "negative" is often added to describe the direction 
in which the concentration changes. In addition, Fleck noted that there 
was evidence that the increases in the acute phase proteins are controlled 
by similar mediators, but different mediators and mechanisms operate to 
decrease the concentration of the "negative" acute phase proteins (Fleck A 
et al., 1985). 
Thus the acute phase proteins are a family of approximately 30 plasma 
proteins produced in increased amounts by the liver in inflammation. 
Extra-hepatic expression of several acute phase proteins has been 
demonstrated, particularly in macrophage rich tissues, and the regulation 
of macrophage protein production may be independent of hepatic 
expression of the same gene. Serum amyloid A (SAA) is an example of 
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this phenomenon. Several cytokines, in particular IL-6, IL-1 and TNF 
induce their synthesis. These cytokines are discussed in Chapter 2. The 
increased plasma concentration of these proteins probably reflects an 
important physiological mechanism providing an increased supply of the 
proteins to the site of tissue injury, where they either modulate the 
inflammatory response or replenish the proteins that are rapidly 
consumed in the inflammatory process. 
They can be grouped according to their role at the site of inflammation, for 
example there are scavengers (haptoglobin), inflammatory mediators 
(complement components) and protease inhibitors (alpha 1 antitrypsin). 
Others are involved in both the repair of tissue damage and the removal 
of products caused by tissue damage. For example CRP is an opsonin, 
binding onto foreign particles, and, once bound, the complex can activate 
complement and enhance phagocytosis. CRP also binds onto nucleosomes 
released from damaged cells and facilitates their removal preventing auto-
antibody production. Haemoglobin, released into plasma after haemolysis, 
is bound by haptoglobin, and haemopexin will bind free haem groups. 
These complexes are rapidly cleared from the plasma. Caeruloplasmin has 
been found to scavenge superoxide ions and transports copper for tissue 
repair (Powanda MC et al., 1981), while alpha 1 acute globulin may be 
involved in tissue repair and modulation of phagocytic cells. Thus, 
although the acute phase protein response is a non specific response, 
many of the proteins involved play an important role in the initial 
control of tissue damage. 
1.9 MEASUREMENT OF THE ACUTE PHASE PROTEIN RESPONSE 
The use of measurements of cytokine production to predict outcome and 
monitor progress is currently under evaluation in a wide variety of 
23 
clinical settings. In most of these studies the results have been set against 
the more established markers of the acute phase response, namely the 
acute phase proteins. Marano et al looked at serum TNF in critically ill 
burns patients and concluded that this cytokine correlated with infection 
and mortality (Marano MA et al., 1990). Nijsten et al noted that IL-6 
displayed a genuine relationship to the generation of fever which they 
called "the hallmark of the acute phase response", noting also, that this 
cytokine increased earlier than the acute phase proteins (Nijsten MWN et 
al., 1987). 
The measurement of acute phase proteins can be used to diagnose the 
presence of inflammation and to monitor changes in inflammatory 
activity. Acute phase proteins can be measured either directly, or indirectly 
via the erythrocyte sedimentation rate (ESR) and plasma viscosity. The 
ESR has long been the gold standard against which other markers of 
inflammation have been measured. It is a measure of the rate at which red 
cells sediment in a column of blood and depends upon the weight, size 
and charge on the cells. The negative charge (zeta potential), holding 
healthy cells in suspension by mutual repulsion, can be neutralised if the 
cells are coated with positively charged polymeric plasma proteins. 
Amongst the plasma proteins, fibrinogen, alpha 2-macroglobulin and the 
immunoglobulins all have this ability. However the ESR is not specific for 
the acute phase response because it is altered by anaemia, blood 
transfusion and changes in erythrocyte morphology such as microcytosis, 
as well as by polyclonal and monoclonal increases in immunoglobulins. It 
is also altered following blood transfusion. Plasma viscosity has been 
developed more recently to obviate the effects of red cell changes, but this 
technique is also influenced by the same group of plasma proteins that 
affect the ESR and its role requires further evaluation. 
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The plasma concentrations of the different proteins vary considerably 
because of differential induction of synthesis by cytokines and differences 
in metabolism. The latter is influenced by molecular size and catabolic 
rate, both at the site of inflammation and in the circulation. Those that are 
rapidly consumed include the complement components, fibrinogen and 
haptoglobin which results in their being unsuitable for use as indices of 
inflammatory activity. 
In assessing the relative values of the different acute phase proteins for 
practical use as non-specific indicators of disease, Crockson et al suggested 
that the ideal protein would be normally absent in plasma, have a wide 
range of quantitative response and a rapid rate of rise and fall (Crockson 
RA et al., 1966). They suggested CRP could satisfy these criteria. As early as 
1957 Yocum and Doerner recommended its use in preference to the ESR, 
having found it to be always elevated in bacterial infections, acute 
rheumatic fever, myocardial infarction and widespread malignant disease 
(Yocum RS et al., 1957). They also found that CRP was commonly, though 
not consistently raised in rheumatoid arthritis, viral infections and acute 
tuberculosis. Hedlund also found that CRP was a good marker of disease 
and found that it was elevated in every instance where an increase in body 
temperature was associated with inflammation (Hedlund P, 1961). After 
measuring CRP, fibrinogen, haptoglobin, ESR and the alpha-globulin 
region of a protein electrophoretic strip in various diseases, Belfrage 
concluded that CRP gave the best indication of disease activity (Belfrage S, 
1963). 
Since then, the popularity of CRP as an indicator of disease has grown, 
largely because it has continued over the years to fulfil the criteria 
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suggested by Crockson et al for a useful non-specific indicator of disease. 
More recently Stahl compared the CRP response in patients undergoing 
surgery of increasing magnitude and his results suggested that peak levels 
of CRP were proportional to the degree of tissue injury. However he also 
confirmed that this peak level was not reached until 48 hours, which 
implies that CRP has little value in the most critical postoperative or post-
trauma period, namely the first 24 hours (Stahl WM, 1987). 
However upon closer scrutiny, Stahl's findings are perhaps not as clear as 
he suggests, because his results refer to mean values for the different 
groups, yet within each group there is a wide range of peak values making 
it difficult to conclude anything about tissue damage for any individual 
patient. This difficulty was emphasised by Colley and Myers et al who 
performed similar studies in surgical patients. They noted that the degree 
of trauma did not appear to influence the time course nor the magnitude 
of the CRP response to surgery. A maximal response was obtained with 
herniorraphy and was of the same magnitude as the concentrations 
reached with partial gastrectomy and cholecystectomy. Moreover the peak 
CRP concentration showed considerable variation between patients, for 
example after herniorraphy, CRP ranged from 38-196mg/l. They concluded 
that this variability made the single estimation of CRP unreliable as an 
indicator of the severity of an acute injury (Colley CM et al., 1983). 
1.10 CONCLUSION 
While the survival advantage of some components of the "acute-phase 
response" is unclear, there is evidence to support the proposal that certain 
components of the "acute-phase response" confer benefit on the host. For 
example, elevation of body temperature has been related to increased 
survival following bacterial infection in invertebrates (Kluger MJ et al., 
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1979), and artificially induced hyperpyrexia (fever therapy) was a mainstay 
of treatment of certain bacterial infections, e.g., typhoid, in past centuries. 
Moreover, T and B cell activity are enhanced by fever (Jampel HD et al., 
1983). Conversely, since the rate of chemical reactions in vitro doubles 
with every 10°C rise in temperature, pyrexia may well contribute to the 
catabolic state of the critically ill host. Similarly, following injury or sepsis, 
systemic hypotension and diminished intravascular volume frequently 
occur and are associated with diminished perfusion of vital organs. 
Activation of the sympathetic nervous system and adrenal medullary 
hormones, in such circumstances, may be essential for restoration of 
adequate blood flow to vital organs. However, chronically elevated 
circulating concentrations of catecholamines and glucocorticoids are 
associated with adverse metabolic alterations, including hyperglycaemia, 
increased peripheral insulin resistance and accelerated proteolysis (Bessey 
P et al., 1984). Death following critical illness has also been related to the 
extent of depletion of catecholamine stores from autonomic ganglia 
(Goodall Met al., 1965). 
Certain other components of the "acute-phase response" have more 
obvious benefits to the host. Alterations in circulating white cell 
populations represent a well recognised component of the integrated 
immunological response of the host to invasion, and failure of this 
response to occur, for example following certain types of chemotherapy for 
malignant disease, is associated with greatly increased mortality following 
bacterial and other infections (Talcott Jet al., 1988). Similarly, the marked 
decrease in circulating iron concentrations associated with host invasion 
by Gram-negative organisms enhances survival since replication of such 
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organisms is inhibited when the availability of iron is re
duced (Powanda 
M, 1977). 
The acute phase responses that occur in infected or inju
red animals have 
been strongly conserved throughout evolution, suggest
ing that they are 
indeed important for host survival. Nonetheless, it is fa
r from clear that 
all components of the response are invariably beneficia
l to the host. An 
increased understanding of the reasons why these respon
ses occur, and of 
the mediators involved in the induction of such change
s, is important if 
future strategies to modify the course of critical illness 
in human beings 
are to be developed. 
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2.1 INTRODUCTION: A mediator cascade 
The host's responses to trauma or infection are orchestrated by a range of 
mediators activated by pain, tissue damage, infection or organ failure. As 
the patient progresses from shock to the acute phase and on to 
convalescence, so the mediators change. There is an enormous variety of 
these mediators ranging from those which act only locally at their site of 
production, to those which evoke responses affecting the whole body, of 
which the neuro-endocrine hormones are an obvious example. Various 




DIFFERENTIATES ANO PRODUCES 
ANTIBODIES 
B LYMPHOCYTE 
Cytokines constitute the molecular language of inflammation and 
immunity 
Th ey form a complex network of overlapping and interacting signals, 
which together propagate the mediator cascade and orchestrate the 
integrated host response 
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2.1.1 Pain and neuro-endocrine mediators 
Pain serves at least two major functions, it warns of tissue injury and it 
indirectly activates neuro-endocrine mediators. Afferent impulses from 
sensory end-organs of skin, parietal peritoneum, bone, and other 
peripheral tissues are transmitted via somatic nerves, whereas impulses 
from most visceral end-organs are carried by sympathetic nerves (White 
JC et al., 1952). 
The paraventricular and medial ganglia of the hypothalamus are activated 
as impulses are transmitted to the sensory cortex, where the sensations of 
pain are recognised. Stimulated hypothalamic ganglia induce autonomic 
nervous activity (Davies CL et al., 1984). Hypovolaemia, hypotension, and 
hypoxia, recognised by baroreceptors and chemoreceptors in the brain, 
great vessels, atria and carotid bodies, also induce autonomic nervous 
system activity (Hume DM et al., 1959). In addition to activation of 
paraventricular hypothalamic nuclei, these same stimuli induce the cells 
of the median eminence to secrete releasing hormone into capillary blood 
of the pituitary portal system which perfuses the anterior pituitary. In 
response to these releasing hormones, specialised cells secrete a variety of 
hormones including adrenocorticotrophic hormone (ACTH). Both neural 
and hormonal feedback systems modulate the neuro-pituitary-adrenal 
responses (Eiseman Bet al., 1977)(Gann DS et al., 1977). 
The use of post-operative epidural anaesthesia was shown to attenuate the 
neuro-endocrine and catabolic changes following major abdominal 
surgery (Kehlet H et al., 1979) and interruption of pain sensation, by 
denervation or cord section, inhibits both catecholamine and ACTH 
secretion (Hume DM et al., 1959). Thus initial studies suggested that these 
neuro-afferent signals from the injury site were primarily responsible for 
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the pain, fever, cardiovascular changes and activation of the 
pituitary/ adrenal axis. 
However, other investigators denervated superficial wounds or utilised 
spinal anaesthesia to block nervous afferent impulses and found that both 
manipulations had little effect on hypermetabolic responses (Wilmore D 
et al., 1975). Moreover, neither the responses of the sympathetic nervous 
system nor the anterior pituitary to bacteraemia or endotoxinaemia, are 
affected by cord section. This evidence, therefore, suggested that 
immunological or other cellular mediators are capable of stimulating the 
sympathetic and pituitary mechanisms of hormone secretion and 
mediating post-traumatic responses. 
Another complex series of hormonal responses to hypotension, 
hypovolaemia, and inadequate perfusion involve release of vasopressin 
from the posterior pituitary, renin from the kidney and aldosterone from 
the adrenal cortex. Insulin is the principal hormone which promotes 
energy storage and protein synthesis. In post-traumatic or septic patients, 
the blood insulin concentration may be high or low. In septic or severely 
injured patients high blood glucose concentrations have been observed 
despite elevated blood insulin concentrations. Insulin resistance has been 
postulated (Kahn CR, 1978) as a cause of this phenomenon. On the other 
hand, the probable mechanism of the hypoinsulinaemia observed in 
shock, is intense sympathetic activity. Several hormones antagonise the 
actions of insulin by inducing glycolysis, gluconeogenesis, and lipolysis. 
Also known as counter-regulatory hormones, they include glucagon, 
cathecholamines and glucocorticoids. 
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2.1.2 Other non-cytokine mediators 
In addition to those which act either locally or systemically, mediators may 
play both a local role in establishing the inflammatory response at the site 
of injury and also have a systemic effect. Histamine, prostaglandins, 
leukotrienes and products of the classical cascades of coagulation-
fibrinolysis, kallikrein-kinin and complement are good examples of this 
type of mediator. In addition to their direct effects, these components 
stimulate a wide variety of cells involved in host defence such as mast 
cells, fibroblasts, neutrophils, monocytes and macrophages. Subsequently 
these cells, in addition to their direct activities (phagocytosis, tissue repair 
and the release of lysosomal and other chemicals such as histamine), 
secrete polypeptide mediators which initiate the systemic acute phase 
response. Thus mediation of the integrated host response can be 
conceptualised as a tiered response which is illustrated in Figure 2.2. 
2.2 MEDIA TOR STUDIES: Animal versus human 
The laboratory animal has been essential in medical research and has 
enabled increased understanding of the mechanisms of human disease. 
Additionally, studies involving lethality to the recipient of administered 
agents can clearly only be performed using this approach. However, 
studies in laboratory animals of the mediators of the integrated host 
response to infection and injury are often unsatisfactory for several 
reasons. 
1) There is a marked inter-species variation in the susceptibility of animals 
to the effects of agents such as endotoxin or cytokines. Laboratory rodents 
are much less susceptible to these agents than human beings (Wolff S, 
1973). 
2) Small animal models are intrinsically limited in the extent to which 
accurate haemodynamic and other measurements can be made, and the 
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extent to which blood can be sampled. These issues have been extensively 
reviewed elsewhere (Appelgren Ket al., 1986). 
3) Most of the recombinant cytokines currently available for research are 
identical to human cytokines. It has been shown that there is a marked 
inter-species specificity not only in relationship to the biological effects of 
these agents, but also in their cytokine-receptor interactions (Smith R et 
al., 1986). Similarly, most of the assay systems available to measure 
cytokines will only measure human-derived moieties. 
4) Ethical considerations also limit animal experimentation and this 
applies particularly in the United Kingdom. In general, a major insult may 
not be inflicted upon a conscious animal and it must be sacrificed before 
reversal of anaesthesia. Therefore burn and multiple injury animal 
models cannot be easily created and can only be studied for a very short 
period after insult. 
5) Finally, many studies are amenable to human research and the value of 
performing them first in animals is often debatable. 
For these reasons, several groups of investigators have focused their 
studies on human subjects, albeit with the considerable limitations that 
this approach sometimes necessitates. For these reasons also, all work 
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Figure 2.2 Mediation of the integrated host response - a cascade 
phenomenon. 
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2.3 L YMPHOKINES TO MONOKINES TO CYTOKINES 
2.3.1 A brief history 
The classical concept enunciated by Metchnikoff at the turn of the century, 
placed phagocytosis and digestion by the mononuclear-phagocyte system 
as the key to host defence (Metchnikoff E, 1905). Sir Almoth Wright, 
following up Metchnikoff's work at St Mary's Hospital in London, coined 
the termed "opsonin" when he observed that "the white corpuscles or 
phagocytes only attack and devour disease germs ... when we butter the 
germs with a natural sauce (opsonin)". The enthusiasm this doctrine 
aroused even reached the theatre stage, where in George Bernard Shaw's 
"The Doctor's dilemma" performed in 1906, Sir Ralph Bloomfield 
Bonnington declared "There is at bottom only one genuinely scientific 
treatment for all diseases; and that is to stimulate the phagocytes. 
Stimulate the phagocytes. Drugs are a delusion." (Figure 2.3) (Shaw GB, 
1906). Shaw was an acquaintance of Sir Almoth Wright. However the 
discovery that macrophages have another important defensive function, 
namely the production of inflammatory mediators, resulted from some 
fascinating studies in the late 1970s. 
The first study took advantage of a spontaneous mutation in a strain of 
mice. They developed near immunity to the effects of Gram-negative 
organisms and their endotoxins. When these mice were irradiated and 
given bone marrow from normal mice, sensitivity to the effects of 
endotoxin, including death, was conferred (Michalek S et al., 1980). 
Furthermore, the infusion into the resistant strain of serum from 
endotoxin treated mice, also resulted in a syndrome similar to endo-
toxaemia (Kawakami M et al., 1982). Thus endotoxin was mediating its 
effects via a serum factor synthesised by a bone marrow cell. At about the 
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Figure 2.3 A copy of the original draft of "The doctor's dilemma" written 
by George Bernard Shaw in 1905-6. 
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same time, Vogel was studying congenitally athymic or B lymphocyte 
depleted strains of mice, showing that neither T nor B cells affected the 
mediation of endotoxicity (Vogel Set al., 1979a)(Vogel Set al., 1979b), thus 
implicating the monocyte/macrophage. The circle was completed when 
the sensitivity of these animals to endotoxin, was shown to be enhanced 
by the administration of macrophage stimulants like glucan, zymosan or 
bacillus Calmette Geurin (BCG) (Di Luzio N et al., 1980). The existence of 
monocyte/macrophage-derived serum factor, a so-called second messeng-
er, was therefore confirmed. 
It had now become clear that macrophages and other cells of the 
reticuloendothelial system, in addition to clearing bacteria, endotoxins and 
other noxious agents from the circulation, produced circulating factors 
which modified the host response to injury or infection. It is interesting to 
reflect that while Metchnikoff and others at the beginning of the twentieth 
century were expounding the importance of phagocytosis as the key 
mechanism of host defence, Walter Cannon was recording clinical 
observations about shock at the battlefront, that hinted at the concept of 
inflammatory mediators. 
No doubt hemorrhage may have an important part in the 
development of this state and infection likewise is important; 
but there are recorded cases in which both hemorrhage and 
infection were absent or slight and in which, nevertheless, 
shock was observed. These facts of observation have led to the 
view that beside hemorrhage and infection there is an 
unknown factor at work. 
Walter Cannon 1919 
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Walter B Cannon was part of a team of British and American basic 
scientists and clinicians sent to France in 1916 to study front-line casualties 
as soon as possible after they were wounded. Problems that were observed 
at the front were recreated in controlled experiments in established 
laboratories in England and America. Much was learnt about the "state of 
shock" and the findings were finally collated by Dr Cannon in the classical 
monograph Traumatic Shock, published in 1923. Interestingly, Cannon 
himself did not favour the term shock, which was introduced in error to 
the English language by an unknown translator of Le Oran's 1743 treatise 
on gunshot wounds, who used it to translate the French "choc" which was 
used in the context of an impact, a blow or a jolt. Cannon and others felt 
the word was not informative and he suggested "exaemia", but none of 
the many suggestions have ever replaced the short and convenient term 
"shock". 
The concept of soluble mediators became more clearly defined as a result 
of the classic work of Sir Henry Dale who investigated the role of 
histamine in acute inflammation (Dale HH, 1929)(Dale HH, 1933). 
He noted 
"The discovery in artificial extract from an organ or tissue of a 
substance which on artificial injection produces a pharmaco-
dynamic effect, provides only a first item of presumptive 
evidence in support of a theory that the action of this substance 
plays a part in normal inflammation." 
Sir Henry Dale 1933 
and suggested 
"What was needed was a system of criteria or postulates 
( comparable to Koch's celebrated postulates dealing with the 
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aetiological significance of a microorganism), representing 
conditions which must be fulfilled before physiological 
significance was attributed to the effects produced by the artificial 
application of an organ extract." 
Sir Henry Dale 1929 
Over the course of the next 50 years many mediators would be described, 
but in the rush to describe immune mediators and mediators of 
intercellular communication, Dale's sage observations would be ignored. 
Numerous soluble factors were described purely on the basis of a 
pharmacodynamic effect resulting from an artificial injection of an 
artificial extract such as culture supernatant, into a laboratory animal. 
In 1943, during investigations into mechanisms of fever, Menkin isolated 
a substance from inflammatory exudates that caused fever when injected 
intravenously into rabbits (Menkin V, 1943). This substance was called 
pyrexin. However the possible presence of endotoxin contamination was a 
criticism of the early work on pyrexin until several years later, when 
Beeson extracted a fever-promoting substance, which was distinct from 
endotoxin, from suspensions of rabbit leucocytes containing 
predominantly polymorphonuclear leucocytes (Beeson PB, 1948). This 
fever promoting substance became known as endogenous pyrogen (EP) 
(Wood WB Jr, 1958). Endogenous pyrogen has been shown to be released 
from the leucocytes of many species, both mammalian and non-
mammalian. 
Then came the discovery that cell-free soluble factors in culture 
supernatants of sensitised lymphocytes incubated with antigen, could (1) 
cause macrophage migration inhibition (Bloom BR et al., 1966), (2) 
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produce skin lesions similar to delayed type hypersensitivity (Bennett B et 
al., 1968) and (3) be mitogenic for lymphocytes (Kasakura S et al., 1970). 
These findings suggested that molecular mediators were involved in 
cellular immune responses. More and more crude culture supernatants 
were shown to influence the in vitro behaviour of a wide variety of target 
cells in many different ways, leading to the view that many cellular 
immune interactions were regulated by soluble factors. 
The term "lymphokine" was introduced in 1969 and was chosen to 
emphasize the origin of these soluble factors (lymphocytes) and also their 
role in the physiology of the immune system (kinesis) (Dumonde DC et 
al., 1969). However during the 1970s the term became more widely used to 
describe the large number of biological activities assumed to be the 
properties of factors in the culture supernatants. Thus lymphokines were 
named on the basis of the activity they produced in vitro and their names 
abbreviated to acronyms. Similar activities were found in body fluids such 
as serum and urine and terms such as "monokine", "cytokine" and 
"interleukin" were used in an attempt to clarify these factors on the basis 
of their cellular origin or function. 
In the early 1970s, Kampschimdt et al and Wannemacher et al described a 
leucocyte derived polypeptide called leucocytic endogenous mediator 
(LEM) which could promote most aspects of the acute phase response in 
animals after intravenous or intraperitoneal injection (Kampschmidt RF 
et al., 1973)(Wannemacher RW Jr et al., 1975). This mediator was shown to 
promote fever, granulocytosis, hypoferraemia, hypozincaemia, hyper-
cupraemia and induce the synthesis of several acute phase proteins in rats 
and rabbits. Leucocyte endogenous mediator was shown to have a 
molecular weight of 14 000 and an isoelectric point of pl 7-7.6, and 
41 
therefore to be similar, if not identical, with EP (Kampschmidt RF, 1981). 
Meanwhile significant advances were made in studies of mediators 
involved in humoral and cell mediated immunity. Gery et al described a 
soluble product necessary for T lymphocyte activation, which was released 
by activated macrophages. This factor was called lymphocyte activating 
factor (LAP) (Gery I et al., 1972a)(Gery I et al., 1972b). 
Not surprisingly, scepticism arose about the very existence of 
lymphokines, because the large number of activities, their disparate 
sources and their lack of chemical characterisation were enough to suggest 
that the whole concept was based on artefact. However the advent of gene 
cloning and the development of improved protein purification and 
sequencing techniques, resulted in a rapid improvement in the 
characterisation of lymphokine structure. From this it became clear that a 
number of biological activities were actually different effects of the same 
substance and eventually an attempt was made to clarify the field at an 
International Lymphokine Workshop in 1979, where more than 100 
factors with bioassay based names were reviewed. A number of factors 
were found to be identical, for example, LAP, LEM, EP, B cell 
Differentiation Factor, B cell Activating Factor and Mitogenic Protein were 
all shown to be one and the same and the term interleukin-1 was agreed to 
describe them all (Aarden LA et al., 1979). Dinarello described IL-1 as a 
single molecule or a family of closely related molecules, because the 
preparations used were not pure and probably contained many 
contaminants (Dinarello CA, 1984). 
Originally it was assumed that the vast majority of these polypeptide 
mediators originated from macrophages and lymphocytes, but in the last 
few years it has become increasingly apparent that a wide variety of cells 
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are able to produce these substances which, in turn, act on many different 
cell types. For this reason there is growing acceptance of the term 
"cytokine" rather than "lymphokine" or "monokine". Two important 
developments of the past few years have helped clarify the role of these 
factors in the immune response: (1) the availability of recombinant 
cytokines has enabled the activities of the individual polypeptides to be 
more accurately defined and (2) the development of monoclonal 
antibodies against individual cytokines (often several different 
monoclonal antibodies against different epitopes of the same cytokine) has 
improved the specificity of both cytokine bioassays and immunoassays and 
also facilitated the purification of these peptides. 
2.3.2 Cytokines - a definition 
Cytokines, which are polypeptides of 100-200 amino acids, are released by 
haemopoietic and non-haemopoietic cells and have multiple actions on 
multiple target cells. They consist of the interleukins (IL-1 to IL-10), the 
interferons, the tumour necrosis factors and the colony stimulating factors 
and these cytokines play essential roles in normal immune and 
inflammatory responses. They act as intercellular mediators not only 
between different leucocytes but also between leucocytes and other cells of 
the body. 
Of the various cytokines, several share the ability to stimulate or augment 
cell proliferation and these act locally in an autocrine or paracrine fashion 
to recruit and activate cells at sites of inflammation. 
Other cytokines, notably IL-1, TNF and IL-6, are able to initiate the 
synthesis of new proteins in a variety of cells and induce the production of 
inflammatory metabolites. They are biologically similar and considerable 
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interest has focused on them as mediators of systemic acute phase 
responses. They are sometimes collectively known as "the acute phase 
cytokines". Injecting experimental animals with either IL-1 or TNF results 
in fever, hypozincaemia, hypoferraemia, increased hepatic acute phase 
protein synthesis and other manifestations of the integrated host response. 
Injection of IL-6 induces fever and hepatic acute phase protein synthesis. 
2.3.3 Interleukin-1 
Structure and synthesis: Two forms of IL-1 have been cloned, IL-la and~ 
which correspond to the previously described acidic (pI=S) and neutral 
(pI=7) forms. Although they are distinct gene products with only limited 
amino acid homology (30 per cent) (March CJ et al., 1985), they share the 
same biological properties and recognise the same receptor on the 
surprisingly large variety of target cells including T and B lymphocytes, 
neutrophils, macrophages, fibroblasts, chondrocytes, epithelial, 
endothelial, muscle cells and even some neurons (Dinarello CA, 1989b). 
Interleukin-1 is synthesised predominantly by blood monocytes and tissue 
macrophages, but is also produced by a variety of other cell types including 
endothelial cells, keratinocytes, neutrophils, Langerhans cells, smooth 
muscle cells, renal mesangial cells, astrocytes, microglia and B lympho-
cytes. The amount of IL-1 secreted depends upon the cell type and the 
conditions of stimulation, but the monocyte/macrophage appears to be the 
cell best equipped to secrete IL-1 (Auron PE et al., 1987). 
Antigens may induce IL-1 production either directly by involvement of 
cell to cell contact, or indirectly by releasing other cytokines from activated 
T cells, particularly IL-2, interferon gamma (IFNy) and the colony 
stimulating factors, which themselves stimulate IL-1 production. 
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Antigenic stimuli that result in IL-1 production include viruses, bacteria, 
and directly acting cytokines, for example, IL-1 itself, TNF, granulocyte-
macrophage colony stimulating factor and IFNy. Factors known to 
downgrade IL-1 production include corticosteroids, IL-4, PGE2, fever and 
malnutrition. 
Both forms are synthesised as 31 kilodalton precursor peptides and both 
are also readily degraded to their 17 kilodalton form. Neither has a signal 
peptide sequence, resulting in a considerable amount of synthesised IL-1 
remaining cell-associated, with IL-la being predominantly membrane 
bound and 80 per cent of IL-1~ being retained intracellularly in precursor 
form. However, human monocytes stimulated with endotoxin produce 
approximately 10-fold more IL-1~ than IL-la. Therefore, a substantial 
amount of IL-1 ~ is, in fact, released from cells while IL-la remains cell 
associated (Dinarello CA et al., 1989a). Cell death and lysis results in 
sufficient protease activity to process, spontaneously, the IL-1~ precursor 
into its lower molecular weight active form. 
Biological effects: Both forms are equipotent and have circulating half-
lives of 8-10 minutes (Newton RC et al., 1988). Interleukin-1 augments T, 
B and natural killer cell responses, including the production of other 
cytokines (Shalaby MR et al., 1989). It induces the slow wave sleep pattern 
(Shoham Set al., 1987) and anorexia (Oomura Y, 1988) seen during illness, 
and attenuates the perception of pain after injury or inflammation by 
increasing the release of beta endorphins and the number of opiate-like 
receptors in the brain (Wiedermann CJ, 1989). It evokes systemic acute 
phase responses including fever, by stimulating a local release of 
prostaglandins in the anterior hypothalamus (Walter JS et al., 1989), 
hepatic acute phase protein synthesis (see Chapter 1), hypoferraemia, 
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hypozincaemia (Goldblum SE et al., 1987) and increased levels of 
hormones including glucocorticosteroids and insulin. It promotes 
myelopoiesis by inducing colony stimulating factors resulting in a 
leucocytosis (Ulich TR et al., 1987). In addition to its inflammatory 
mediating and immuno-enhancing effects, IL-1 is also a growth promoter 
of several types of cells, including fibroblasts and vascular smooth muscle 
cells (Schmidt J et al., 1984). Further properties of this cytokine are listed in 
Table 2.1. 
This pluripotent peptide exerts important beneficial influences during 
injury but inappropriate synthesis of IL-1 maybe harmful. At high dose it 
induces hypotension and a "shock-like" state (Okusawa S et al., 1988). 
Chronic release of IL-1 has also been implicated in the pathogenesis of 
rheumatoid arthritis, atherosclerosis and cancer cachexia. 
Technical considerations: Much early work reporting the presence of IL-1 
in various samples has been discounted. In the past, preparations of IL-1 
were often contaminated with lipopolysaccharide which confused the 
specificity of any response observed. In addition, early bioassays relied on 
the ability of this protein to stimulate proliferation of lymphocytes. 
However numerous more recently discovered cytokines are also 
mitogenic for T cell blastogenesis, moreover these cytokines may also 
induce IL-1 production. It is not suprising, therefore, that recent studies 
using sensitive immunoassays (radioimmunoassays and ELISA), have 
failed to confirm the frequent appearance of IL-1 in the circulation of 
individuals with inflammation that was reported in the original bioassays 
(Fong Yet al., 1990a). 
IL 1 receptor antagonist (IL-lra): The discovery of this cytokine, first 
reported in 1985 (Arend W et al., 1985) but only recently purified 
46 
(Hannum CH et al., 1990) and cloned (Eisenberg SP et al., 1990) by the same 
group in Colorado, may have important clinical consequences. It is 
produced by both monocytes and tissue macrophages, indeed the same 
population of human monocytes produces both the agonists IL-la and IL-
1 ~ as well as IL-lra. This fact supports the view that IL-lra is a 
physiologically significant regulator of IL-1 and that an appreciation of its 
properties will be essential to understand the function of IL-1 (Hannum 
CH et al., 1990). However, what stimuli induce and whether other cells 
produce IL-lra has yet to be determined. 
Interleukin-1 receptor antagonist appears to be a pure receptor antagonist, 
not activating target cells. Target cells are highly sensitive to IL-1, therefore 
excess amounts of IL-lra are required to flood the system and block IL-1 
activity (Arend WP et al., 1990a). Nonetheless there have been several 
studies suggesting that IL-lra may be important in regulating the 
inflammatory response. Administration of endotoxin to human 
volunteers led to measurable IL-lra activity in plasma (Spinas GA et al., 
1990), while a Swedish study reported a reduction in the lethality of 
endotoxin-induced shock in rabbits (Ohlsson K et al., 1990). Similarly, 
inflammatory responses in mice, including the IL-6 response, were 
attenuated by IL-lra (Gershenwald JE et al., 1990). 
The discovery of IL-lra will facilitate a better understanding of the 
biological actions of IL-1, even though its own role in normal physiology 
remains uncertain. However, its discovery and these early studies have 
led to the assumption that this molecule may function in vivo to regulate 
the pleiotropic extracellular effects of IL-1 in physiological or pathological 
processes (Arend WP, 1990b). 
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2.3.4 Tumour necrosis factor (cachectin) 
As its names suggest, this cytokine's role in inflammation was discovered 
after its metabolic and anti-cancer properties. During the 1890s, Dr 
William Coley (Figure 2.4), an assistant surgeon at The Hospital for 
Ruptured and Crippled (now the Memorial Sloan-Kettering Hospital) in 
New York, deliberately infected tumour-bearing patients with various 
killed bacterial preparations (Coley's toxins) and demonstrated that local 
tumour regression was obtained with these agents (Coley W, 1893)(Coley 
W, 1906). 
"I innoculated a case of recurrent sarcoma of the neck and tonsil. .. which at 
operation had proved too extensive to remove. Five decigrammes of a 
fresh culture of streptococcus erysipelatis were injected into the tumour 
substance ... Within an hour he had severe pain, nausea, vomiting and a 
chill...his temperature rose to 105 ° ... and the erysipelas ran the usual 
course. At the end of ten days the tumour began to break down .. and 
discharged. . .. At the end of two weeks the neck tumour had 
disappeared ... The patient continued well for eight years." 
William Coley 1906 
Coley and others believed that cancer was caused by a parasite. This was 
because microbiologists claimed to be able to demonstrate the constant 
presence of protozoa in a very large number of cancer specimens. 
Therefore Coley explained his results thus: " ... The toxic products of the 
erysipelas streptococci ... bring about such changes in the blood-serum as to 
destroy the parasite of cancer." 
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Figure 2.4 William Coley. 
Subsequent work made it clear that the active agents in Coley's 
preparations were bacterial endotoxins (Shear M et al., 1943). In 1934, the 
American Medical Association listed Coley's toxins as the only recognised 
systemic treatment for cancer (Merz B, 1986). However the results had 
been inconsistent, and radiotherapy and chemotherapy soon supplanted 
Coley's approach. 
During the 1930s and 1940s researchers confirmed that injection of live or 
killed Gram-negative bacteria could cause haemorrhagic necrosis of 
mouse tumours and lipopolysaccharide or endotoxin was identified as the 
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active component of Gram-negative bacteria. Dr Lloyd Old and colleagues 
at the Memorial Sloan-Kettering Hospital, New York noted that blood 
from endotoxin treated mice induced haemorrhagic necrosis in tumours 
of other animals and was highly toxic to cancer cells in vitro. They 
correctly concluded that the mice had produced large amounts of an anti-
tumour factor which was responsible for the cancer killing and called it 
tumour necrosis factor (Carswell E et al., 1975). Subsequently, this protein 
was sequenced and found to be a protein with a molecular weight of 17 000 
kilodaltons (Aggarwal Bet al., 1985). 
Over the same period, Beutler and Cerami and others at the Rockefeller 
University in New York, had found a factor produced by activated 
macrophages that inhibited lipoprotein lipase, an enzyme essential for the 
normal storage of fat, and which was suppressed in infected cachectic 
mammals (Kawakami M et al., 1982). They called this factor "cachectin". 
However when this protein was isolated and characterized, its amino acid 
sequence proved indistinguishable from that of tumour necrosis factor 
(Beutler B et al., 1985). 
Synthesis and structure: Tumour necrosis factor, a product of stimulated 
monocytes and macrophages, is also produced by lymphocytes, endothelial 
cells and keratinocytes. It has a molecular weight of 17 kilodaltons and a pl 
of 5.3 (Aggarwal Bet al., 1985). Tumour necrosis factor is translated as a 233 
amino acid precursor which undergoes proteolysis to become the active, 
157 amino acid TNF polypeptide (Beutler B et al., 1987). It has a circulating 
half-life of 14 to 18 minutes (Blick M et al., 1987). Lymphotoxin, a 
structurally related polypeptide sometimes known as TNF~, is produced 
in smaller quantities by activated T cells. 
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Biological properties: These are remarkably similar to IL-1. Tumour 
necrosis factor modulates immune function by activating neutrophils and 
lymphocytes and induces the synthesis and release of immunostimulatory 
polypeptides like IL-1 and IL-6 from both immune and accessory cells 
(Shalaby MR et al., 1989)(Dinarello CA et al., 1986). In addition, TNF 
initiates neutrophil margination, transendothelial migration and 
degranulation (Shalaby MR et al., 1985). Nearly every non-immunological 
biological property of IL-1 has been observed with TNF including fever, 
mediated by this cytokine's ability to stimulate hypothalamic 
prostaglandin synthesis (Dinarello CA et al., 1986). Both molecules induce 
fibroblast proliferation and collagen synthesis as well as bone and cartilage 
resorption (Kohase Met al., 1986) (Table 2.1). 
Hepatic amino acid uptake (Warren RS et al., 1987), acute phase protein 
synthesis and complement component synthesis are increased, while 
albumin synthesis is decreased by TNF (Moldawer LL et al., 1987). This 
polypeptide exerts a direct effect on carbohydrate metabolism in muscle 
cells and may represent an early signal for anaerobic glycolysis within 
somatic tissues (Lee DM et al., 1987), while further catabolism is induced 
via muscle protein wasting (Flores EA et al., 1989). Thus from a metabolic 
point of view, TNF is primarily catabolic while nonetheless shifting the 
metabolic processes of the liver to anabolism. 
Tumour necrosis factor produces hypotension, leukopaenia and local 
tissue necrosis (Tracey K et al., 1986) and is more potent than IL-1 in 
producing shock (Okusawa S et al., 1988) which is probably a reflection of 
its effects on the vascular endothelium. The acute, exaggerated secretion of 
TNF is thought to be pathogenic in the cardiovascular collapse, shock and 
death associated with severe endotoxaemia or infection. Pathological 
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findings, similar to those seen in septic shock, are seen in animals infused 
with high doses of TNF, including adrenal necrosis, pulmonary 
congestion and caecal necrosis (Tracey K et al., 1986). However, the most 
convincing evidence for the role of endotoxin in endotoxic shock was seen 
when a TNF antiserum was shown to be protective against endotoxin 
infusion in rabbits (Mathison JC et al., 1988) and a prophylactic 
monoclonal antibody protected baboons against the consequences of a 
lethal dose of bacteria. Furthermore this blockade attenuated the 
appearance of IL-1 and IL-6 providing evidence for the synergism of these 
cytokines in mediating the acute phase response (Fong Y et al., 1989a). 
Further properties of this cytokine are listed in Table 2.1. 
Technical considerations: Depending on the assay used, TNF is or is not 
detectable in the plasma of healthy individuals. This is probably because 
some assays measure both free TNF and TNF already bound to its 
antibody, while others measure only the free (and therefore, it is thought, 
clinically relevant) form. The TNF assay used in this thesis is of the latter 
type. In addition, studies as recently as 1989, have been devalued because 
heparin was used as the anticoagulant and this has been shown to 
stimulate TNF release (Freeman R et al., 1990). Finally, and for reasons 
that are not known, high levels of TNF appear to be a feature of some 
healthy people. 
2.3.5 Interleukin-6 
Interleukin-6 is probably unique among cytokines, because it was cloned 
inadvertently, in 1980, long before the discovery of its major biological 
activities (Weissenbach J et al., 1980). It was called interferon-b2 because it 
showed some anti-viral activity. During the next ten years a variety of 
other teams were independently involved in trying to identify various 
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growth and differentiation factors, so that by 1988 these groups, all of 
whom assumed they were involved in the identification of unrelated 
factors, came to the unsettling conclusion that they had cloned or purified 
the same protein. The primary amino acid sequence is the ultimate 
criterion used to assign an interleukin number to a substance and the term 
IL-6 was proposed when the nucleotide sequences of all these factors were 
determined and found to be identical (Van Damme Jet al., 1987)(Poupart P 
et al., 1987). The term 'Interleukin-6' therefore replaced approximately 10 
different names and resulted in a remarkable simplification of cytokine 
nomenclature: 
IFNb2 = 26K = BSF-2 = IL-HPI = HGF = HSF = CDF = IL-6. 
Structure and synthesis: This 212 amino acid polypeptide has a molecular 
weight of 21-28 kilodaltons depending on its cellular source and includes a 
hydrophobic signal sequence (Hirano T et al., 1986). The gene for human 
IL-6 has been mapped to chromosome 7 (Sehgal PB et al., 1987). 
Interleukin-6 is produced by an extraordinary variety of cells including 
fibroblasts, hepatocytes and kupfer cells, microglial cells, astrocytes, 
endothelial cells, keratinocytes, monocytes/macrophages, T and B cells, 
anterior pituitary folliculostellate cells, mast cells, endometrial stroma 
cells, pancreatic beta cells and some tumour cell lines (Wolvekamp MCJ et 
al., 1990). However accessory cells are undoubtedly the major source of IL-6 
in freshly isolated cell preparations (Aarden LA et al., 1987). The plasma 
clearance of IL-6 is biphasic with a rapid first phase followed by a slower, 55 
minute, disappearance phase. 
Biological activity: The improved discrimination of cytokine activities, 
resulting from the advent of cytokine immunoassays and improvements 
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in bioassays, has demonstrated that several activities, formerly ascribed to 
IL-1, are in fact the result of the combined action of IL-1 and IL-6 or even 
IL-6 alone (Figure 2.5). For example, the original IL-1 assay system of 
murine thymocyte costimulation partially responds to IL-6, resulting in 
many actions of IL-6 being originally ascribed to IL-1. However, while 
many of the functions of IL-6 are overlapping or synergistic with IL-1 and 
TNF (Table 2.1), it is of singular importance in the induction of hepatic 
acute phase protein synthesis. 
For many years researchers have attempted to identify the mediators of 
the hepatic acute phase response. Experiments in vivo could not provide 
unequivocal answers because of the possibility of second messengers 
produced by other cells, so hepatoma cell lines became the established 
investigation model. Although IL-1 and TNF were reported to induce this 
response in certain cell lines, neither was capable of inducing the full 
spectrum of proteins, in particular, C reactive protein. The missing 
cytokine turned out to be IL-6 in the guise of hepatocyte stimulating factor 
(HSF), originally described in 1983 (Gauldie J et al., 1987). The recognition 
that IL-6 is the most potent mediator of APP synthesis has been confirmed 
by the observations that it induces acute phase proteins in vivo (Geiger T 
et al., 1988) and is the only cytokine capable of inducing the full spectrum 
of acute phase protein synthesis in human hepatocytes (Castell JV et al., 
1989). 
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Figure 2.5 The coordinated and synergistic response to insult of IL-1 and 
IL-6 (after van Snick 1990). 
Like TNF this cytokine appears to be rapidly released into the circulation 
in response to injury and can be detected within 60 minutes of an 
endotoxin infusion (Michie HR et al., 1988a). However, unlike IL-1 and 
TNF, IL-6 does not induce IL-1 or TNF. In fact it suppresses endotoxin- and 
TNF-induced IL-1 production (Dinarello C, 1988). 
Thus IL-6 appears to be a weak inflammatory peptide when compared to 
IL-1 and TNF, but with a spectrum of activities that include 
haematological and neurological influences. Its multiple effects all 
contribute to a co-ordinated response by the body to injury and, unlike IL-1 
and TNF, it seems incapable of inducing adverse effects, even when 
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administered in high dose. Evidence that IL-6 adversely influences 
cardiovascular stability or cellular integrity has not been found, so that the 
major effects of this protein appear to be beneficial to the host by 
enhancing immune function and acute phase protein synthesis. If one 
adds that injury or infection are promptly followed by a massive induction 
of IL-6 and that essentially every cell is capable of making IL-6, it becomes 
clear that this cytokine is tailored to function as an "SOS signal" (van 
Snick J, 1990). The high titres of IL-6 associated with inflammation and 
infection may result from complex amplification mechanisms involving 
IL-1 and TNF, which both induce strong IL-6 responses in vivo (Jablons 
DM et al., 1989)(Shalaby MR et al., 1989). 
In conclusion, while IL-6 appears to be one of the most pleiotrophic 
cytokines yet discovered, the claim of some IL-6 investigators that "it has 
the capacity to cause clinical abnormalities, directly or indirectly, by non-
physiological over-production during the course of several diseases" 
(Wolvekamp MCJ et al., 1990), remains unproven and perhaps unlikely in 
the face of current evidence. 
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Table 2.1 A comparison of the biological properties of IL-1, TNF and IL-6. 
BIOLOGICAL PROPERTIES IL-1 TNF IL-6 
Metabolic 
acute phase protein synthesis + + ++ 
decreased plasma Iron/ Zinc + + 
decreased albumin synthesis + + + 
increased insulin production + + 
inhibition of lipoprotein lipase + ++ 
increased corticosteroid synthesis + + + 
lactic acidosis + + 
Central nervous system 
fever + + + 
increased ACTH production + + + 
decreased REM sleep + + 
increased slow wave sleep + + 
anorexia + + 
CNS prostaglandin synthesis + + + 
Haematologic and vascular wall 
haemod ynamic shock + ++ 
stem cell (haemopoietin-1) activity + + + 
endothelial activation + + 
radioprotection + + ± 
non-specific resistance to infection + + + 
neutrophilia + + + 
increased cardiac output + + 
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Immunological 
induction of IL-1 and TNF + + 
induction of IL-6 + + 
T /B cell activation ++ + + 
activation of NK cells ++ + 
Local non-immune effects 
neu trophil degran ula tion + + 
bone resorption + + 
keratinocyte proliferation + + 
collagen synthesis + + 
chemotaxis + + 
increased prostaglandin synthesis + + + 
tumour cytotoxicity + ++ 
fibroblast proliferation + + 
2.3.6 lnterleukin-2 
This cytokine was discovered through its activity as a T cell growth factor 
(Morgan DA et al., 1976). It is produced by mitogen or antigen stimulated T 
lymphocytes, has two distinct polypeptide chains and a molecular weight 
of 15 kilodaltons (Smith KA, 1988). Unlike IL-1, TNF and IL-6 which are 
pleiotrophic, IL-2 acts predominantly as an immunostimulant. Besides 
being a growth factor for mature T cells and thymocytes, IL-2 enhances 
cell-mediated T cell cytotoxicity and stimulates natural killer cell activity 
(Rosenberg SA et al., 1988). It is, therefore, able to promote host defences 
against infection and its administration to mice has been shown to protect 
them against lethal doses of intraperitoneal E coli administration 
(Goronzy Jet al., 1989). 
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Because IL-2 is immunostimulatory, antibodies against its receptors are 
potentially immunosuppressive and therefore may be useful in organ 
transplantation, or protective in conditions of aberrant immune function 
such as autoimmune diabetes mellitus or systemic lupus erythematosus. 
Additionally, it could be a useful agent in restoring immune function to 
immunocompromised patients, including trauma or septic patients. 
This cytokine does not appear to have any active role in the integrated 
host response and its direct role in mediating detrimental changes in any 
clinical disease remains to be demonstrated (Fong Yet al., 1990a). 
2.3.7 Interferon gamma 
Three distinct classes of interferon (a,p and y) are recognised. Although 
they all have anti-viral activity in common, IFNy differs from the other 
interferons both in structure and function. Interferon gamma (IFNy) is 
produced during an immune response by antigen-specific T cells and 
natural killer (NK) cells, recruited by IL-2 (Green JA et al., 1969). 
This glycoprotein has pronounced immunoregulatory effects, including 
activation of macrophages to enhanced phagocytosis and tumour killing 
capability, activation and growth enhancement of cytolytic T cells and NK 
cells, induction of class II MHC antigen on many cells including 
macrophages and the proliferation of B-cells and induction of their 
immunoglobulin secretion (Trinchieri G et al., 1985). Production of IFNy is 
triggered by microbial antigens (Kelly CD et al., 1987) or IL-2 (Kasahara T et 
al., 1983) and increased transcription for IFNy can be detected within six 
hours. Release of this protein peaks at approximately 48-72 hours (Kelly 
59 
CD et al., 1987), but may continue for seven to eight days (Green JA et al., 
1969). 
In vitro studies have demonstrated a decrease in interferon gamma (IFNy) 
production by peripheral blood mononuclear cells (PBMC) isolated from 
major injury patients (Faist E et al., 1988)(D Livingstone et al., 1988). 
However the bioassays and immunoassays used in these studies measured 
only the bulk release of cytokines by entire populations of cells in culture 
after lengthy mitogen stimulation. Work presented in Chapter 8 will 
suggest that the spontaneous release of IFNy from PBMC is, in fact, 
augmented in the post-surgical patient. 
Studies in which IFNy has been administered to injured (thermal and 
non-thermal) animals have suggested an improvement in outcome after a 
bacterial challenge (Hershman MJ et al., 1988b)(M Malangoni et al., 1989), 
and preliminary results from a multicentre clinical trial have suggested 
some reduction in septic complications in certain subgroups of major 
trauma patients given IFNy therapy (Polk H C, Presentation of preliminary 
data from a multicentre trial of interferon gamma therapy in major injury 
patients: at the 2nd International Congress on the Immune consequences 
of Trauma, Shock and Sepsis; Munich, March 1991). Interferon gamma 
release could therefore be interpreted as a beneficial component of the 
host's immune response to injury, and a possible target for 
immunotherapy to augment the patient's own endogenous release of 
IFNy. 
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2.4 CONCLUSION - Cytokine interactions (Figures 2.1, 2.5 and 2.6) 
This chapter began with an outline of the cascade of inflammatory 
mediators involved in the integrated host response, then some of the 
cytokines most central to the theme of this thesis were introduced. It is 
therefore appropriate that it should end with a re-emphasis of the complex 
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Figure 2.6 Cytokine interactions and synergism (courtesy of Dr Salmon, 
University of Birmingham). 
Cytokines constitute the molecular language of inflammation and 
immunity, and as such they form a complex network of overlapping and 
interacting signals, which together propagate the mediator cascade and 
orchestrate the integrated host response. They can elicit the release of non-
cytokine mediators, for example, TNF elicits the release of the counter-
regulatory hormones and prostaglandins, and along with IL-1 and IL-6, 
stimulates the release of adrenal and pituitary hormones. They also 
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exhibit synergy with non-cytokine endogenous mediators, which also 
helps propagate the mediator cascade, for example TNF enhances the 
glucagon-mediated uptake of amino acids (Warren RS et al., 1987). 
Finally, cytokines exhibit synergy among themselves; IL-6 induces IL-2 
receptor expression, IFNy potentiates interleukin-4 induced proliferation 
of human B-cells and the synergism of IL-1, TNF and IL-6 has been 
frequently mentioned (Figures 2.5 and 2.6). These three cytokines, probably 
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3.1 PATIENTS 
All subjects studied were managed in the surgical wards, operating 
theatres and intensive therapy unit at the John Radcliffe Hospital in 
Oxford. Three groups were recruited: (1) patients admitted for elective 
aortic surgery for either aneurysmal or occlusive disease, (2) patients 
admitted for elective inguinal hernia repair, (3) victims of major trauma 
admitted through the Accident and Emergency department. Patients in the 
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first two groups gave informed consent for the studies, all of which were 
approved by the Central Oxford Research Ethics Committee. 
Twenty eight patients (25 men and three women), aged between 59 and 83 
years, undergoing elective aortic aneurysm repair were studied in the 
work reported in chapters 4, 6, 7 and 8. No patient had liver disease, 
inflammatory or ischaemic bowel disease. Preoperative bowel preparation 
was not performed, but all patients received a prophylactic dose of 
cefuroxime (l.5gram) at induction. Operative and post-operative details 
were recorded, including the durations of operation, aortic clamping and 
ventilation, as well as blood transfusion volume, post-operative 
temperatures, leucocyte count, APACHE II scores and duration of 
admission. AP ACHE II scoring was performed on the basis of the initial 
and worst physiological parameters during the first 24 hours post-
operatively. 
Five patients (four men and one woman), aged between 50 and 75 years, 
undergoing elective inguinal hernia repair, were studied. 
The victims of major trauma were all admitted via the Accident and 
Emergency Department of the John Radcliffe Hospital, between January 
1991 and July 1991. It is department policy to transfer to the Regional 
Neurosurgical Unit at the Radcliffe Infirmary, those with major head 
injuries and relatively minor involvement of other systems. These 
patients were therefore excluded. Severely injured patients with minor 
head injuries, or those with both major head injuries and major injuries 
of other systems were included. This last group were managed on the 
intensive care unit of the John Radcliffe Hospital. All major burns 
patients are admitted directly to the Regional Burns Unit in Aylesbury and 
therefore thermally injured patients were not available for inclusion. 
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Using these criteria, six patients were studied. At admission, patients were 
assigned an Injury Severity Score (ISS) using the Abbreviated Injury Scale 
(AIS) scoring system (Greenspan Let al., 1985). 
3.2 ANAESTHESIA AND SURGERY 
Standard anaesthetic techniques were used for the first three patient 
groups. Two anaesthetists were involved in the operative management of 
the first group, one of whom anaesthetised more than 80 percent (%) of 
the patients. Only one anaesthetist was responsible for all patients in the 
second group, while two were involved in the operative management of 
the third group. By necessity, there was no uniformity of these techniques 
for patients in the fourth group. 
Four different consultant vascular surgeons performed all operations in 
the first group, although two performed more than 80 percent of them. 
The operations all involved replacement of the abdominal aorta with a 
dacron tube or bifurcated graft to the iliac or femoral arteries. Two 
surgeons performed all the cardiac surgery. Surgery in the other two 
groups was performed by several surgeons. 
3.3 PLASMA PREPARATION 
Five ml of venous blood was collected in standard disposable pyrogen free 
sterile syringes and added to pyrogen free glass tubes containing EDTA 
(0.34M) (Becton-Dickinson) and the proteinase inhibitor aprotinin 
(20µ1/ml) (Sigma). Samples were immediately microfuged, in the 
operating suite, at 11 OOOg. Aliquots of plasma were stored at -70°C. The 
sample preparation time was less than 5 minutes. 
During the course of the study two alterations were made to the sampling 
method. The first followed a comparison of results obtained when blood 
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was collected into tubes with and without aprotinin. This showed no 
variation in cytokine levels and thereafter aprotinin was not used. The 
second alteration resulted from a comparison between venous and arterial 
blood. Synchronous venous and arterial samples were drawn at various 
time points during the sampling of the first ten patients. It was observed 
that there was no significant difference between the levels of cytokines 
measured in 30 synchronous samples. While venous blood continued to 
be sampled whenever possible, there were occasions when the central 
venous catheter was not accessible because of complex anaesthetic 
monitoring and on these occasions arterial blood was sampled. 
A different method was used to prepare plasma for endotoxin analysis 
(section 3.8). 
3.4 CORTISOL 
This hormone was measured by radioimmunoassay, after plasma 
extraction with dichloromethane. 
3.5 C-REACTIVE PROTEIN 
This was measured using flow nephelometry (Array Protein System, 
Beckman Diagnostics) with a minimum detectable level of 6mg/L 
3.6 FULL BLOOD COUNT 
These were performed by a H-6000 coulter counter on blood anticoagulated 
with ethylene diamine tetra-acetic acid (EDTA). 
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3.7 CYfOKINES 
The wide range of cytokine levels reported in clinical studies in the 
literature is evidence of the absence of standardisation of both bio- and 
immunoassays. This makes it difficult to compare different studies in 
quantitative terms, with the result that a comparison of kinetics or 
positives and negatives is often all that is possible. With large profits at 
stake there has been, without doubt, an unseemly rush by some 
biotechnology companies to present their commercial immunoassays to 
researchers. The result has been that some of the assays have been 
inadequately tested for specificity, and standardisation has been 
insufficiently rigourous. 
For this reason several weeks were spent at the beginning of this research 
experimenting with the products of several well-known companies. Intra-
and interassay variation was checked using in house plasma samples. 
Because of the potentially large order it was possible to obtain 'pilot' kits 
free of charge or at nominal expense. The assays were only selected after 
this scrutiny and, moreover, it was possible to virtually elimate batch-to-
batch variability by bulk ordering or booking from a particular batch. The 
biotechnology companies all had their headquarters close to Oxford and it 
was not difficult to elicit their cooperation in holding stock from particular 
batches. 
3.7.1 INTERLEUKIN - 6 
Principle of the assay 
This assay employs the quantitative "sandwich" enzyme immunoassay 
technique. Samples are pipetted into the wells of a microtitre plate coated 
with a monoclonal antibody specific for IL-6. Any IL-6 will be bound by the 
immobilised antibody. After washing away any unbound sample proteins, 
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an enzyme-linked polyclonal antibody, specific for IL-6, is added to the 
wells. This, in turn, binds to any IL-6 which was bound during the first 
incubation. Following a wash to remove the excess enzyme-linked 
polyclonal antibody, a substrate solution is added to the wells and colour 
develops in proportion to the amount of IL-6 bound in the initial step. 
Along with the samples to be tested, a series of wells is prepared using 
known concentrations of the IL-6 standard and a standard curve is 
prepared by plotting the optical density (OD) versus the known 
concentration of IL-6 in the standard wells. The concentration of the IL-6 
in the unknown samples is determined from their OD, using this standard 
curve. 
Materials 
Storage: all materials were stored at 2-8°C. 
IL-6 microtitre plate: a 96 well polystyrene microtitre plate coated with a 
mouse anti IL-6 monoclonal antibody. 
IL-6 conjugate: Polyclonal antibody against IL-6, conjugated to horse-radish 
peroxidase, with preservative. 
IL-6 standard: Recombinant human IL-6 (lOng) in a buffered protein base 
with preservative, lyophilised. 
Assay Diluent : 6ml of a buffered protein base with preservative. 
Calibrator Diluent : 21ml of bovine serum with preservative. 
Wash buffer concentrate: 21ml of a 25-fold concentrated solution of 
buffered surfactant with preservative. 
Substrate solution(a): 12.5ml of stabilised hydrogen peroxide. 
Substrate solution (b): 12.5ml of stabilised chromogen. 
( tetrameth y 1 benzydine). 
Stop solution: 6ml of 2N sulphuric acid. 
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Note: This enzyme linked immunosorbance assay (Quantikine™) for IL-6 
was developed by R & D Systems Inc, 614 McKinley Place, Minneapolis, 
MN 55413. The materials listed were supplied by this company. 
Preparation of reagents 
Wash buffer: The concentrate was diluted 25 fold with doubly distilled 
water to prepare 500ml of wash buffer. 
Substrate solution: Solutions (a) and (b) were mixed together in equal 
volumes and used within 15 minutes of preparation. 
Interleukin-6 standard: The lyophilised standard was reconstituted with 5 
ml of calibrator diluent producing a reconstituted stock solution of 
2000pg/ml. 
Preparation of the standard curve 
The stock solution was serially diluted with calibrator diluent in reagent 
tubes. The resulting standards were 2000pg/ml, 1000pg/ml, 500pg/ml, 
250pg/ml, 125pg/ml, 62.Spg/ml, 31.3pg/ml and Opg/ml. The stock solution 
was used for the highest point on the standard curve and calibrator 
diluent for the lowest point. 
A fresh standard curve was made up for each assay. 
Assay procedure 
(1) Assay diluent (50µ1) was added to each well on the plate prior to 
adding the sample or standard. 
(2) The standard or sample (200µ1) was added to each well and the plate 
incubated for 2 hours at room temperature. All samples and standards 
were assayed in duplicate. 
(3) After the incubation, all wells were emptied by inverting the plate. 
Each well was washed with the wash buffer, using a wash bottle. Three 
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washes were performed. At the end of each wash the plate was inverted 
and forcefully blotted against clean tissue paper to ensure removal of all 
liquid. 
(4) After the last wash IL-6 conjugate (200µ1) was added to each well and 
the plate incubated for a further 2 hours at room temperature. 
(5) The washing procedure was repeated as in (3). 
(6) Substrate solution (200µ1) was added to each well and the plate 
incubated for 20 minutes at room temperature. 
(7) Stop solution (50µ1) was added to each well and mixed thoroughly. 
Spectrophotometry 
The OD of each well was determined within 30 minutes of completing the 
assay. The spectrophotometer used was an Anthos Reader 2001. This filter 
photometer combines an optomechanical system with micro-computer 
electronics and is able to read a microtitre plate within 5 seconds. The data 
reduction programme was adjusted for use with this assay. Samples were 
read at a wavelength of 450nm with wavelength correction set to 540nm. 
The data reduction programme calculated the average of the duplicate 
readings and subtracted the zero standard OD from the sample optical 
density. After drawing a linear standard curve using a log/log trans-
formation, the sample values were calculated from the standard curve. 
Assay sensitivity: The minimum sensitivity was determined by adding 2 
standard deviations to the mean OD value of 20 zero-standard replicates 
and calculating the corresponding concentration from the standard curve. 
Using this method, the minimum detectable IL-6 level was 3.Spg/ml. 
Interassay variation (% CV): less than 10%. 
71 
3.7.2 INTERLEUKIN-1 
Principle of the assay 
The plasma cytokine concentration was measured using a modified ELISA 
assay called EASIA (Enzyme Amplified Sensitivity Immuno-Assay). It is 
based on an oligoclonal system in which several monoclonal antibodies, 
directed against different distinct epitopes of IL-1, are used. This avoids 
hyperspecificity and allows high sensitivity of the assay with an extended 
standard range and a short incubation time. 
The assay is performed on a 96 well microtitre plate. Each well is coated 
with "catcher" monoclonal antibodies. The standards or samples 
containing IL-1 react with these antibodies and also with the added 
monoclonal antibodies labelled with horse radish peroxidase. An 
incubation period allows the formation of a "sandwich" of IL-1 on the 
microtitre plate before it is washed to remove unbound enzyme labelled 
antibodies. The substrate solution (tetramethylbenzydine) is added and 
after a short incubation, the reaction stopped with sulphuric acid. 
Materials 
IL-1 Standard: Recombinant human IL-1 in a buffered human serum 
solution; lyophilised. 
Calibrator Diluent: 8ml of human serum and preservative. 
IL-1 conjugate: anti IL-1 monoclonal antibody conjugated to horseradish 
peroxidase. 
Wash buffer: 10ml of 20% Tween. 
Substrate solution: chromogen tetramethylbenzydine. 
Substrate solution buffer: Hydrogen peroxide in acetate/ substrate buffer 
21ml. 
Stop solution: 6 ml of sulphuric acid (1.8 N). 
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Note: This enzyme amplified sensitivity immunoassay (EASIA™) for IL-1 
was developed by Medgenix Diagnostics, PO Box 42, 1160, Brussels. The 
materials listed were supplied by this company. 
Preparation of reagents 
IL-1 Standard: Reconstituted in 2ml of double distilled water. 
Calibrator diluent: Reconstituted with 8ml of double distilled water. 
Wash buffer solution: 2ml of the 20% Tween solution was made up to 
400ml with double distilled water. 
Substrate solution: 0.2ml of the chromogen tetramethylbenzydine was 
pipetted into 21ml of substrate buffer. This was performed within 15 
minutes of use. 
Preparation of the Standard Curve 
A standard curve was created by a serial dilution of the IL-1 standard 
concentrate using the human serum calibrator diluent. The resulting 
standard curve series was 150pg/ml, lOOpg/ml, 75pg/ml, 50pg/ml, 
33pg/ml, 16pg/ml and Opg/ml. 
Assay Procedure: 
(1) Each standard or sample (200µ1) was pipetted into the appropriate 
wells. The assay was performed in duplicate. 
(2) Anti IL-1 horse-radish peroxidase conjugate (50µ1) was pipetted into 
each well and the plate allowed to incubate for 2 hours at room 
temperature on a horizontal shaker set at 400rpm. 
(3) After the incubation, all wells were emptied by inverting the plate. 
Each well was then washed with the wash buffer, using a wash bottle. 
Three washes were performed. At the end of each wash the plate was 
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inverted and forcefully blotted against clean tissue paper to ensure 
removal of all liquid. 
(4) Freshly prepared substrate solution (200µ1) was dispensed into each 
well and the plate incubated for 15 minutes at room temperature on a 
horizontal shaker set at 400 rpm. 
(5) The stop reagent (50µ1) was pipetted into each well and mixed 
thoroughly. 
Spectrophotometry 
This was performed with the same equipment used for the IL-6 samples 
(see section 3.7.1). Samples were read at a wavelength of 450nm with 
wavelength correction set to 630nm and a linear standard curve was 
drawn using a linear /linear transformation. 
Assay sensitivity: The minimum sensitivity was determined by adding 2 
standard deviations to the mean optical density value of 20 zero-standard 
replicates and calculating the corresponding concentration from the 
standard curve. Using this method, the minimum detectable IL-1 level 
was 2pg/ml. 
Interassay variation (% CV): less than 5%. 
3.7.3 TUMOUR NECROSIS FACTOR 
Tumour necrosis factor (TNF) was measured using a sandwich type 
ELISA. Microtitre plates were coated with murine monoclonal antibody to 
human TNF (Rockefeller University: SDW 18.1.1) in carbonate buffer (pH 
9.0). This antibody has been tested against TNF~, IL-la, IL-1~, IL-6 and 
IFNy and shown to be specific for TNFa. of After washing plates with 
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phosphate-buffered saline plus 'Tween 20' (PBS-T), duplicate samples 
(plasma diluent) were incubated in the wells. The following reagents were 
then applied successively, with PBS-T washes before each step: (1) 
ammonium-sulphate-precipitated rabbit anti-serum to recombinant 
human TNF (rhTNF) with 2% normal goat serum in PBS-T, (2) affinity-
purified, alkaline-phosphate-conjugated goat antibodies to rabbit IgG 
(adsorbed to mouse and human immunoglobulin, supplied by American 
Qualex) with 2% human serum in PBS-T, and (3) p-nitrophenylphosphate 
in diethanolamine buffer. 
Optical densities at 405nm were determined by automated dual-beam 
ELISA and TNF concentrations in the samples were determined by 
reference to a serially diluted rhTNF standard (Amersham International, 
UK) included on each plate. Data were analysed with the software package 
SPSS/PC + v3.l. The detection limit of the assay was 10pg/ml. Both 
plasma samples 'spiked' with TNF and clinical samples known to contain 
TNF, have been used to determine intra- and interassay variations (%CV) 
of approximately 8%. 
3.7.4 INTERFERON GAMMA 
Interferon gamma was measured using a modified ELISA (Medgenix 
Diagnostics, High Wycombe, Bucks, England). The principles and 
utilisation of this assay are identical to the description for the IL-1 
immunoassay (section 3.72). Random samples were also independently 
assayed using a different ELISA system at the National Institute for 




Principal of the assay 
Gram-negative bacterial endotoxins catalyse the activation of an enzyme 
system in the circulating amoebocytes of the horseshoe crab, "Limulus 
polyphemus". The terminal enzyme reacts with a clottable protein 
resulting in a gel formation (Figure 3.1). By using the clot forming 
capability of the limulus amoebocyte lysate (LAL) it has been possible to 
obtain a semi-quantitative determination of endotoxin. 
It has been shown that the terminal enzyme also splits certain 
chromogenic substrates, for example peptide-pNA, to form a coloured 
product which can be measured photometrically. The amount of enzyme 
needed to obtain suitable hydrolysis of a chromogenic substrate is less than 
the amount needed to form a clot. In addition, the intensity of the yellow 
colour is linearly proportional to the amount of endotoxin present. For 
these reasons the chromogenic assay has replaced the gel formation assay 
in almost all laboratories where an attempt is being made to quantify 
endotoxin. 
The blood from the horseshoe crab is taken directly from the heart using a 
syringe (the crab is then returned to the water alive). The blood cells are 
centrifuged down and washed. They next undergo ultra-sound lysis, 
followed by chloroform extraction to destroy inhibitory components. All 
factors involved in the chain of reactions except endotoxin (the trigger) 
and the peptide-pNA substrate are present in the LAL reagent. 
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Endotoxin 
Proenzyme clotting enzyme 
[Coagulen - -'- ..,.._ firm gel ] Peptide-pNA 
Figure 3.1 The principal of the LAL test: the chain of enzyme reactions in 
the limulus amoebocyte lysate which is initiated by endotoxin. 
Materials and their preparation 
Endotoxin: Freeze dried in albumen. Reconstituted using endotoxin free 
water (EFW) to a standard concentration of lOOOpg/ml (1 Endotoxin 
Unit=83pg/ml). Stored at 4°C. 
Limulus amoebocyte lysate (LAL): Freeze dried. Reconstituted with 1.4ml 
EFW at room temperature 10-15 minutes prior to use to ensure complete 
dissolution (loss of activity begins after this time). Avoiding vortexing, the 
LAL solution was swirled gently to mix. Stored at -20°C for up to one 
month. 
Chromogenic substrate (Ac-Ile-Glu-Gly-Arg-pNA HCl) (Kabi S-2423): 
Freeze dried (9mg) with mannitol. Reconstituted with 6.6ml of EFW to a 
concentration of 2.0mmol/1. The solution is stable for 1 month at 2-8°C 
provided that no contamination occurs. 
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Substrate-buffer solution: Sterile, endotoxin free Tris buffer (50 mmol/1, 
pH9.0). 
Microtitre plate: 96-well, flat bottomed plate (Sterilin) (catalogue No: 
N29AR). 
Note: All analyses were done with the Coatest Endotoxin kit (Kabi 
Diagnostica, Molndal, Sweden). The materials listed were supplied by this 
company. 
Sample preparation: Blood was aspirated into a pyrogen free syringe and 
immediately transferred to a sterile endotoxin-free heparinised (15 units 
per ml) polypropylene skirted screw top tube (Astra). The heparin (Evans 
Laboratories) used was also endotoxin-free and this was confirmed by 
testing each new batch on the LAL assay. After mixing, the blood was 
immediately centrifuged (in theatre) at 4°C for 10 minutes at 1 500g. The 
plasma was aliquoted into further polypropylene skirted screw top tubes 
and stored at -70°C. 
Preparation of the standard curve 
The endotoxin stock solution was vortexed for 10 minutes, and then 
diluted 1:10 (100µ1 of stock solution + 900µ1 water), before vortexing again 
for 1 minute. Endotoxin standards were made up according to Table 1 and 
vortexed for 1 minute. 
Assay procedure 
All reagents and laboratory utensils were sterile and endotoxin free. All 
analyses were calculated as mean values of either duplicate or triplicate 
samples. Controls were also used in this assay. A high (100 pg/ml) and a 
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low (lOpg/ml) standard were made from donor plasma and EFW. These 
were ready for use after thawing and vortexing for one minute. 
(1) Samples and standards were heated at 75°C for 10-15 minutes and 
left to cool for 15 minutes. This step is required to denature plasma 
inhibitors of endotoxin (Friberger P, 1985)(Cooperstock Met al., 1985). 
(2) After each sample had been vortexed for 1 minute, the microtitre 
plate was loaded with standards and samples (50µ1 per well) and placed on 
a heating block to equilibrate to 37°C for 5 minutes. 
(3) 50µ1 of LAL was added to each well. The timer was started on 
addition of LAL to the first well. The plate was incubated at 37°C for exactly 
30 minutes. 
(4) During the incubation, the chromogenic substrate was reconstituted 
with 6.6ml of EFW and a solution of one part substrate + one part buffer 
(sufficient for 100µ1 per well) was prepared and incubated for 10 minutes at 
37°C. 
(5) At the end of the 30 minute assay incubation, substrate was added to 
each well (100µ1 per well). The timer was restarted on addition of substrate 
to the first well. 
(6) Incubation continued at 37°C for exactly 5 minutes after which the 
reaction was stopped with 20% Acetic acid (100µ1 per well). 
Spectrophotometry 
This was performed using the same equipment as for the cytokine studies 
(section 3.71). Samples were read at a wavelength of 405nm without wave-
length correction and a linear standard curve was drawn using a 
linear /linear transformation. 
Assay sensitivity: the detection limit, defined as the concentration corres-
ponding to the mean OD405 of the blank sample of the standard curve plus 
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three times the standard deviation, was 3.65pg/ml. On the basis of other 
studies of healthy volunteers, the upper limit of the normal range with 
this assay system was considered to be 4.Spg/ml (van Deventer SJH et al., 
1988). 
3.9 GLUTAMINE 
Preparation of plasma samples 
Five ml of venous blood was aspirated directly from a central venous 
catheter into standard disposable pyrogen free sterile syringes and added to 
pyrogen free glass tubes containing EDTA (0.34M). After mixing, the blood 
was transferred to Eppendorf tubes and immediately centrifuged (in 
theatre) for 2 minutes at 1 100g. The plasma was aliquoted into further 
Eppendorf tubes and stored at -70°C. 
Plasma was extracted in ice-cold perchloric acid (5%) and, after 
centrifugation, the supernatant was neutralised with ice-cold potassium 
hydroxide (3.SM, plus 7.7mM triethanolamine). The neutralised samples 
were centrifuged at 9000g for 90 seconds and the supernatant collected and 
stored at -20°C. All procedures were carried out in previously cooled 
Eppendorf tubes on ice and only two samples were extracted and 
neutralised at one time. 
Assay procedure 
Glutamine concentration was measured in plasma extracts using the 
method of Windmueller & Spaeth (Windmueller HG et al., 1974), with 
some minor modifications. Asparaginase was dialysed for 24 hours against 
two changes of potassium dihydrogen phosphate buffer (80mM, pH 6.6) 
prior to use. This is an enzyme-linked spectrophotometric assay based on 
the disappearance of nicotinamide adenine dinucleotide hydride (NADH), 
which is followed at 340nm. Measurements were made using a 
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spectrophotometer (Gilford, Stasar III) or a fluorimeter (Perkin-Elmer). 
Standard solutions of glutamine and a blank (water) were included in each 
assay. The composition of the assay system is outlined below. 
Substance 
















Neutralized perchloric acid extracts of plasma were also analysed using 
enzymatic assays for concentrations of glutamate (Bernt E et al., 1974), 
alanine (Williamson DH, 1974) and branched chain amino acids (Livesey G 
et al., 1980). These three similar methods are also enzyme linked 
spectrophotometric assays. However they are based on the formation of 
NADH, rather than its disappearance, and the reaction is again followed at 
340nm. 
3.10 REVERSE HAEMOLYTIC PLAQUE ASSAY 
The description and methodology of this assay is described in full in 
Chapter 7. 
3.11 STATISTICAL ANALYSIS 
Data was analysed by Mann-Whitney U testing and Spearman correlation. 
Criticism of the use of peaked curves in the analysis of serial biological 
measurements has recently been restated (Matthews JNS et al., 1990). This 
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prompted a comparison of some results (Chapter 4) with the method of 
summary measures which requires the calculation of the area under the 
response curve (Matthews JNS et al., 1990). Statistical methods used in the 
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Surgery and trauma have been shown to induce a generalised state of 
immunodepression (Lennard TWJ et al., 1985), and this state has been 
shown to correlate with sepsis (Baker CC et al., 1980) and late death 
(Christou NV et al., 1986). Cytokines act as mediators of both the immune 
and the acute phase response. Each mediates a variety of often overlapping 
effects and their actions are frequently additive. 
Tumour necrosis factor alpha, IL-1 and IL-6 are regarded as major 
mediators of the acute phase response in humans. While TNF and IL-1 are 
thought to be primarily responsible for the non-hepatic manifestations of 
the response such as fever, prostaglandinaemia, tachycardia and 
catabolism (Dinarello CA, 1989b), IL-6 has been shown in vitro to be 
primarily responsible for the hepatic component of the acute phase 
response, resulting in the synthesis of acute phase proteins (Castell JV et 
al., 1989)(Gauldie J et al., 1987). Nonetheless IL-1 and TNF also induce 
synthesis of acute phase proteins, in particular C-reactive protein (CRP) 
(Hasselgren P et al., 1988)(Perlmutter DH et al., 1986)(Baumann H et al., 
1990). The transcription and production of IL-6 in fibroblasts, endothelial 
cells, keratinocytes and monocytes has been shown to be enhanced in vitro 
by IL-1 and TNF (Bauer AR et al., 1978)(Kohase Met al., 1986)(Tosatu Get 
al., 1990)(Shalaby MR et al., 1989). Therefore there is evidence that IL-1 and 
TNF may be partly responsible for the induction of IL-6, and all three of 
these cytokines then mediate the acute phase response. 
These cytokines also have in common immunostimulatory capabilities. 
Interferon gamma acts primarily on monocytes and macrophages to 
enhance cell mediated cytotoxicity (Trinchieri G et al., 1985). The release of 
these cytokines may therefore represent an attempt by the body to counter 
the observed immunodeficiency of injury or sepsis. Indeed the current 
explosion of interest in immunotherapy, in both oncological and 
inflammatory conditions, centres around the evaluation of the 
administration of both cytokines and their inhibitors in various disease 
states. 
The measurement of cytokines in the peripheral blood has proved 
difficult and most reports of circulating cytokines in humans have been of 
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sporadic detections involving single or daily measurements. There have 
been very few attempts to assay cytokines longitudinally over a 
predetermined series of time points during an acute illness or after a 
severe insult. Tumour necrosis factor has seldom been consistently 
detected except after endotoxin administration, which does not induce a 
detectable IL-1 response in vivo (Michie HR et al., 1988a). Recently 
Shenkin detected a consistent rise in the serum IL-6 of elective surgical 
patients but was unable to detect a consistent rise in IL-1 or TNF (Shenkin 
A et al., 1989). All these patients had an uncomplicated clinical course, and 
the difference, therefore, between a pathological and a physiological IL-6 
response remains far from clear. 
The aim of this study was to sample patients frequently before, during and 
after major surgery, and to explore the association between cytokine levels 
in their plasma and their clinical course and CRP response. The levels of 
IL-1, IL-6, TNF and IFNy have been assessed in patients undergoing 
elective aortic aneurysm surgery. A study of patients undergoing this 
operation has several advantages. Besides being a relatively uniform 
population in terms of age, race and general health, they also undergo a 
reasonably comparable surgical insult. They are tumour free and have a 
relatively low risk of bacterial contamination and sepsis, thus allowing the 
impact of major surgical trauma on cytokine levels to be evaluated 
without the conflicting influence of bacterial contamination or 
malignancy on the immune system. 
A smaller group of inguinal hernia patients were also assessed in order to 
determine whether the cytokine response was related to the magnitude of 
surgical insult. 
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4.2 PATIENTS AND METHODS 
4.2.1 Patients: (Group 1) Twenty patients (17 men and three women), aged 
between 59 and 83 years, were studied. All underwent elective aortic 
aneurysm repair. Operative and post-operative details were recorded, 
including the durations of operation, aortic clamping and ventilation, as 
well as blood transfusion volume, post-operative temperatures, leucocyte 
count, AP ACHE II scores and duration of admission. AP ACHE II scoring 
was performed on the basis of the initial and worst physiological 
parameters during the first 24 hours post-operatively. 
(Group 2) Five patients (four men and one woman), aged between 50 and 
75 years, who all underwent elective inguinal hernia repair, were studied. 
4.2.2 Samples: A detailed description of sample preparation is given in 
section 3.6. In brief, cold spun plasma was prepared from venous blood 
collected in pyrogen free tubes containing EDTA (0.34M) (Becton-
Dickinson) and the proteinase inhibitor aprotinin (20µ1/ml) (Sigma). 
Aliquots of plasma were stored at -70°C. 
4.2.3 Sample times: Samples were taken the day before surgery and a 
preoperative sample was taken after induction of anaesthesia. Thereafter 
patients were sampled after incision at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6, 8, 
12, 24, 48, 72, 96, 120 hours and selected times thereafter. Patients in Group 
2 were sampled until their discharge at 24 hours. 
4.2.4 Cytokine assays: A detailed description of these assays is given in 
section 3.7. Interleukin-6, IL-1 and IFNy were measured using 
commercially available "sandwich" ELISA. Tumour necrosis factor was 
measured by ELISA using a murine monoclonal antibody as previously 
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described (Kwiatkowski D et al., 1990). In each assay a standard curve using 
recombinant cytokine was constructed and each sample was assayed in 
duplicate. The minimum sensitivities of the assays were: IL-1 and IFNy 
3pg/ml; IL-6 4pg/ml; TNF 10pg/ml. In addition, 20 random samples were 
assayed independently for IFNy using a different ELISA at the National 
Institute for Biological Standards and Controls, Hertfordshire, England 
(minimum sensitivity 10pg/ml). 
4.2.5 C reactive protein assay: This was measured using flow 
nephelometry (Array Protein System, Beckman Diagnostics) with a 
minimum detectable level of 6mg/l. 
4.3 RESULTS 
4.3.1 Clinical: Seventeen patients had an uncomplicated post-operative 
course. Three patients suffered profound complications. The first (patient 
1), who had chronic obstructive airways disease, was thought to be 
progressing well after uncomplicated surgery until he developed 
hypotensive shock at 36 hours. In view of associated abdominal distension 
and no evidence of sepsis, a relook laparotomy was performed at 50 hours 
which was normal. Shortly thereafter pus was aspirated from the 
bronchial tree and antibiotic therapy initiated for septicaemia secondary to 
pneumonia. The patient made a slow recovery and was discharged 3 
months after admission. 
The second (patient 2) was thought to have done well after a routine 
operation and was discharged from the Intensive Care Unit after 22 hours. 
At 36 hours her renal function was noted to be grossly abnormal and she 
went on to develop intractable renal failure. One week later she infarcted 
her gallbladder and required an emergency cholecystectorny. Three weeks 
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later she underwent resection of her left colon for ischaemic colitis. She 
was discharged to a high dependency nursing home after 7 months. 
The third patient (patient 3) had a routine operation and was not admitted 
to the Intensive Care Unit. At about 24 hours renal failure was noted and 
he required dialysis. He went on to develop a bleeding peptic ulcer, which 
required oversewing, and bowel infarction for which he underwent a 
sigmoid colectomy. He died on post-operative day 13 after developing 
adult respiratory distress syndrome and respiratory failure. 
All five hernia patients underwent a routine operation and were 
discharged on the first post-operative day. 
4.3.2 Interleukin 6: This cytokine was detectable in 5 patients from both 
groups before surgery. In Group 1 patients this basal level did not increase 
until a continuous rise began at 90-180 minutes after skin incision in all 
patients. Interleukin 6 peaked at four-48 hours (median=eight hours) after 
the commencement of the operation and had fallen rapidly by 48-72 hours 
in all patients who had an uncomplicated post-operative course. The three 
patients who suffered major complications each had a greater and more 
prolonged IL-6 response (Figure 4.1). In each case this difference was 
apparent during surgery or within eight hours of incision, which was well 
in advance of clinical suspicion of complications (Figure 4.2). Figure 4.3 is 
a plot of peak IL-6 levels in the complicated and uncomplicated patients. 
This cytokine was not detectable in stored blood prior to transfusion. 
In Group 2, the IL-6 response showed similar kinetics to Group 1 and 
concentrations peaked at four-12 hours (median 8 hours) after 
commencement of operation. The peak concentrations obtained in the 5 
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patients were very significantly lower than those seen in Group 1 (6, 20, 21, 
51, 37 pg/ml) (p<0.001), with the highest value seen in the only patient 
who underwent bilateral inguinal hernia repair. 
Recent criticism of the use of peaked curves in the analysis of serial 
biological measurements prompted a comparison of these results with the 
method of summary measures which requires the calculation of the area 
under the response curve (Matthews JNS et al., 1990). Peak IL-6 levels were 
found to correlate closely with the IL-6 response as derived from the area 
under the IL-6 curve (r=0.88; p<0.001) (Figure 4.4). 
4.3.3 Interleukin 1 was not detected preoperatively in any patient (Figure 
4.5). However between one and four hours, a short-lived rise in IL-1 was 
detected in 17 patients in Group 1. In each patient it preceded the IL-6 
response by several hours and disappeared rapidly. An example of this 
sequential pattern, from a patient without subsequent complications, is 
given in Figure 4.6. There was no significant difference in the IL-1 
response of complicated and uncomplicated patients. This cytokine was 
not detected in any Group 2 patients. 
4.3.4 Interferon gamma was not detected by either ELISA in any samples 
either before, during or after surgery. 
4.3.5 Tumour necrosis factor was detected in only one sample (42pg/ml) 
which was taken at 12 hours from one of the complicated patients in 
Group 1 (patient 3). 
4.3.6 C reactive protein: In all patients plasma CRP was noted to increase 
between eight and 24 hours, peaking around 48 hours after incision 
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(Figure 4.7). Although the CRP values were slightly higher in the 
complicated patient group, the difference was not statistically significant 
nor was it apparent until 48 hours, by which time the complications were 
clinically evident. 
Correlations were sought between various clinical data and the cytokine 
responses (Table 4.1). There was no correlation between the IL-1 and IL-6 
responses, nor between either of these cytokines and the post-operative 
temperatures, WCC and the durations of operation, aortic clamping and 
ventilation. Weak correlation was seen between the IL-6 response and the 
APACHE scores, between IL-6 and the blood transfusion volume, and 
between the peak CRP and IL-1 responses. 
Table 4.1: Correlation coefficients between peak IL-1 and IL-6 responses 
and various clinical parameters. 
Peak IL-1 response 
Duration of operation 
Aortic clamp time 
Duration assisted ventilation 
Blood transfusion volume 
Total fluid infusion volume 
Postoperative temperature 
Postoperative leucocyte count 
AP ACHE II score 
Peak CRP response 
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Correlation Coefficients (p values) 
IL-1 IL-6 
0.019 (0.94) 
0.01 (0.96) 0.079 (0.74) 
-0.39 (0.10) 0.065 (0.79) 
0.02 (0.47) 0.41 (0.07) 
0.13 (0.58) 0.49 (0.03) 
0.07 (0.08) 0.42 (0.07) 
0.04 (0.89) 0.04 (0.87) 
0.04 (0.67) -0.19 (0.43) 
0.36 (0.12) 0.44 (0.05) 
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Figure 4.1: The different plasma IL-6 response (mean + SEM) in Group 1 
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Figure 4.2: The individual plasma IL-6 response in three patients in 
.Group 1 with major post-operative complications. 
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Figure 4.3: Scatter plot of peak IL-6 level in complicated and 
uncomplicated patients in Group 1. 
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concentration (r=0.88; p<0.001). 
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Figure 4.5: The plasma IL-1 response in Group 1 patients. * = significantly 
different from time 0.5 hrs (p<0.001). 
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Figure 4.6: An example in one patient of the plasma IL-1 response 
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Figure 4.7: The plasma CRP response (mean + SEM) in Group 1 patients 
(n.s.). 
4.4 DISCUSSION 
An early and brief IL-1 response to major surgical injury has been shown. 
This always preceded the IL-6 response in any individual patient. These 
data provide in vivo evidence consistent with the in vitro observation 
that IL-1 induces IL-6 synthesis and release (Bauer AR et al., 1978)(Kohase 
M et al., 1986)(Tosatu G et al., 1990)(Shalaby MR et al., 1989). While the 
absence of any correlation between the IL-1 and IL-6 response in certain 
patients could be viewed as less consistent with this conclusion, it could be 
explained by the action of IL-1 being more local than IL-6, with a less 
consistent overflow into the peripheral circulation. An IL-1 receptor 
antagonist (IL-lra) has recently been described (Hannum CH et al., 1990) 
and the lack of correlation between the IL-1 and IL-6 response could also be 
explained thus: differences in IL-lra concentration cause similar IL-1 
concentrations to induce a different IL-6 response in different patients. In 
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view of the recent development of an IL-lra assay it is hoped to test this 
hypothesis in the near future. 
Interleukin-1 has only occasionally been detected in the peripheral plasma, 
for example in four patients with meningococcal septicaemia (Baumann H 
et al., 1990). In most studies where IL-1 was not detected, the patients were 
only sampled daily and the period when detectable IL-1 was present in 
these patients could easily have been missed. In another study in which 
human volunteers were administered TNF and endotoxin, IL-1 was not 
detected in the circulation (Michie HR et al., 1988a)(Michie HR et al., 
1988b), but no samples were taken between one and three hours, the time 
at which the results reported in this chapter suggest that IL-1 might have 
been present. Alternatively, the radioimmunoassay used in the latter 
study may have been less sensitive than the ELISA used in the present 
work. It is clear from these results that an IL-1 response will be detected 
only by frequent sampling of the intra-operative or equivalent period after 
a major insult, as represented by major aortic surgery. 
The IL-6 response seen in the uncomplicated patients is similar to those 
published in two recent reports (Cruickshank AM et al., 1990)(Pullicino EA 
et al., 1990), but of interest are the patients who had a complicated post-
operative course. Their IL-6 levels rose above the mean within a few 
hours of incision, well in advance of their subsequent complications. In 
each case there was no suspicion of poor progress until 24-48 hours had 
passed. Their IL-6 response not only preceded their clinical signs by 12-36 
hours but was also significantly greater and persisted longer than the 
response seen in the uncomplicated group. 
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An exaggerated IL-6 response after major surgery was associated with the 
development of significant complications in this small series. Interleukin-
6 is released by most tissues in the body and its plasma concentration may 
therefore provide a measure of tissue damage during injury. The smaller 
IL-6 response seen in the Group 2 hernia patients is consistent with this 
hypothesis. The surgeon is unable to assess tissue damage at the cellular 
level resulting from harmful influences such as ischaemia and pH change. 
This tissue damage may induce the observed early rise of IL-6, either 
directly or via IL-1 mediation. Such intra-operative changes may have a 
direct impact on the subsequent development of major complications and 
are reflected in the correlation between IL-6 and AP ACHE II scores. Thus 
the high levels of IL-6 seen may represent a relatively passive accessory 
cell response reflecting the degree of tissue damage or alternatively a more 
active elaboration of the cytokine in an attempt to ameliorate the adverse 
factors giving rise to later complications. 
There have been many attempts to correlate isolated cytokine levels with 
patient prognosis, the most notable of these being the detection of TNF. 
Although the increases have not been consistent, circulating levels of TNF 
have been associated with poor clinical outcome in septic or burnt patients 
(Kwiatkowski D et al., 1990)(Girardin E et al., 1988)(Hack CE et al., 
1989)(Debets JMH et al., 1989). Serum levels of TNF, IL-1 and IFNy were 
shown by Girardin et al to correlate with the severity of 
meningococcaemia and they suggested that the level of TNF may have 
prognostic value in this disease. Debets et al in Holland,reported a study of 
critically ill septic patients which demonstrated that sepsis was 
accompanied by detectable circulating TNF in 25 percent of patients and for 
those patients mortality was twice that of comparable TNF negative 
patients. On the other hand, serum levels of TNF have also been shown to 
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have negligible impact on the prediction of outcome when assessed in 
conjunction with simple clinical and laboratory variables (Calandra T et 
al., 1990). Despite intensive sampling and the use of a sensitive 
immunoassay, TNF was not detected in this study nor in a similar study of 
trauma patients (Pullicino EA et al., 1990). Nonetheless TNF has been 
detected in plasma 90-120 minutes after endotoxin administration (Michie 
HR et al., 1988a) which corresponds to the period of IL-1 appearance in this 
study. It is possible therefore, that a very low concentration of TNF may be 
present which, along with IL-1, may be involved with IL-6 induction at 
this time. Alternatively endotoxin may induce different cytokine 
responses from surgical trauma. 
Plasma IL-6 has been shown by others to correlate well with duration of 
surgery when either cholecystectomies alone or a selection of operations, 
including hip replacement, colorectal, vascular and minor surgery were 
studied (Shenkin A et al., 1989)(Cruickshank AM et al., 1990). However, in 
this study of a single major surgical procedure, namely replacement of an 
abdominal aortic aneurysm, no correlation with length of surgery was 
observed. It seems reasonable to assume that the duration of many 
operations influence the extent of surgical tissue injury and therefore 
perhaps IL-6 release. This assumption may not be as true of aneurysm 
surgery in which ischaemia and marked changes in blood pressure may be 
more important determinants of cell damage than duration of surgery. 
The blood transfusion requirement may also be a better reflection of 
surgical trauma than operative duration and there was a significant 
correlation between IL-6 and blood transfusion requirement in this study. 
The CRP response confirms that described in previous studies (Colley CM 
et al., 1983)(Stahl WM, 1987). Moreover the 20-30 hour delay between the 
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appearance of the cytokines and the CRP response is consistent with the in 
vitro and in vivo evidence that IL-1 and IL-6 are mediators of acute phase 
proteins synthesis (Geiger T et al., 1988)(Gauldie Jet al., 1990). The results 
of this study suggest that CRP is less sensitive than IL-6 as a marker of 
surgical complications. Moreover the comparatively slow CRP response 
times of about 48 hours mean this parameter has little predictive value in 
this setting. These CRP findings are in line with clinical experience, where 
its value in the early post-operative period has proved limited. 
The source of IL-1 and IL-6 released in patients undergoing surgery 
remains to be established, although data presented in Chapter 7 implicates 
the bowel as the major organ producing IL-6. Preliminary studies appear to 
rule out cytokine induction by endotoxaemia in this setting (Chapter 7) 
and peripheral blood mononuclear cells do not increase IL-6 secretion in 
response to surgery (Chapter 8). 
This study demonstrates that the IL-1 and IL-6 response increases with the 
severity of the surgical insult and suggests that IL-6 levels are maximal in 
patients who go on to develop major complications. Routine 
measurement of IL-6 after major surgery may have a valuable role in 
identifying patients in need of careful post-operative monitoring. Further 
studies are needed to determine whether the plasma IL-6 concentration is 
simply reflecting the degree of tissue insult or whether it is playing a more 




The systemic cytokine response to major surgical trauma has been studied 
in 20 patients undergoing elective aortic surgery and five patients after 
inguinal hernia repair. 
Tumour necrosis factor alpha and IFNy were not detected in these 
patients. An early and short-lived IL-1 response to major surgery was 
detected only by intensively sampling the peri-operative period. The IL-1 
peak preceded a more marked IL-6 response which peaked between four 
and 48 hours post-operatively. Interleukin-6 levels had fallen sharply by 
48-72 hours in all patients who had an uneventful post-operative course. 
The IL-6 peaks were significantly lower after minor hernia surgery 
compared to major aortic surgery (p<0.001) and IL-1 was not detected in 
any samples. 
Three aortic aneurysm patients developed major post-operative 
complications not anticipated during surgery. Their IL-6 levels were 
significantly higher than the other aneurysm patients, even within 6-8 
hours of skin incision, and their levels remained elevated longer. These 
rises in plasma IL-6 levels preceded the clinical onset of major 
complications by 12-48 hours. 
The systemic IL-1 and IL-6 response to surgical trauma increased with the 
severity of the surgical insult. An early, exaggerated IL-6 response was 
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5.1 INTRODUCTION 
The work reported in this chapter is the natural sequel to Chapters 4 and 5, 
which studied patients undergoing comparatively uniform surgical 
injury. This study was similar in structure, but the patients studied were 
all victims of road traffic accident trauma. Abdominal aortic aneurysm 
patients have a relatively low risk of bacterial contamination and sepsis 
which allowed assessment of the impact of a major surgical injury on 
cytokine levels, without the conflicting influence of such bacterial 
contamination. Major accidental trauma patients, on the other hand, have 
a higher risk of bacterial contamination and sepsis, although it is 
obviously impossible to obtain baseline cytokine levels on these patients 
prior to their trauma. 
5.2 PATIENTS AND METHODS 
5.2.1 Patients 
The victims of major trauma were all admitted via the Accident and 
Emergency Department of the John Radcliffe Hospital, between January 
1991 and July 1991. It is department policy to transfer to the Regional 
Neurosurgical Unit at the Radcliffe Infirmary, those with major head 
injuries and relatively minor involvement of other systems. These 
patients were therefore excluded. Severely injured patients with minor 
head injuries, or those with both major head injuries and major injuries 
of other systems were included. This last group were managed on the 
intensive care unit of the John Radcliffe Hospital. All major burns 
patients are admitted directly to the Regional Burns Unit in Aylesbury and 
therefore thermally injured patients were not available for inclusion. 
Using these criteria, six patients were studied. At admission, patients were 
assigned an Injury Severity Score (ISS) using the Abbreviated Injury Scale 
(AIS) scoring system (Greenspan Let al., 1985). 
5.2.2 Samples and sampling times 
Patients were sampled as soon as possible after admission, and thereafter 
along a longitudinal time course as before: 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 
hours and selected times thereafter. Samples were taken from a peripheral 
or central vein and prepared for cytokine analysis as described in section 
3.3. 
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5.2.3 Cytokine assays 
Cytokines were assayed using the methods described in section 3.7, using 
commercially available "sandwich" ELISA for IL-1 and IL-6 (IL-6 by R&D 
Systems, from British Biotechnology Ltd, Oxford, England and IL-1 from 
Medgenix Diagnostics, High Wycombe, Bucks, England). Tumour necrosis 
factor was measured by ELISA using a murine monoclonal antibody. In 
each assay a standard curve using recombinant cytokine was constructed 
and each sample was assayed in duplicate. The minimum sensitivity of 
the assays were: IL-1 3pg/ml, IL-6 4pg/ml and TNF 10pg/ml. 
5.3 RESULTS 
5.3.1 Clinical: Six male patients were studied and their injuries are 
summarised in Table 5.1. All were road traffic accident victims. Five 
underwent emergency surgery, of which four were solely for orthopaedic 
indications and one required a thoracotomy to repair an aortic arch tear. 
There was one death, specifically the single patient who did not undergo 
surgery. Under normal circumstances this patient would have undergone 
laparotomy for a major retroperitoneal haemorrhage, but his neurological 
prognosis was assessed as very poor and it was decided to provide only 
supportive management. Although his haemodynamic condition 
stabilised and he stopped bleeding, life-support was withdrawn 24 hours 
after admission when he was confirmed brain dead. 
5.3.2 Interleukin-6: Plasma levels of this cytokine varied greatly, with peak 
levels ranging from 180 to 9 OOOpg/ml (Figure 5.1). 
Patient DS, who had relatively stable injuries requiring minimal initial 
resuscitation, had a small IL-6 response which was declining until he 
underwent major surgery to his thoracic aorta. This was followed by an IL-
6 peak. A subsequent Klebsiella septicaemia was also accompanied by a 
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Table 5.1 Synopsis of patients' injuries, blood transfusion requirements in 
the first 24 hours, injury severity scores and outcome. Abbreviations: 
C=compound; F=fracture; ISS=injury severity score. 
Patient Age Injuries & blood requirements ISS Outcome 
Bilateral C F tibia & fibula; C F 
femur & humerus; avulsion brach-
JG 21 ial plexus; myocardial contusion; 38 alive 
disrupted pelvis; pneumothorax; 
F ribs; head injury; 52 units blood. 
C F tibia; myocardial contusion; 
CB 52 Pneumocephalus; minor injuries; 41 alive 
13 units blood 
F clavicle, humerus & lumbar ver-
PH 40 tabrae; severe head injury; major 38 brain 
retroperitoneal haematoma; dead 
6 units blood. 
F femur; bilateral small pneumo-
DS 24 thoraces; transected aorta; 5 units 38 alive 
blood; Klebsiella septicaemia on 
day four. 
F pelvis and ribs; bilateral femurs 
BM 49 & ankles; CF radius & ulna; head 29 alive 
injury; 10 units blood. 
Flail ribs; haemopneumothorax; 
FH 63 F humerus, ankle & mandible; 4 24 alive 
units blood. 
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major rise in levels of IL-6. Surgery (bilateral femoral nailing) also affected 
the response in patient BM, but had little effect when it was less traumatic, 
as seen in Patient FH who underwent plating of his mandible and patient 
CB who had external fixators applied to his tibia. 
Patient IQ suffered by far the most extensive soft tissue damage. His initial 
level of 2 200pg/ml was prior to significant resuscitation but over the next 
16 hours he received 50 units of blood. Despite this rapid and continuous 
replacement of his blood volume with stored blood (which contains no IL-
6), which continued during prolonged orthopaedic surgery, IL-6 levels 
remained above 500pg/ml for more than 48 hours. 
Patient PH, who died, had by far the greatest IL-6 response (peak 
level=9000pg/ml) despite apparently having less soft-tissue damage than 
patient IQ. However, he did not undergo laparotomy which meant the 
extent of injury to the gut, kidneys and other organs resulting from the 
retroperitoneal haemorrhage could not be assessed. 
5.3.3 lnterleukin-1: While IL-1 again proved detectable with frequent 
sampling, the profile of this cytokine was neither consistent nor similar to 
that seen in Chapter 4 (Figure 5.2). A high IL-1 peak in response to surgery 
was seen in only two patients, DS and CB. An early, brief IL-1 response was 
seen in another two patients, PH and BM, while FH and IQ had detectable 
IL-1 only at 12 hours. Four patients were incompletely sampled within the 
first two hours of injury when a brief IL-1 response may have been 
detectable. 
5.3.4 Tumour necrosis factor: Within four hours of injury TNF was 
detected in all six patients (Figure 5.3). In five patients it was detected in 
the first sample obtained. There appeared to be a pattern of an early TNF 
peak followed by an absence or a decline in plasma levels. Every patient 
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had at least one sample in which the cytokine was not detectable above the 
minimum sensitivity of the assay, indicating that none of these patients 
were intrinsic producers of TNF as discussed in section 2.3.4. The TNF 
concentration rose above lOOpg/ml (highest concentration=263pg/ml at 3 
hours) in only one patient, PH, who was also the only patient to die. This 
patient also had by far the greatest IL-6 response (peak 
concentration=9000pg/ml at 6 hours). Tumour necrosis factor was not 
detected in association with the Klebsiella septicaemia in patient DS, 
although sampling was infrequent at this time and a brief response may 
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Figure 5.1 The plasma IL-6 response of six accidental trauma patients, 
compared with the IL-6 response of the 17 uncomplicated abdominal aortic 
aneurysm (AAA) patients in Chapter 4. Note that the time scale has been 
chosen to accentuate the sample times, and is neither linear nor 
logarithmic. The "y" axis scale extends to 10 OOOpg/ml in patients PH and 
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Figure 5.2 The plasma IL-1 response in six accidental trauma patients. 
Abbreviations: ns=no sample taken at this time point; O=no IL-1 detected 
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Figure 5.3 The plasma TNF response in six accidental trauma patients. 
Abbreviations: ns=no sample taken at this time point; O=no TNF detected 
at this time point. Assay minimum sensitivity=lOpg/ml. 
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5.4 DISCUSSION 
This small pilot study has demonstrated wide variability in cytokine 
responses in major trauma patients, but has provided several useful 
conclusions. 
It has emphasised the value of a comparatively uniform cohort of patients 
(as in Chapter 4) in a study of cytokine elaboration. An initial study of 20 
major accident trauma patients would have been unlikely to yield as 
much useful information as the aneurysm study. To increase the 
likelihood of any patterns of cytokine production emerging in this 
heterogeneous group, it would be necessary to study a very large number 
of patients or, alternatively, focus on particular categories of injury such as 
burns or neurological damage. For this reason the pilot study was 
concluded after only six patients. Only one patient developed major sepsis 
and this was accompanied by a rise in IL-6. Again, more information on 
trauma patients developing sepsis would require large numbers. 
This study has confirmed that tissue injury results in major IL-6 release 
within a few hours of injury. In addition, minor surgery did not to induce 
the significant IL-6 response seen in patients undergoing extensive 
orthopaedic and thoracic surgery. These results suggest that, in a larger 
study, a correlation may be found between IL-6 and severity of tissue 
damage. In contrast, the ISS attempts to score injuries according to 
expected outcome and does not take cognisance of severity of tissue 
damage, for example, one fractured femur is scored identically with 
bilateral compound tibial fractures plus bilateral fractured femurs. 
Therefore, as this small series suggests, plasma IL-6 would be unlikely to 
correlate with the ISS in a large series. 
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Several trauma patients had levels of IL-6 far in excess of the complicated 
patients in Chapter 4 and yet had an uncomplicated clinical course. This 
observation is consistent with the hypothesis that IL-6 levels simply reflect 
tissue damage and this cytokine does not mediate adverse inflammatory 
events. As mentioned in Chapter 2, evidence that IL-6 adversely 
influences cardiovascular stability or cellular integrity has not been found, 
so that the major effects of this protein appear to be beneficial to the host 
by enhancing immune function and acute phase protein synthesis (van 
Snick J, 1990). It may also prove to be clinically useful, serving as a 
circulating measure of cell damage. 
Interleukin-1 again proved to be detectable provided patients were 
sampled regularly. Levels were usually low, probably reflecting "overflow" 
into the plasma from sites of its production. Late peaks (12 hours) were 
seen in two patients. The diverse nature of these injuries compared to 
those in the aneurysm patients, means that ongoing haemorrhage, 
hypotensive episodes and changes in tissue tension could all be 
responsible for these secondary peaks of cytokines. 
The detection of TNF was an important finding, for it proved that this 
cytokine is detectable in the plasma of trauma patients using the ELISA 
described. It suggests that the trauma suffered by the aneurysm patients 
was simply insufficient to generate an overflow of TNF into plasma. 
Moreover, its absence in the plasma of the three complicated aneurysm 
patients argues against it having any predictive association with major 
morbidity, as seen with IL-6. Tumour necrosis factor generally appeared 
early in the clinical course before IL-6. Although this sequential 
appearance is not as consistent as that seen with IL-1 and IL-6 in the 
previous chapter, if one takes into consideration the diversity of the 
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injuries, then this finding could be said to support the in vitro evidence of 
IL-6 induction by TNF. 
Data in Chapter 7 will show that the bowel is the major source of IL-6 in 
patients undergoing abdominal aortic surgery. Five patients in this study 
definitely did not have significant bowel injuries, yet produced very high 
levels of IL-6. This may provide indirect evidence for the elaboration of 
cytokines by a wide variety of tissues besides bowel, and this will be 
discussed further in Chapter 10. Alternatively splanchnic shutdown, in 
response to the injuries, could result in 11-6 production by the gastro-
intestinal tract. However it is interesting to speculate over the source of 
the prodigious IL-6 response in patient PH who had severe head injuries, 
but appeared to have comparatively little soft-tissue damage. The 
possibility of undiagnosed intestinal ischaemia has been mentioned, but 
studies have also shown that brain tissues readily produce IL-6, and 
elevated levels of IL-6 have been noted in the cerebrospinal fluid of 
patients with a wide range of neurological diseases, including bacterial and 
viral meningitis and encephalitis (Frei K et al., 1989)(Helfgott DC et al., 
1989). It could prove clinically useful to explore the possibility of a 
correlation between IL-6 production and the severity of brain damage. On 
the basis of this, a pilot study of plasma IL-6 levels in patients undergoing 
major brain surgery is planned. 
There is only one report in the English language literature about plasma 
cytokines in non-thermal accidental trauma patients. Moore et al studied 
trauma patients requiring laparotomy and measured their portal and 
systemic cytokines (Moore FA et al., 1991). Therefore this paper is 
reviewed at length in Chapter 7. Researchers in this field have tended to 
concentrate on in vitro lymphocyte or macrophage studies (Browder W et 
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al., 1990)(Ertel W et al., 1990)(Faist E et al., 1988)(Rodrick Ml et al., 1986). 
Others have studied specific models of trauma such as elective surgery 
(discussed in Chapter 4) or burns. Nijsten et al followed 13 patients with 30 
percent burns and correlated IL-6 with temperature and acute phase 
proteins. The IL-6 response, measured with a bioassay, was remarkably 
uniform (Nijsten MWN et al., 1991). Others attempted to show that the 
presence of TNF in plasma in critically ill burns patients correlated with 
sepsis and mortality (Marano MA et al., 1990). 
This pilot study has suggested that a great deal of information would 
emanate from a large, well constructed study of cytokine elaboration and 
clinical parameters in trauma victims. In order to recruit sufficient 
numbers, a multicentre trial would almost certainly be required. 
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Major surgical and other trauma induces the release of IL-6 into the 
circulating blood (Chapters 4, 5 and 6) and this cytokine is produced by 
innumerable cell types (Section 2.4.5). However, in the steady state IL-6 is 
not produced constitutively by normal cells which require a stimulus to 
begin production. Cytokine production is part of a cascade of mediator 
responses (Chapter 2) and the main stimuli, earlier in the cascade, for the 
production of IL-6 and other cytokines in the injured patient have not 
been demonstrated in vivo. 
In vitro IL-6 expression has been shown to be induced by a variety of 
factors, including viral infection and endotoxin (Helfgott DC et al., 1987). 
In addition a variety of cytokines including IL-1, TNF, platelet derived 
growth factor, IL-3, GM-CSF and IFNy (van Snick J, 1990) also induce IL-6 
production. However not all cells respond similarly to all these factors: for 
example, IL-1 is probably the most potent inducer of IL-6 in fibroblasts but 
has little effect on bone marrow cells which, in contrast, respond very well 
to IL-3 or GM-CSF. 
6.1.1 The biology of endotoxin 
Lipopolysaccharides (LPS), whose toxic properties account for their other 
name, endotoxins, were first identified and purified in 1943 by Shear 
(Shear Met al., 1943) and are constituents of the outer membrane of Gram-
negative bacteria (Ryan JL, 1985). They are now known to consist of a 
polysaccharide and a covalently bound lipid, designated lipid A, which is 
thought to mediate most of their biological effects. The biochemical 
structure of lipid A from different Enterobacteriaceae and Pseudomon-
aceae are similar. Endotoxins have been implicated as a causal factor in 
complement and coagulation activation, the generation of vasoactive 
kinins and the induction of cytokine mediators (Morrison DC et al., 1987). 
The gut contains large amounts of Gram-negative bacteria, that con-
tinuously shed endotoxins. Under normal circumstances, the intestinal 
mucosa permits only the selective passage of nutrients into the 
circulation, while maintaining a protective barrier against the absorption 
of various intra-luminal particles, including bacteria and their toxins. The 
impermeability of the cellular membranes and the tight junctions between 
the mucosa! cells play an essential role in this function. Low flow states 
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have been shown to cause the disruption of the gut mucosal barrier (Gurd 
FN, 1965). Hypoxia per se has been held to be the key factor causing the 
ischaemic mucosal lesion. However there has been recent evidence to 
suggest that reperfusion after an episode of ischaemia releases oxygen free 
radicals responsible for increasing the severity of the mucosal injury 
(Deitch EA et al., 1988). During abdominal aortic aneurysm surgery the 
aorta is cross-clamped and, even in the presence of a chronically occluded 
inferior mesenteric artery, there is at least 30 to 60 minutes of partial 
intestinal ischaemia. 
The mechanism of endotoxin clearance in man is not well understood, 
but involves binding to high-density lipoproteins and naturally occurring 
anti-endotoxin antibodies as well as detoxification in the Kupffer cells of 
the liver (Saadia R et al., 1990). The portal vein is considered the most 
important absorption route, but lymphatic transport has also been 
identified in dogs and rats (Olofsson Pet al., 1986). 
There have been several studies of endotoxin levels in portal and 
peripheral blood and results have varied widely. Jacobs et al studied 
patients undergoing laparotomy and concluded that endotoxins were a 
normal constituent of portal blood, as 97 per cent of their portal blood 
samples yielded a positive LAL assay (Jacob AI et al., 1977). Prytz et al drew 
a similar conclusion after a study of laparotomy patients (Prytz H et al., 
1978). A Danish group detected high levels in all their patients (up to 
64pg/ml) in both peripheral and portal blood drawn during aortic cross-
clamping (Andersen LW et al., 1988). In patients undergoing surgery for 
Crohns disease (Dr I Halliday, Belfast; personal communication) and in 
post-colonoscopy patients (Kelley CJ et al., 1985), significant endotoxaemia 
was measured. 
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Thus the classical hypothesis has always been that continuous endotoxin 
transmigration through the bowel mucosa, into the portal circulation, is a 
normal physiological event and systemic endotoxaemia is prevented by 
removal of these lipopolysaccharides by the Kupffer cells of the liver 
(Nolan JP, 1981). However some recent research has questioned this 
dogma. Brearley et al detected no endotoxin, or only very low levels (5-
10pg/ ml) in portal blood prior to cholecystectomy (Brearley S et al., 1985). 
van Deventer et al detected no endotoxin in peripheral and portal samples 
from cholecystectomy patients and only low levels (5-7pg/ml) in a small 
minority of peripheral and portal samples taken during aortic cross-
clamping (van Deventer S et al., 1988a). 
The role of endotoxin in liver disease itself remains controversial. 
Although the importance of endotoxin in the experimental animal in 
relation to liver disease is well established (Nolan JP et al., 
1968)(Bhagwandeen et al., 1987), its place in clinical practice remains 
controversial. The development of the chromogenic LAL assay has not 
solved the controversies in liver disease any more than it has in other 
clinical settings. Recent publications have reported no less than a 1000-fold 
difference in endotoxin levels in cirrhotics using this technique (Triger 
DR. 1991). Although plasma endotoxin levels have recently been shown to 
be higher in alcoholic cirrhosis than in non-alcoholic cirrhosis, 
concentrations were significant in the latter (Fukui et al., 1991). In the 
same way, while high levels of circulating endotoxins are undoubtedly 
associated with terminal liver failure (Wilkinson et al., 1974), such an 
association does not necessarily imply causality. The failure of Fukui et al 
to demonstrate any correlation between peripheral endotoxin levels and 
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the clinical complications of cirrhosis adds doubt to the validity of the 
association. 
Infusions of endotoxin in animals simulate the changes of clinical 
infection and injury (Hinshaw LB, 1982). These physiological changes are 
however not simply the direct effect of the endotoxin, but are orchestrated 
by a complex network of endogenous mediators amongst which IL-1, IL-6 
and TNF are dominant. Hesse et al and Michie et al reported a rise in 
circulating TNF in endotoxin-challenged volunteers (Hesse DG et al., 
1987)(Michie HR et al., 1988a), while the former group and others were 
able to produce a monophasic rise in circulating IL-6 in man (Fong Yet al., 
1989b)(van Deventer SJH et al., 1990)(Spinas GA et al., 1991), peaking two 
to four hours after the endotoxin challenge and one to two hours after the 
TNF response. In addition, endotoxin has been shown to enhance IL-6 
mRNA expression and IL-6 activity in human fibroblasts and monocytes 
in culture (Helfgott DC et al., 1987). Thus there is considerable evidence 
supporting endotoxin as a key mediator of IL-6 production in injured 
patients. 
If endotoxin was indeed the prime inducer of the IL-6 response seen in the 
abdominal aortic aneurysm patients (Chapter 4), then it seemed likely that 
its origin would be the colon and its highest concentration would be found 
in the portal blood. The results of the endotoxin administration studies 
mentioned above noted a lag-time of two to four hours between 
endotoxaemia and detectable plasma IL-6. Interleukin-6 levels reported in 
the abdominal aortic aneurysm patients began their rapid rise about four 
to six hours after incision. With these kinetics in mind it seemed likely 
that portal and systemic endotoxin levels would be highest during the first 
two hours after incision. This also coincides with the timing of 
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intraoperative aortic cross-clamping when any hypoxia-induced mucosal 
permeability would logically be initiated. 
The aim of the work reported in this chapter was to test a hypothesis that 
arose out of the findings in Chapter 4: Major injury and colonic ischaemia, 
which occur during abdominal aortic aneurysm surgery, result in early 
endotoxin release into the portal blood and this, in turn, induces the 
cytokine responses seen in these patients. Therefore this chapter reports a 
study of the endotoxin and cytokine levels in blood samples collected 
synchronously in both the systemic and portal circulation, at sequential 
times, in patients undergoing abdominal aortic aneurysm surgery. 
6.1.2 Endotoxin assays 
Twenty seven years ago Drs Frederik Bang and Jack Levin published the 
initial paper describing blood coagulation and the role of endotoxin in 
Limulus blood (Levin J et al., 1964). They also described the first in vitro 
assay for the detection of endotoxins in the blood - the Limulus 
amoebocyte lysate (LAL) gelation assay and used it in the clinical setting 
(Levin J et al., 1970). However acceptance of the test took some time and 
not until the 1980s did its use become widespread. Prior to this a number 
of other assays were used, which have all gradually lost popularity (Table 
6.1). 
Table 6.1: Other assays which correlate with the LAL test for endotoxin. 
Pyrogenicity 
Dermal Schwartzman reaction 
Tissue factor generation 
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Chick embryo lethality 
Mi togenici ty 
Complement activation 
The most widely used of these was the rabbit pyrogen test, indeed 
endotoxin was equated with pyrogenicity. This is probably no longer 
appropriate as pyrogenicity is one of the safer and better tolerated effects of 
endotoxin. 
Limulus polyphemus, the horseshoe crab (Figure 6.1), is the source of the 
LAL reagent used in the assay. It is not really a crab at all, but is in the 
phylum Arthropoda (subphylum Chelicerata) and therefore related more 
to spiders and scorpions than crabs. It can be considered a living fossil and, 
indeed, is very similar to Trilobitis, a common fossil with a worldwide 
distribution. This primitive yet successful creature has evolved very little 
in 300 million years. 
The plasma of the crab is blue due to the presence of the oxygen carrying 
protein haemocyanin, which contains copper (Figure 6.2). Amoebocytes 
are the only type of circulating blood cell in limulus and are packed with 
cytoplasmic granules (Figure 6.3). The presence of the entire coagulation 
mechanism within these granules allows it to be isolated in a convenient 
package, free of plasma proteins. 
The principles and method of the LAL assay are described section 3.8. The 
original LAL assay was based on the formation of a gel clot, but the use of 
chromogenic substrates in conjunction with the lysate has become 
increasingly popular. However, although they increase the sensitivity of 
the assay these substrates create their own difficulties, because different 
endotoxins have different relative activities when measured with a single 
chromogenic substrate and small differences in incubation time (minutes) 
may alter the results significantly (van Noordwijk J, 1985). These problems 
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have resulted in numerous assay modifications in various labs, including 
the development of various kinetic assays. 
Figure 6.1: Dorsal view of Limulus polyphemus, the horseshoe crab. 
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Figure 6.2: The horseshoe crab is bled directly from a heart puncture and 
then returned to the sea alive. The plasma is blue due to the presence of 
haemocyanin. 
Figure 6.3: Limulus amoebocytes. Three complete cells are shown. Normal 
amoebocytes are flat discs like mammalian platelets, but are the size of 
human monocytes. The nucleus occupies the the area devoid of 
cytoplasmic granules (seen in the two cells on the left). 
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6.2 PATIENTS AND METHODS 
6.2.1 Patients 
Eight patients undergoing elective abdominal aortic aneurysm surgery 
were studied. No patient had liver disease, inflammatory or ischaemic 
bowel disease. Preoperative bowel preparation was not performed, but all 
patients received a prophylactic dose of cefuroxime (1.Sgram) at induction. 
6.2.2 Sampling 
Samples were obtained from both a central venous catheter (systemic 
sample) and the inferior mesenteric vein (portal sample) using a pyrogen-
free needle and syringe. Sample collection times are given in Table 6.2. 
Systemic and portal samples were taken simultaneously and prepared for 
both cytokine and endotoxin analysis as described in sections 3.3 and 3.8. 
At least three aliquots of each sample were prepared. 
Table 6.2: Sample times during abdominal aortic aneurysm surgery. 
Sample A was aspirated immediately after induction of anaesthesia, 
Sample B just prior to cross-clamping of the aorta; Sample C at the end of 
the proximal anastomosis; Sample D at the end of the distal anastomosis; 
Sample E just prior to wound closure and Sample F was taken 15 minutes 
after skin closure. 
systemic blood portal blood 
A. Post induction + 0 
B. Pre cross-clamping + + 
C. During cross clamping (1) + + 
D. During cross clamping (2) + + 
E. Post cross-clamping + + 
F. 15 minutes post-operation + 0 
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6.2.3 Endotoxin assay 
All samples were tested with Coatest Endotoxin (Kabi Diagnostica), a 
chromogenic LAL assay. A detailed description of methodology is given in 
section 3.8. All reagents and laboratory utensils were sterile and endotoxin 
free. All analyses were calculated as mean values of duplicate samples. At 
the completion of the assay, samples were read at a wavelength of 405nm 
without wavelength correction and a linear standard curve was drawn 
using a linear /linear transformation. The detection limit was 3.7pg/ml. 
Note: Samples were also assayed in two independent laboratories which 
used the same LAL assay supplied by Kabi Diagnostica. 
6.2.4 Cytokine assays 
Cytokines were assayed using the methods described in section 3.7, using 
commercially available "sandwich" ELISA for IL-1 and IL-6 (IL-6 by R&D 
Systems, from British Biotechnology Ltd, Oxford, England and IL-1 from 
Medgenix Diagnostics, High Wycombe, Bucks, England). Tumour necrosis 
factor was measured by ELISA using a murine monoclonal antibody. In 
each assay a standard curve using recombinant cytokine was constructed 
and each sample was assayed in duplicate. The minimum sensitivities of 
the assays were: IL-1 3pg/ml, IL-6 4pg/ml and TNF lOpg/ml. 
6.3 RESULTS 
6.3.1 Cytokines 
In all patients studied, there was a dramatic difference between systemic 
and portal IL-6 levels (Figure 6.4 and 6.5). The IL-6 concentration in the 
portal circulation was significantly higher and the portal-systemic ratio 
increased with time. The appearance of IL-6 in the portal blood preceded 
the systemic appearance in only one patient. The levels seen in the 
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systemic circulation were similar to those in the other group of abdominal 
aortic aneurysm patients (three patients are shared by both studies) 
reported in Chapter 4. 
Tumour necrosis factor was not detected in any systemic or portal blood 
samples. Interleukin-1 levels in the portal blood did not differ significantly 
from those in the systemic circulation (Table 6.3), while the systemic levels 
were similar to those reported in Chapter 4. 
Table 6.3: Mean interleukin-1 levels (pg/ml) in the portal and systemic 
circulation of eight patients undergoing abdominal aortic aneurysm 
surgery. 
A. Post induction 
B. Pre cross-clamping 
C. During cross clamping (1) 
D. During cross clamping (2) 
E. Post cross-clamping 
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Figure 6.4: Portal and systemic IL-6 levels, in each of the eight patients 
studied, at time points B. Pre cross-clamping; C. During cross-clamping (1); 
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Figure 6.5 Mean portal and systemic IL-6 levels of all patients studied, at 
time points B. Pre cross-damping; C. During cross-damping (1); D. During 
cross clamping (2); E. Post cross-clamping. Error bars represent the standard 
errors of the mean. The significance of the portal-systemic difference at 
each time point is: B p=0.22, C p<0.05, D and E p<0.001. 
6.3.2 Endotoxin 
The results obtained were inconsistent and interassay variation was high. 
In order to investigate these inconsistencies further, coded and unopened 
sample aliquots were sent to two other laboratories (Institute of Clinical 
Science, Queens University, Belfast and Celltech Laboratories, Slough) for 
blind analysis and comparison with the Nuffield Department of Surgery 
findings. Both these laboratories were actively engaged in clinical 
endotoxin studies with recent publications on the subject in the 
international literature. Results from the independent laboratories are 
simply labelled (x) and (y) to preserve a degree of anonymity. 
There had been three aliquots prepared at each time point for each of the 
eight patients. One complete set of sample aliquots was assayed in the 
Nuffield Department of Surgery. However technical difficulties meant 
that several of the second set of aliquots were required to obtain a valid 
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result. In spite of this, no result was obtained for two patients. The 
remaining aliquots from the second set were measured in laboratory (y). 
The third complete set of samples was reserved for testing by laboratory 
(x). 
Thus at each sample point in Figure 6.6, there are eight results from 
laboratory (x), six from the Nuffield Department of Surgery and a variable 
number from laboratory (y). Uniformly high levels were found by lab-
oratory (y). Results from both laboratory (x) and the Nuffield Department 
of Surgery were generally below the limit of detection, but there was a 
wide range observed. 
Laboratory (y) range: 10-lSOpg/ml; median 13pg/ml. 
Laboratory (x) range: 0-125pg/ml; median Opg/ml. 
Nuffield Department of Surgery range: 0-134pg/ml; median Opg/ml. 
Because of the high number of negative results in the two sets of data (o) 
and (x), their overall correlation was high, but this did not apply when 
only positive samples, by either one assay or the other, were scrutinised. 
Even when disregarding their picogram values, there was only a 33 
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Figure 6.6 Endotoxin levels in systemic (sys) and portal (port) blood 
sampled during the operation at four time-points: before cross-clamping 
the aorta (pre-damp), at the end of the proximal anastomosis (clamp 1), at 
the end of the distal anastomosis(es) (clamp 2), and just prior to closure of 
the abdomen (post-clamp). 
Aliquots of samples taken from eight patients were assayed in three 
different laboratories: Nuffield Department of Surgery (o), laboratory (x) 
and laboratory (y). 
Minimum detectable concentration=4pg/ml. 
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6.4 DISCUSSION 
This study is the first to report on portal and systemic cytokine analysis in 
patients undergoing major surgical injury. During the course of the study 
a report of portal and systemic cytokine analysis, in accidental trauma 
patients, was published by Moore et al. Their paper is relevant to this 
discussion and will be reviewed at length in this section. 
While TNF was not detected and IL-1 levels were similar in both 
compartments, the portal IL-6 levels greatly exceeded systemic levels. This 
suggests that the colon is a major source of IL-6. In a comprehensive 
review of IL-6, van Snick suggested that this cytokine is tailored to 
function as an "SOS signal". His rationale for this was the absence of any 
evidence that IL-6 adversely influences cardiovascular stability or cellular 
integrity, so that the major effects of this protein appear to be beneficial to 
the host by enhancing immune function and acute phase protein 
synthesis. In addition, injury or infection are promptly followed by a 
massive induction of IL-6 and almost every cell is capable of making IL-6 
(van Snick J, 1990). The colon is directly affected by aortic cross-clamping, 
as explained below, and therefore vulnerable to hypoxic injury. The 
release of large quantities of IL-6 by the colon, under the circumstances 
reported in this chapter, provides direct and substantial evidence for van 
Snick's suggestion. 
Blood supply to the colon is primarily via the inferior mesenteric artery, 
with contributions from collaterals via the marginal artery and the 
haemorrhoidal arteries arising from the internal iliac arteries and their 
branches. In the majority of abdominal aortic aneurysm patients, the 
inferior mesenteric artery is occluded and collateral supply is dominant. 
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Aortic cross-clamping will affect not only a patent inferior mesenteric 
artery, but also iliac collaterals. 
In vivo, the liver seems to be the major target organ for IL-6. Both the 
biological activity and radioactivity of J125-labelled recombinant human IL-
6, injected intravenously into rats, disappears very rapidly from the 
circulation. The kinetics of clearance are biphasic with a rapid initial 
elimination, corresponding to a half-life of about 3 minutes, and a second 
slower decrease corresponding to a half-life of about 55 minutes (Castell JV 
et al., 1989). This organ has a high first pass effect for protein and the 
efficient clearance of this cytokine from portal blood would account for the 
high portal-systemic ratio seen in the samples taken simultaneously from 
both circulatory compartments. Nonetheless it seems likely that the portal 
system is the major contributor to the systemic levels of IL-6 reported 
during injury. 
On the other hand, IL-1 levels were similar and of low concentration in 
both portal and systemic blood. This cytokine is produced primarily by 
blood monocytes and tissue macrophages, although other cells may 
produce it in smaller quantities under certain circumstances (Dinarello 
CA, 1989b). Our findings are compatible with this knowledge. 
Most of the endotoxin studies quoted in the introduction used exactly the 
same chromogenic endotoxin assay described in section 6.2.3, including 
the same chromogenic substrate, S-2423, from Kabi Diagnostica. This 
allows direct comparison of results (van Deventer SJH et al., 1988a)(van 
Deventer SJH et al., 1990)(Brearley S et al., 1985)(Andersen LW et al., 
1988)(Kelley CJ et al., 1985) (Dr I Halliday, Belfast; personal 
communication). 
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The results obtained in the Nuffield Department of Surgery were 
inconsistent and difficult to interpret. Prior to using this assay, extensive 
enquiries were made within the scientific community in Oxford in search 
of a group with experience of the LAL test. Surprisingly no such expertise 
was found, moreover preliminary work with this assay proved that it was 
more difficult than the methodology suggested. This was confirmed 
during subsequent correspondence and meetings with, as well as demon-
strations from other groups elsewhere in the country who were actively 
involved with the assay. As a result, a fresh series of samples was collected 
using "pyrogen-free" techniques, and the assay was carried out using the 
method of two other groups (Halliday et al, Belfast and McCathy et al, 
Glasgow - personal communications). 
Despite these precautions, interassay variation was high. Nonetheless the 
overall picture was of low level endotoxaemia (less than lOpg/ml) in 
some patients, and an absence of endotoxaemia in others. This finding is 
consistent with the results reported by van Deventer and Brearley, but are 
different to those of Andersen, Kelly and Halliday, although the latter two 
groups were studying a different category of surgical patient (van Deventer 
SJH et al., 1990)(Brearley Set al., 1985)(Andersen LW et al., 1988)(Kelley CJ 
et al., 1985) (Dr I Halliday, Belfast; personal communication). All these 
groups were using the chromogenic LAL test. 
However, attempts to validate these results by sending samples to two 
laboratories which had experience with the identical LAL assay provided 
contradictory data. The results from one group (x) were broadly similar to 
those obtained in the Nuffield Department of Surgery, in that they 
recorded low levels or an absence of endotoxin. However closer scrutiny of 
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the results for each sample revealed very poor correlation between the two 
sets of results. Moreover the results from the other group (y) were 
uniformly high, indeed higher than the levels they usually saw in the 
blood of patients with inflammatory bowel disease. The assay controls and 
blanks had all performed normally and therefore this group concluded 
that the results were accurate. 
Thus, the inconsistency of the results makes it is impossible to draw any 
reliable conclusion from the endotoxin data reported in this study. 
Perhaps the only valid conclusion (and the most important) is that this 
assay remains extremely susceptible to experimental error, and results 
reported in the literature should be interpreted in this light. Nonetheless, 
the (unvalidated) impression obtained, is of, at most, low level endo-
toxaemia in the portal and systemic blood of abdominal aortic aneurysm 
patients. 
The only other report of portal cytokines and endotoxin was published in 
May 1991. This report, by Moore et al in Colorado, of patients with "major 
torso trauma" is comparable in certain respects to the study reported in 
this chapter (Moore FA et al., 1991). 
They inserted portal vein catheters into major injury patients who 
required laparotomy, and sampled portal and systemic blood synchron-
ously at insertion and thereafter at 6, 12, 24 and 48 hours. They found no 
evidence of bacteraemia, endotoxaemia or elevated TNF in either vascular 
compartment. Levels of IL-6 were raised in both compartments but there 
was no difference observed between the two. Close scrutiny of their 
methodology reveals that their IL-6 assay was very similar to that used in 
this chapter and, indeed, the systemic IL-6 levels in both studies are 
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comparable. Curiously, these levels were considerably lower than those 
recorded in the trauma patients in Chapter 6. 
They concluded: "while animal studies (which implicate gut-derived 
bacteria or endotoxin as primary factors in the genesis of post-injury 
multiple organ failure) are consistent and compelling, the clinical 
evidence that bacterial translocation (and endotoxaemia) play a significant 
role in the the genesis of post-injury multiple organ failure is, at best, 
circumstantial." The absence of endotoxaemia was a finding common to 
both their study and the work reported in this chapter. However, when 
this paper was discussed at the Fiftieth Annual Session of the American 
Association for the Surgery of Trauma, several delegates with an interest 
in endotoxin were reluctant to discuss the implications of this report and 
instead returned to the technical details of the chromogenic endotoxin 
assay, with at least one critic suggesting the results were negative because 
samples had been overdiluted and the incubation period was too short. 
Moore et al did not observe a difference in their portal and systemic IL-6 
levels. There are several possible reasons for this. They sampled the portal 
vein as opposed to the inferior mesenteric vein and hence their sample 
may have been diluted by superior mesenteric and splenic vein blood. It 
was for precisely this reason that the inferior mesenteric vein was chosen 
as the sample site in the aneurysm patients. A second reason relates to 
sample times. Although they did not detail the duration of the interval 
between injury and operation, it was apparent from the discussion that 
laparotomy rarely took place earlier than 4-6 hours after injury. Therefore 
their first sample was probably taken a substantial time after the initial rise 
in IL-6. In support of this, their highest IL-6 levels were seen in their first 
intraoperative sample, with a rapid decline thereafter. The porto-systemic 
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IL-6 differences recorded in this chapter were all observed within the first 
few hours of incision and it is possible that the two vascular 
compartments may have equilibrated by the time of their first sample. 
The third consideration centres on the differences in injury. In abdominal 
aortic surgery, the insult of acute distal ischaemia resulting from aortic 
cross-clamping is unique and likely to have a direct and profound effect on 
distal tissues, including the gut. Moore et al do not give details of specific 
organ injuries, but no major bowel resection was performed. Thus the IL-6 
"SOS signal" from the bowel may not be as significant in their patients. 
This point is discussed again in Chapter 10. 
In summary, this paper provides further clinical evidence for an absence 
of detectable portal and systemic endotoxaemia after injury. Although the 
injury scores were high, the delay and infrequency of sampling probably 
prevented early TNF and IL-6 kinetics from being observed. 
In 1985, at "The Fourth International Conference on the Detection of Bact-
erial Endotoxins with the LAL test" held at Woods Hole, Massachusetts, 
Dr Jack Levin, who pioneered the LAL test with Dr Frederik Bang, made 
these remarks in his conclusion: 
"I have alluded to the increasing use of the chromogenic substrates in 
conjunction with the Limulus test, but have not meant to imply 
unqualified approval .... " 
He then spoke at some length of the pitfalls of this assay and finished: 
"My remarks are not meant to disparage this important development, but 
only to caution that much more information is needed before we assume 
the ability to calculate the concentration of an endotoxin based on this 
assay". 
(Levin J, 1985) 
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Our findings support his caution. Certainly, the technical difficulty of the 
assay is probably the single most important reason for the absence of 
widespread clinical studies which test van Deventer's finding of a 
predictive role for endotoxaemia in septic patients (van Deventer SJH et 
al., 1988b). Until an immunoassay for endotoxin is developed, the 
problems with this assay are likely to persist. The development of 
monoclonal "capture" antibodies for immunoassay use is likely to be 
problematical because of the variety of endotoxins that occur. However, 
anti-endotoxin monoclonal antibodies are already in therapeutic use 
(Ziegler EJ et al., 1991), and the small error which is likely to created by 
their use in immunoassays, may well prove to be outweighed by the 
advantages of a reliable and rugged immunoassay over the vagaries of the 
LAL test. 
The absence of endotoxaemia in these patients does not argue against an 
important role for endotoxin in the induction of cytokines, because it is 
probable that the endotoxin concentration required to induce cytokine 
production is very low. In all the studies of endotoxin administration 
discussed in the introduction (Hinshaw LB, 1982)(Hesse DG et al., 
1987)(Michie HR et al., 1988a)(Fong Yet al., 1989b)(van Deventer SJH et al., 
1990)(Spinas GA et al., 1991), only van Deventer measured the level of 
endotoxaemia induced by this administration. This group noted a 
transient endotoxaemia peaking five minutes after administration (7 to 
13pg/ml) and this low level was sufficient to induce TNF and IL-6 release 
approximately 90 and 120 minutes later. 
Alternatively, our findings suggest the induction of IL-6 by endotoxin may 
be a local phenomenon, without the need for systemic or portal 
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endotoxaemia. The high IL-6 levels in the portal blood may reflect a local 
action of endotoxin, within the ischaemic bowel wall, where this bacterial 
product may induce IL-6 production without itself reaching detectable 
levels in the portal circulation. 
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Generalised immunosuppression after major surgical injury is a well 
characterised phenomenon and is thought to contribute to the high 
incidence of associated septic complications. 
In vitro studies have demonstrated a decrease in interferon gamma (IFNy) 
production by peripheral blood mononuclear cells (PBMC) isolated from 
major injury patients (Faist E et al., 1988)(D Livingstone et al., 1988). 
However the bioassays and immunoassays used in these studies measured 
only the bulk release of cytokines by entire populations of cells in culture 
after lengthy mitogen stimulation. Not only are such studies unable to 
address the question of whether the spontaneous release of this cytokine 
may be affected by surgical trauma, but also the use of such 'bulk release' 
methods implies that all cells in a population secrete equal amounts of a 
given cytokine. 
Scientists in the Nuffield Department of Pathology have recently applied a 
technique called the reverse haemolytic plaque assay (RHP A) (Neill JD et 
al., 1983) to detect and measure the secretion of a number of cytokines by 
individual human cells derived from the plasma and dispersed tumour 
biopsies of cancer patients (Lewis CE et al., 1990). In this immunoassay, 
secretory cells in a mixed cell population form plaques (zones of 
haemolysis around secretory cells) when incubated in a monolayer with 
protein A coated ovine erythrocytes in the presence of a specific antibody 
and complement (Figure 7.1). 
Although TNF, IL-1 and IFNy were not detected in the plasma of the 
aneurysm patients, there remained the possibility that these cells were 
secreting cytokines in concentrations that were too low to detect with 
ELISA, but which nevertheless could be important when these cells 
migrated to a site of inflammation. This chapter is a report of the use of 
this technique to study the release of cytokines by PBMC from patients 




Figure 7. la: Photomicrograph of IFNy plaques (areas of erythrocyte lysis) 





Blood samples were taken from three patients undergoing abdominal 
aortic aneurysm repair. No patient developed significant post-operative 
complications. One patient received three units of blood between one and 
three hours after incision, the other two received only colloid and 
crystalloid fluids. All three patients were men aged between 60 and 75 
years. Blood samples were also taken from a healthy male donor over the 
same period which were used to control for interassay variation at the 
four time-points studied for each patient. 
7.2.2 Samples 
Ten ml of venous blood was collected in standard disposable pyrogen-free 
sterile syringes and added to pyrogen free glass tubes containing EDT A 
(0.34M). Samples for the RHPA were taken prior to incision and again at 
nine hours, nine days and three weeks after incision. 
7.2.3 Isolation of human PBMC 
A modification of the technique described by Boyum was used (Boyum A, 
1968). 
(1) Venous blood anticoagulated with EDTA was diluted with an equal 
volume of phosphate buffered saline (PBS) and mixed. 
(2) Aliquots (4ml) of the diluted blood were layered onto 3ml of Ficoll-
Hypaque in 12ml polypropylene centrifuge tubes, and spun at 1700rpm (no 
brake) for 25 minutes. 
(3) Following centrifugation, the upper plasma layer was discarded, 
leaving a PBMC rich layer at the interface which was transferred by pipette 
to a new tube and diluted with fresh calcium-and-magnesium-free-Hanks 
buffered salt solution (HBSS) (Flow Laboratories). 
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(4) Cells were resuspended, washed (1400rpm, 10 minutes) three times 
in fresh HBSS, and diluted to a final concentration of 5 x 106 mononuclear 
cells/ml in assay medium (see below). 
7.2.4 Conjugation of Staphylococcal protein A to sheep red blood cells 
(1) Four ml of sheep erythrocytes (oRBC) in Alsevers solution (Serotec) 
was diluted 1:1 with saline (0.9%) and subjected to a Ficoll-Hypaque 
density gradient treatment (see previous section) to remove the 
leukocytes. 
(2) The erythrocyte pellet was harvested and pooled and washed three 
times by repeated suspension and centrifugation (1200rpm; 5 minutes) in 
saline. 
(3) A 1ml pellet of oRBC was diluted with 5ml of saline to which 1ml 
of protein A (0.Smg/ ml saline)(Sigma) and 5ml of Chromium chloride 
hexahydrate (BDH) (0.2mg/ml saline; stored in the dark at 4°C for at least 1 
week before use) was added. The tube was then incubated at 30°C for 1 
hour 
(4) Protein A-oRBC (1ml) was then harvested by centrifugation at 
1500rpm for 6 minutes and washed three times by repeated suspension 
and centrifugation steps in saline (first wash) and subsequent washes with 
Dulbeccos MEM (Gibco) {containing hepes, sodium pyruvate, 0.1 % bovine 
serum albumin (Miles), penicillin (lOOU / ml) and streptomycin 
(lOOµg/ml)}. NB. if considerable lysis of erythrocytes occurred after the first 
centrifugation, or the pellet did not resuspend readily, the preparation was 
discarded and the procedure restarted using a different batch of oRBC. 
(5) The Protein A-oRBC were resuspended in 50ml of Dulbeccos MEM 
{to create a 2% solution(v/v)} and kept at 4°C. for a maximum of 9 days. 
For best results, cells were left overnight before use. 
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7.2.5 Preparation of poly-I-Lysine coated Cunningham chambers 
Chambers were freshly coated for each assay. 
(1) Glass microscope slides (Denley) were washed in sterile H20, 
immersed for 10 minutes in poly-I-Lysine (Sigma)(5mg/60ml H20), then 
washed in sterile H20 to remove excess poly-I-lysine and allowed to air dry. 
(2) Cunningham chambers were constructed by applying two strips of 
double-sided adhesive tape across the slide, 2cm apart, and placing a 
coverslip on top, thereby creating a small chamber beneath the coverslip. 
7.2.6 Protocol of the reverse haemolytic plaque assay 
The RHPA was performed as previously described for the detection of 
luteinizing hormone secretion by rodent gonadotrophs (Neill JD et al., 
1983). The protocol for the RHPA is shown in Figure 7.2. 
(1) Freshly isolated human PBMC were mixed thoroughly with an 
equal volume of protein A-oRBC. Aliquots (100µ1) of this cell suspension 
was applied to the entrance of each Cunningham chamber and allowed to 
settle for 30-45 minutes in an atmosphere of 5% C02/95% air, at 37°C. 
(2) Excess unattached cells were removed by rinsing each chamber with 
warm assay medium {RPMI 1640 (100ml) containing streptomycin 
(lOOµg/ml), penicillin (lOOU /ml) and Pentex Bovine Albumin (0.1 %) 
(Miles)}.to leave a virtually confluent monolayer of cells attached to the 
floor of the chamber. Chambers were then filled with a test solution of 
antibody at a dilution of 1:50 in assay medium {Anti-TNF, anti IL-6, anti 
IL-1, anti IFNy: All antibodies were rabbit anti human polyclonal 
(Genzyme)}. 
(3) The slides were incubated at 37°C for nine hours, after which the 
contents of the chambers were washed with medium to remove any 
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unbound antibody or stimulants and filled with guinea-pig complement 
at a dilution of 1:50 in assay medium to initiate plaque formation. 
(4) After 25 minutes, cells were exposed to 3% (v /v) glutaraldehyde 
(Sigma) in phosphate buffer and the slides stored at 4°C for later analysis. 
Each antibody test condition was duplicated on 10 separate slides in each 
assay for both the patient and the control. 
7.2.7 Quantitative analysis of plaque size and number and statistics 
Studies involving the use of the RHPA to measure luteinizing hormone 
release from rodent gonadotrophs have coupled the plaque assay with a 
highly specific and sensitive radioimmunoassay for luteinizing hormone 
to demonstrate that the area of haemolysis (plaque) which forms around a 
secretory cell is directly proportional to the amount of product secreted. 
Thus, the size of haemolytic plaques provides a quantitative estimate of 
the amount of product secreted by single cells. 
The area of haemolytic plaques was measured using a Wild M20 
microscope to which a forward-projecting drawing device had been 
attached. This permitted the image of a computer (Apple Macintosh) 
screen to be superimposed on the image of each plaque in the 
Cunningham chamber. Plaque sizes were measured using a computer 
programme written by Dr J Lorenzen in this department which measured 
the area of each plaque image on the screen and stored the data in a file 
which could be accessed by the Statworks™ statistical analysis software 
program. The standard deviation of measurements was calculated to be ± 
l.9µm. The first 10-20 plaques on replicate slides (until 100 plaques in total 
per treatment had been measured) were measured by this computer-
assisted morphometry and the mean value expressed in µm3. 
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Simple image analysis 
for size/number of plaques 
The number of plaques produced in the Cunningham chambers was 
counted with a cell counter in each experiment, by scanning chambers 
with a microscope at a total magnification of 25X. 
Data are presented as means + SEM in Figure 7.3. Statistical analysis of the 
data was performed using the Mann Whitney U test. 
7.3 RESULTS (Figure 7.3) 
There was no significant difference in the amount of IFNy released by 
individual PBMC derived from the healthy male donor over the various 
time points assayed for each patient. This uniformity of average plaque 
size for control patients indicates that inter-assay variation in the use of 
sequential RHPA was successfully controlled. In contrast, individual 
PBMC from all three surgical patients released significantly more IFNy by 
nine hours after incision than that released prior to surgery (p<0.001). This 
change persisted up to nine days after surgery but was not present at 25 
days, by which time IFNy levels had returned to preoperative values. No 
significant difference in the proportion of PBMC secreting IFNy was 
detected at the various time intervals. Plasma IFNy was not detectable 
using either of the two ELISA techniques. 




























9 hrs 9 days 
-----post-op 
* 
D Healthy donor 
• Patient 
25 days 
Figure 7.3: Mean ( + SEM) size of IFNy plaques formed by PBMC isolated 
from sequential blood samples taken either from three patients 
undergoing major surgery or healthy control patients. * p<0.001 compared 
with pre-operative sample. 
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7.4 DISCUSSION 
As a result of its increased sensitivity when compared with ELISA, the 
RHP A allows the measurement of the very low quantities of cytokine 
released by individual, unstimulated PBMC. While previous studies 
suggest that PBMC from patients undergoing major surgery have 
diminished responsiveness to lengthy mitogen stimulation in terms of in 
vitro IFNy release (Faist E et al., 1988)(D Livingstone et al., 1988), use of the 
RHP A in this study has demonstrated the spontaneous release of IFNy 
from PBMC to be augmented in the post-surgical patient. Although the 
number of patients studied was small, these results, involving four assays 
per patient, are remarkably consistent. 
In this study, IFNy release peaked at nine hours and was returning to 
preoperative levels by nine days. Kasahara et al have shown that increased 
transcription for IFNy can be detected within six hours of stimulation with 
microbial antigens or IL-2 (Kasahara T et al., 1983), while release of this 
protein peaks at approximately 48-72 hours (Kelly CD et al., 1987) and may 
continue for seven to eight days (Green JA et al., 1969). In these three 
studies cells were given a single stimulus to produce IFNy, compared to 
our model in which cells were derived from a patient recovering from 
major injury, where the postoperative host response was likely be 
providing an ongoing stimulus for IFNy production. Given these 
differences in experimental model, the kinetics seen in our findings are 
not inconsistent with these in vitro reports. 
This laboratory has recently used the RHPA, coupled to 
immunocytochemistry, to show that the majority of cells which 
spontaneously secrete IFNy in vitro are CD16+NK cells (Lewis C et al., 
1991). This accords well with the recent finding by Young and Ortaldo that 
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NK cells are the predominant source of IFNy in vitro (Young H et al., 
1987). This implies that whilst the cytotoxicity of both NK and T cells in 
the peripheral blood of trauma patients may be suppressed (Faist E et al., 
1988), another important aspect of their cellular activity, namely cytokine 
secretion, is augmented. Alternatively, these results could be due to an in 
vitro 'release phenomenon', in which the removal of these cells from 
their plasma environment results in their no longer being inhibited by 
possible post-surgical, blood-borne factors. Nonetheless, these results do 
demonstrate that PBMC from such patients are capable of enhanced IFNy 
secretion, even in the absence of mitogen stimulation. 
It was suprising that secretion of none of the other three cytokines was 
seen. Using this technique and the same antibodies, the secretion of these 
cytokines from cancer cells has been detected in this laboratory. Therefore 
technical shortcomings would seem an unlikely explanation. Tumour 
necrosis factor and IL-1 were also not detectable in plasma at any of the 
times assayed and it is therefore probable that these cytokines are simply 
not being secreted at these times. However IL-6 has been shown to be 
easily detectable in plasma at 9 hours. Therefore its secretion from PBMC 
might reasonably be expected at this time. It is known that a wide and 
heterogeneous range of cell types secrete IL-6 (Wolvekamp MCJ et al., 
1990), but what is not known is the proportion of plasma IL-6 being 
secreted by any particular cell type at any given time after injury. For 
example, by nine hours IL-6 production by PBMC may have ceased, with 
plasma levels being derived from other cells. This explanation could be 
tested by undertaking more frequent early assays. However the nature of 
the RHP A means that a second worker would be required to perform the 
assay between O and 9 hours. This technical support was not available 
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during the study but it is hoped to extend this area of research in the 
future. 
Studies in which the IFNy has been administered to injured (thermal and 
non-thermal) animals have suggested an improvement in outcome after a 
bacterial challenge (Hershman MJ et al., 1988b)(M Malangoni et al., 1989), 
and preliminary results from a multicentre clinical trial have suggested 
some reduction in septic complications in certain subgroups of major 
trauma patients given IFNy therapy (Polk HC, Proceedings of the 2nd 
International Congress on the Immune consequences of Trauma, Shock 
and Sepsis; Munich, March 1991, in press: Springer Verlag). The increased 
secretion of this cytokine by PBMC following major surgery could 
therefore be interpreted as a beneficial component of the host's immune 
response to injury, and a possible target for immunotherapy to augment 
the patient's own endogenous release of IFNy. 
7.5 SUMMARY 
The release of IFNy by peripheral blood mononuclear cells from patients 
undergoing abdominal aortic aneurysm repair was measured using a 
technique called the reverse haemolytic plaque assay. The plasma of these 
patients was also assayed for IFNy using ELISA. Peripheral blood 
mononuclear cells from the surgical patients released significantly more 
IFNy by nine hours after incision than that released prior to surgery 
(p<0.001). This change persisted up to nine days after surgery. Plasma IFNy 
was not detectable using either of two different ELISA techniques. The 
increased secretion of IFNy by PBMC following major surgery may be a 
beneficial component of the host's immune response to injury. 
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The phenomenon of postoperative ileus has resulted in surgeons 
traditionally assuming that the gastrointestinal tract rests after major 
operations and injuries. In fact, this organ has been shown to play a key 
metabolic role after surgery and after other catabolic stresses. This role is 
largely related to the ability of the intestine to metabolise glutamine. 
Despite the lack of oral intake, the small intestine exhibits accelerated 
metabolic activity and the uptake of glutamine by the gastrointestinal tract 
far exceeds that of any other amino acid (Windmueller HG et al., 1974). 
Glutamine has several unique properties that suggest it plays an 
important role in the acute phase response (reviewed in (Klimberg VS et 
al., 1990a)). It is the most abundant amino acid in blood and tissues (50-80 
per cent of the free amino acid pool), and is avidly consumed by 
replicating cells such as fibroblasts, lymphocytes, tumour cells and 
intestinal epithelial cells. Glutamine uptake by the gastrointestinal tract is 
increased in vivo by 75 per cent after the stress of a standard laparotomy. 
This continues postoperatively despite a reduction in both portal blood 
flow and the arterial concentration gradient, which suggests that this 
change may be regulated by some circulating mediator. This accelerated 
consumption contributes to the low blood glutamine levels associated 
with catabolic states (Klimberg VS et al., 1990a). Skeletal muscle, the 
kidneys (Squires EJ et al., 1976), the lungs and cells of the immune system 
(Newsholme EA et al., 1988) are other tissues that have quantitative 
importance in the exchange of glutamine. Muscle glutamine release is 
accelerated after surgical stress, helping to maintain the circulating 
glutamine pool which fuels the enterocytes and renal ammoniagenesis. 
Until recently, the purpose of these high rates of glutamine utilisation in 
rapidly dividing cells has been considered to be the provision of energy 
and/ or the provision of both nitrogen and carbon for precursors for the 
synthesis of macromolecules, for example purine and pyrimidine 
nucleotides for DNA and RNA. However, these high rates of utilisation 
occur even in resting or quiescent human lymphocytes and mouse 
macrophages (Ardawi MSM, 1988), these rates are greatly in excess of 
requirements for DNA and RNA synthesis, and, furthermore, glutamine 
has been shown to have a relatively minor role in the generation of 
adenosine triphosphate (ATP)(Szondy Z et al., 1989). 
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The only explanation for these observations has come from Newsholme 
et al. They suggest that a high rate of glutamine utilisation has a more 
specific purpose, namely the "precise regulation of the rates of synthesis" 
of nucleotides and other compounds required in cell proliferation, or for 
other functions related to the role of these cells in the immune response 
(Newsholme EA et al., 1988). They point out that the rate of utilisation of 
glutamine by these cells depends on its external concentration, and 
therefore maintenance of physiological glutamine concentrations in blood 
would appear to be important for the normal functioning of these 
immune cells. Indeed, it has been shown that lowering the concentration 
of glutamine in culture medium, below that normally present in human 
plasma, decreases lymphocyte proliferation, antibody synthesis and 
macrophage phagocytosis despite the presence of other amino acids and 
other fuels, such as glucose (Parry-Billings Met al., 1990). 
These considerations also apply to intestinal cells. Studies have shown 
that following irradiation there is a deterioration in intestinal cell 
structure in the rat and an increase in bacterial translocation, associated 
with a decrease in plasma glutamine. Feeding with glutamine leads to an 
increase in plasma glutamine and a restoration of gut structure and 
function (Klimberg VS et al., 1990b). 
It is known that surgery increases the rate of utilisation of glutamine by 
the intestine (Souba WW et al., 1985) and it would be expected to increase 
the rate of utilisation by cells involved in the immune response to 
surgery. However, there have been no studies of the acute and sequential 
change in plasma glutamine levels in response to surgical operations of 
different severity and no studies following major surgery. 
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It has already been pointed out that the accelerated uptake of glutamine, 
despite a reduction in both portal blood flow and the arterial concentration 
gradient, suggests that this uptake may be regulated by some circulating 
mediator. Cytokines act as mediators of both the immune response and 
the response of other tissues in the body to injury. As previously 
discussed, IL-1, IL-6, TNF and IFNy are considered to be important 
mediators of the integrated host response. Interleukin-6 is particularly 
important in amino acid metabolism in that it stimulates the production 
of acute phase proteins by the liver (Castell JV et al., 1989). The plasma 
level of this cytokine rises after surgery and excessively high postoperative 
IL-6 levels are associated with the development of major complications 
(Chapter 4). 
In order to elucidate further the mechanisms of postoperative immuno-
suppression, this study examines the relationship between cytokine 
elaboration and glutamine metabolism. Consequently, the plasma levels 
of glutamine and other amino acids, IL-1, IL-6, TNF and IFNy have been 
measured frequently in patients before, during and after elective 
abdominal aortic aneurysm surgery ("major surgery") or inguinal hernia 
repair ("minor surgery"). The advantages of studying this patient group, in 
terms of their uniformity of injury and relatively low risk of bacterial 
contamination, has already been stressed in Chapters 4, 5 and 6. The 
impact of major surgical trauma can be evaluated without the conflicting 
influence of bacterial contamination or malignancy on the immune and 
metabolic systems. 
8.2 PATIENTS AND METHODS 
8.2.1 Major surgery: Nine patients (7 men and 2 women), aged between 59 
and 83 years, underwent elective aortic aneurysm repair. A preoperative 
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blood sample was taken after induction of anaesthesia. Thereafter patients 
were sampled after incision at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 
120 and 168 hours. 
8.2.2 Minor surgery: Five patients (4 men and 1 woman), aged between 50 
and 75 years, underwent inguinal hernia repair. A preoperative blood 
sample was taken after induction of anaesthesia. Thereafter patients were 
sampled after incision at 0.5, 1, 4, 8 and 24 hours. 
The patients from both these groups were also used as subjects in Chapter 
4 and/ or Chapter 6, and their cytokine results have therefore been 
analysed as part of the studies in those chapters. 
8.2.3 Samples: A detailed description of sample preparation is given in 
section 3.9. 
8.2.4 Amino acid analysis (section 3.9): Neutralized perchloric acid extracts 
of plasma were analysed using enzymatic assays for concentrations of 
glutamine (Windmueller HG et al., 1974), glutamate (Bernt E et al., 1974), 
alanine (Williamson DH, 1974) and branched chain amino acids (Livesey G 
et al., 1980). Glutamine was present at physiological levels in infused 
blood. 
8.2.5 Cytokine assays: IL-1, IL-6, TNF, and IFNy were measured as before 
(section 3. 7) 
8.3 RESULTS 
8.3.1 Amino acids: Following major surgery, the plasma concentration of 
glutamine was rapidly and markedly decreased in all patients: the 
concentration was decreased 2.5 hours after incision and remained so until 
the end of the study (168 hours after incision) (Table 8.1). Although the 
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extent of this decrease varied between subjects, it was by far the most 
significant change in amino acid concentration seen (as reflected in the p 
values in Table 8.1), and in four of the nine subjects the decrease was 
greater than 40 percent. The plasma concentrations of the other amino 
acids also changed after surgery, but in contrast to glutamine they returned 
to pre-surgery values by 168 hours after incision. The plasma 
concentration of alanine increased between 2 and 3.5 hours after incision 
and decreased between 48 and 120 hours after incision. The plasma 
concentration of glutamate decreased between 12-120 hours, and that of 
the branched chain amino acids was decreased between 12-24 hours after 
incision (Table 8.1). In contrast to the marked effect of major surgery on 
plasma glutamine levels, minor surgery was without effect on these levels 
(Table 8.2). 
8.3.2 Cytokines: Following major surgery, the concentration of IL-6 was 
increased at 1.5 - 3 hours after skin incision in all patients. The 
concentration attained a maximum between 4 and 48 hours (median 8 
hours) after the beginning of the operation and fell rapidly by 48-72 hours 
(Figure 8.1). The IL-6 response in patients undergoing hernia repair 
showed similar kinetics to that after major surgery, in that concentrations 
peaked at 4-12 hours (median 8 hours) after commencement of operation. 
However, the peak concentrations obtained were markedly lower than 
those following major surgery (p<0.001) (Figure 8.1) 
Following major surgery, the concentration of IL-1 was increased in seven 
of the nine patients (mean±SEM = 17 +5pg/ ml) between 1 and 4 hours after 
incision (median 2 hours). This cytokine was not detected in any minor 
surgery patients while TNF and IFNy were not detected in any patients. 
155 
8.3.3 The relationship between plasma glutamine and cytokine levels: 
Following major surgery, there was no correlation between plasma levels 
of IL-1 and glutamine (r= 0.01, p=0.97), and since TNF and IFNywere not 
detected, no correlation was observed between these cytokines and the 
plasma glutamine level. In marked contrast, there was a significant 
negative correlation between the plasma concentrations of IL-6 and 
glutamine (0-4 hours r=-0.91, 0-8 hours r=-0.95, 0-48 hours r=-0.89, p<0.0001 
for all times) (Figure 8.1). However, following minor surgery there was no 
correlation (0-24 hours, r= -0.64, p=0.17). 
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Table 8.1. The effect of major surgery on plasma amino acid 
concentrations. Values are mean (SEM) and time is given in hours. BCAA 
denotes branched chain amino acids and nd denotes not determined. The 
significance of the differences from the preoperative values are denoted by 
a (p<0.05), b (p<0.01) and c (p<0.001). 
Time after Number of Plasma amino acid concentration (uM) 
incision patients Glutamine Glutamate Alanine BCAA 
0 9 653(21) 78(14) 308(34) 366(23) 
0.5 9 617(14) 105(21) 316(41) 372(28) 
1 9 599(27) 82(12) 312(34) 356(24) 
1.5 9 609(45) 86(12) 347(48) 372(26) 
2 9 636(41) 82(10) 408(52)a 398(26) 
2.5 9 589(39)a 77(13) 430(53)a 405(38) 
3 9 573(42)a 83(15) 429(61)a 415(37) 
3.5 9 554(46)a 87(12) 440(73)a 429(42) 
4 9 521(4o)a 76(15) 380(65) 391(41) 
6 9 477(35)b 76(12) 365(58) 369(36) 
8 9 478(26)b 59(12) 392(93) 325(16) 
12 8 529(33)b 44(12)a 385(53) 264(13)b 
24 9 542(30)b 46(9) 345(55) 306(32)a 
48 9 455(26)C 43(12)a 204(29)a 368(39) 
72 6 458(32)b 25(6)b 203(33)a nd 
120 8 472(19)C 39(13)a 234(21)a nd 
168 7 504(32)b 54(15) 278(24) 415(38) 
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Table 8.2. The effect of minor surgery on plasma glutamine 
concentrations. Values are mean (SEM) and time is given in hours. n=5 
patients at all time points. The differences between control (0 hours) and 
all other times are not significant (p>0.05) 
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Figure 8.1. The relationship between the plasma concentrations of 
glutamine and interleukin-6 following major surgery in nine patients 
(upper graph) and minor surgery in five patients (lower graph). Values are 
means with standard error bars. 
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8.4 DISCUSSION 
Previous studies have shown that surgery results in either no change 
(Hammarqvist F et al., 1990) or a small decrease (10-22 percent) (Vinnars E 
et al., 1975)(Stjernstrom H et al., 1986) in the plasma glutamine level at 
specific times post-surgery. However, neither a detailed time course of 
changes in concentrations nor the effect of major surgery upon plasma 
glutamine has been reported. Furthermore, in most studies the 
concentration of glutamine has been measured by automated amino acid 
analysis which may be unsatisfactory because glutamine is unstable in the 
acidic conditions used in this technique. The present study demonstrates 
that the plasma concentration of glutamine rapidly decreases after incision 
(2.5 hours) and remains markedly lower (30 percent) than preoperative 
values for at least 7 days following major surgery. Larger decreases (51-58 
percent) in the plasma glutamine concentration have been reported 
following major burns (Parry-Billings M et al., 1990) and in patients 
suffering acute pancreatitis and multiple organ failure (Roth E et al., 1985). 
In contrast, in the present study minor surgery caused no change in the 
plasma glutamine level. The rate of glutamine release by muscle is 
increased following major surgery (Newsholme EA et al., 1988), therefore 
the rapid decline in plasma glutamine levels, reported in this chapter, is 
likely to result from increased rates of glutamine consumption by cells of 
the immune system and intestinal cells. 
Given the proposed regulatory role of glutamine for cells of the immune 
system (Newsholme EA et al., 1988) and the experimental evidence which 
suggests that normal plasma levels of this amino acid are essential for a 
response of these cells to an immune challenge, it is suggested that this 
large and prolonged decrease in the plasma glutamine level may be one 
factor causing immunosuppression following major surgery. The 
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hypothesis that maintenance of an adequate supply of glutamine to the 
small intestine prevents malfunction of this organ and enhances survival 
following injury has recently been successfully tested (Klimberg VS et al., 
1990b). Nutritional or pharmacological regimens that enhance the supply 
of glutamine to cells of the immune system after surgery may improve 
clinical outcome by maintenance or stimulation of the body's defence and 
repair mechanisms and require further evaluation in the clinical setting. 
The correlation found in this work between changes in the plasma 
concentrations of glutamine and IL-6 is intriguing. Moreover the plasma 
levels of other cytokines (IL-1, TNF and INFy) were not correlated to the 
plasma concentration of glutamine. It is possible that changes in the rate of 
glutamine utilisation and IL-6 production are controlled by the same 
factors (hormonal or biochemical), which change in response to the 
surgical insult. This hypothesis would be consistent with the synchronous 
timing of alterations in plasma IL-6 and glutamine concentrations after 
major surgery and the attenuated response of both parameters following 
minor surgery. Alternatively, IL-6 may be involved in the regulation of 
glutamine utilisation by intestinal cells, cells of the immune system and 
those involved in tissue repair. An increased rate of utilisation would 
enable these cells to respond more effectively to the immune challenge 
and the requirement for tissue repair following major surgery. 
Tumour necrosis factor is another possible link between IL-6 and this 
amino acid. As discussed previously, this cytokine affects IL-6 production 
and is also known to induce glutamine release from muscle, independent 
of its effect on protein breakdown. Of itself, protein breakdown releases 
very little glutamine because the glutamine content of muscle protein is 
less than three percent. However there is a large free glutamine pool in 
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muscle, and the release of muscle glutamine by TNF is thought to occur 
via its effect on the transport mechanism of this free pool (Newsholme 
EA; personal communication). 
Finally, the finding in Chapter 7 that the intestine, with its known high 
consumption of glutamine, is a major source of IL-6 but not of the other 
acute phase cytokines, adds substance to the suggestion that the correlation 
observed in this chapter reflects a significant physiological interaction 
between glutamine and IL-6. 
The findings in both this chapter and Chapter 7 suggest that the 
measurement of plasma glutamine in the portal circulation may 
contribute to a better understanding of the utilisation of glutamine by the 
gut. However in addition to sampling the portal venous drainage the 
afferent arterial blood could also be sampled. In most surgical models, the 
relative inaccessibility of the portal vein has made it difficult to measure 
fuel requirements of the gastrointestinal tract. Samples from the arterial 
and hepatic venous blood have provided information about the 
splanchnic bed as a whole (Fong Yet al., 1990b) but are unable to partition 
the individual contributions of intestine and liver. Therefore abdominal 
aortic aneurysm patients provide a unique opportunity to study the 
immune and metabolic behaviour of the gastrointestinal tract. 
8.5 SUMMARY 
The plasma levels of glutamine and cytokines have been measured 
frequently in patients before, during and after elective aortic aneurysm 
surgery ("major surgery") or inguinal hernia repair ("minor surgery"). 
The plasma glutamine level declined rapidly following major surgery and 
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remained markedly below preoperative levels until at least 7 days post-
surgery. This response of plasma glutamine concentration was 
significantly correlated with the elaboration of interleukin-6, but not with 
that of IL-1, TNF or IFNy. In contrast, following minor surgery, the plasma 
glutamine concentration was unchanged and the elaboration of 
interleukin-6 was attenuated. It is concluded that the decrease in plasma 
glutamine following major surgery may contribute to 
immunosuppression following major surgery and the relationship 






"The measurement of any substance in the plasma reflects the net result of 
its synthesis and release into the circulating blood and degradation, 
binding or excretion of the substance with removal from the plasma. Thus 
sequential plasma levels reflect only the state of this dynamic balance." 
Aleksander Koj 1988 
The aim of this thesis was to provide further insight into the sequence of 
events leading to the induction of the integrated host response to injury. 
There are many valid ways of investigating this subject. However, this 
work has concentrated primarily on studies of mediators and components 
in the plasma of injured patients. 
Studies in the first experimental chapter (Chapters 4) examined cytokine 
and other responses in patients undergoing major surgery. The sequel to 
this, in Chapter 5, was a study of the cytokine response to major accidental 
trauma. 
Using a clean, uniform model of major injury, namely abdominal aortic 
surgery patients, IL-1 was shown to be detectable in plasma after injury. 
This preceded a rise in IL-6 (Chapter 4). While no TNF was detected in 
these patients, this cytokine was detected in the accidental trauma group 
within a few hours of injury, usually preceding the peak in IL-6 levels 
(Chapter 5). Together these two findings have provided uniquein vivo 
clinical evidence in keeping with the widely accepted in vitro finding that 
IL-1 and 1NF induces the production of IL-6. 
It is likely that there are other mediators of IL-6 production in this trauma 
model, and the lack of correlation between plasma concentrations of these 
cytokines is not surprising. TNF and IL-1 probably exert their main effect 
locally, at the inflammatory site, where they are primarily produced.by 
monocyte/macrophages. They therefore "overflow" into the systemic 
circulation less freely than IL-6 whose major source is accessory cells. For 
these reasons the amount of 1NF and IL-1 in the plasma is unlikely to 
reflect either their overall production or, therefore, their activity in the 
integrated host response at any particular time. Of more relevance, 
perhaps, is whether or not they are detectable at all in the plasma, 
regardless of concentration, because detection implies that overflow has 
occurred and hence a host response of some substance is in progress. For 
this reason, most studies describing a correlation between TNF and 
mortality have reported 1NF in terms of its being either present or absent, 
and less in terms of the actual amounts detected (Debets JMH et al., 
1989)(Marano MA et al., 1990). Tumour necrosis factor was not detected in 
any of the aneurysm patients who developed complications, but the 
highest levels detected in the trauma group were seen in the only patient 
who died. In contrast to reports linking 1NF and mortality, others have 
shown that serum levels of TNF have a negligible impact on the 
prediction of outcome (Browder Wet al., 1990)(Calandra T et al., 1990), and 
this research has not provided evidence to contradict this. 
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Endotoxin is usually placed at the beginning of the sequence of events 
leading to the host response. Encouraged by the finding of plasma IL-1 and 
TNF prior to IL-6 in the injured patients' time-course, it seemed logical to 
look for endotoxin in plasma samples early in the time course. Most 
research has implicated the gut as the source of endotoxin and bacteraemia 
in injured patients, therefore both the systemic and portal mesenteric 
blood were sampled (Chapter 6). Because of the special preparation 
required for endotoxin samples, sampling was begun afresh on a new 
series of patients and samples were also prepared for cytokine analysis. 
This work produced some interesting findings. The gut appears to be 
capable of massive IL-6 production and is almost certainly the primary 
source of this cytokine in aneurysm patients. The absence of TNF and IL-1 
suggests that the same does not apply for these two cytokines. Endotoxin 
was not detected in either portal or systemic blood. Although the 
methodology of the LAL assay is open to question, this finding is in 
keeping with several recent studies casting doubt on the presence of 
detectable endotoxaemia in injured patients. Endotoxin may well be an 
important "trigger" in this setting, but not in quantities that make it easily 
measurable. 
Interest in IL-6 and its role in the host response to injury is very recent, so 
that not even current text-books make particular mention of it. During the 
course of this research, evidence from other groups has emerged also 
stressing the value of IL-6 as a marker of injury severity. van Snick has 
suggested that it is tailored to function as an "SOS signal" because injury 
or infection are promptly followed by a massive induction of IL-6, and 
essentially every cell is capable of making this cytokine (van Snick J, 1990). 
Moreover its major effects appear to be beneficial to the host by enhancing 
immune function and acute phase protein synthesis. Our results, for both 
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the trauma and aneurysm patients, support van Snick's suggestion. 
However this observation begs another question: why is IL-6 produced in 
this way and which tissues are responsible for its production? 
The work in Chapter 6 addresses this question. The portal blood contained 
very high levels of IL-6, implicating the bowel as the major source of IL-6 
in the aneurysm patients. Aortic cross-clamping ensures that the colon 
undergoes considerable changes in tissue perfusion pressure, pH and 
oxygenation, all of which are likely to adversely alter cell homeostasis. If 
the cellular response to these stresses is to secrete IL-6, then the high portal 
levels would be explained. If this hypothesis is applied to the trauma 
patients in Chapter 5 then it would have to explain the very high levels of 
IL-6 seen in all these patients despite the absence of any obvious injury to 
the gut. However, they all had in common extensive injuries to other 
tissues (usually the soft tissues), no doubt resulting in considerable cell 
damage and alterations in cellular homeostasis within these tissues. The 
hypothesis would suggest that the high levels of IL-6 were released from 
these cells. The absence of high portal IL-6 levels in trauma patients, as 
reported in Moore's paper (discussed at length in Chapter 6), supports this 
hypothesis. It can also be applied to the aneurysm patients in Chapter 4, 
who suffered complications. These complications included acute renal 
failure and respiratory sepsis and were not related to bowel ischaemia. The 
hypothesis would propose that the high IL-6 levels seen in these patients 
reflects production by injured kidney or lung tissue, and it would require 
their portal IL-6 concentrations not to be any greater than those seen in 
uncomplicated patients' portal blood. Thus measurement of the portal IL-
6 levels in these patients could have provided a means of indirectly testing 
the hypothesis. Unfortunately, portal sampling was not part of the 
protocol at that time. 
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Thus the proposed hypothesis states that IL-6 is released in response to 
cellular injury. There is no evidence in this thesis, or the literature, that 
this cytokine mediates any of the deleterious consequences of trauma 
which may result in the development of clinical complications. In fact all 
available evidence suggests that this cytokine attempts to ameliorate the 
consequences of injury through its immune and hepatic effects. 
It seems clear from the literature, that production of cytokines in vivo 
may occur in a variety of tissues, for example gene transcription for TNF is 
increased in numerous sites after injection of endotoxin in rodents, 
including liver, kidney, lung and spleen. However what has not been 
clearly shown, is that the production of cytokines by these various tissues 
may be different, depending on the location of the injurious stimulus. 
Meningitis has provided an excellent model for testing this and, indeed, 
levels of TNF and IL-6 are decidedly higher in the cerebrospinal fluid than 
the systemic circulation. This concept of a discrete production of acute 
phase cytokines by different tissues, is supported by the results in Chapter 6 
demonstrating large scale IL-6 production by "injured" colon, as well as 
the IL-6 and TNF production after soft tissue injury (Chapter 5). This same 
concept fits easily with the hypothesis proposed above. 
Consideration can then be directed more specifically, from the level of 
production by different tissues to that of production by different cell types. 
Many cell types have been shown to be capable of acute phase cytokine 
synthesis. The monocyte is a well documented source of IL-1, TNF, IL-6 
and IFNy (NK cells) in vitro. The work in Chapter 8 set out to examine the 
production of cytokines by monocytes from a different and unique 
perspective, in the hope of learning more about this process. 
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Although TNF, IL-1 and IFNy were not detected in the plasma of the 
aneurysm patients, there remained the possibility that these cells were 
secreting cytokines in concentrations that were too low to detect with 
ELISA, but which nevertheless could be important when these cells 
migrated to a site of inflammation. Results from cell culture studies 
(monocyte/macrophages isolated from trauma patients) showed reduced 
secretion of IL-1 and IFNy (Faist E et al., 1988) and increased IL-6 secretion 
(Ertel W et al., 1990). These studies measure only the 'bulk release' of 
cytokines by entire populations of cells in culture after lengthy mitogen 
stimulation. Not only are such studies unable to address the question of 
whether the spontaneous release of this cytokine may be affected by 
surgical trauma, but also the use of such 'bulk release' methods implies 
that all cells in a population secrete equal amounts of a given cytokine. 
While no in vitro method provides a perfect model of cell behaviour in 
the body, it was hoped to address some of these shortcomings by the use of 
the reverse haemolytic plaque assay (RHPA) to study the release of 
cytokines by individual monocytes, without the influence of mitogens. 
This in vitro technique demonstrated an increase in IFNy production by 
NK cells at 9 hours after injury, which persisted for more than a week. 
Production of IL-6 was not found, suggesting that monocytes are not a 
particularly important source of the high plasma levels of IL-6 seen 9 
hours after incision. The other two cytokines were not detectable by either 
ELISA or RHP A. When interpreting the results of any in vitro study of cell 
function, it has to be remembered that sampling cells after the injury 
means only those cells that have not already left the circulation or 
migrated to the site of inflammation will be studied. 
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As easily measurable products of cytokine mediation, acute phase proteins 
serve as useful indicators of cytokine activity. As in many studies, CRP has 
been measured in this thesis, but there have been no reports of a link 
between the amino acid glutamine and cytokine activity. This is 
surprising, because recent evidence has pointed to glutamine as an 
important component of the host response, making it seem plausible that 
this amino acid might indeed be associated with the activity of cytokine 
mediators of the host response. The observed correlation between plasma 
IL-6 and glutamine is remarkable and adds weight to the argument that 
the importance of this amino acid in immune function has been greatly 
underestimated. 
There is an obvious sequel to this work namely the measurement of 
plasma glutamine in the portal circulation. However in addition to 
sampling the portal venous drainage we hope to sample the afferent 
arterial blood. In most surgical models, the relative inaccessibility of the 
portal vein has made it difficult to measure fuel requirements of the GI 
tract. Samples from the arterial and hepatic venous blood have provided 
information about the splanchnic bed as a whole but are unable to 
partition the individual contributions of intestine and liver. Our 
abdominal aortic aneurysm patients therefore provide us with a unique 
opportunity to study the immune and metabolic behaviour of the 
gastrointestinal tract. 
Thus, the theme running through this thesis begins with injury and 
endotoxin as the initiators of the host response, which is mediated in turn 
by the acute phase cytokines. These are induced in different quantities and 
in different organs, tissues and cells, depending on the initial insult, but a 
sequential pattern of production seems apparent. Consideration has been 
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given to the role these cytokines might play in the pathogenesis of an 
inappropriate host response or their use as markers of this response. 
The present data provide information which may be of value in the 
management of injured patients, namely the quantitation of the 
magnitude of injury and the prediction of its outcome. An important 
limitation in our current management is the lack of a reliable method of 
grading the severity of injured patients, with a view to predicting 
outcome. Various scoring systems have been devised including the ISS 
and AP ACHE methods reported in this thesis, as well as methods of sepsis 
scoring. Although these methods have proved moderately successful 
when used in the clinical evaluation of large series of patients for audit or 
research purposes, they have little predictive value for the individual 
patient. This may be due to their simply utilising numerous clinical and 
biochemical parameters which have only been shown to be of predictive 
value when multivariate analysis has been applied to large numbers of 
patients. 
The present data suggests that the cytokine signal appears to antedate, by 
several hours, the maximum clinical response. Others have studied IL-6 
levels in the urine of renal transplant patients and shown that high IL-6 
levels precede clinical evidence of rejection by several days (van Oers MHJ 
et al., 1988)(Raasveld MHM et al, Proceedings of the 2nd Basic Sciences 
Symposium of the Transplant Society; Oxford, September 1991). 
In principle, the use of cytokine assays, in particular the SOS signal of IL-6, 
would appear to be a potentially useful adjunct to the clinical assessment 
of critically ill patients. There is the added benefit of it being an isolated 
measurement, therefore able to be interpreted on its own without the 
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entry of complex data into a scoring data base. It is planned to test the 
value of this cytokine measurement in a large clinical study, which would 
be designed to include patients undergoing a wide variety of major surgery 
in all specialties. Each patient would be sampled only once, or perhaps 
twice, at five and ten hours after incision, and the results correlated with 
patient outcome. 
THE FUTURE 
Cytokines are integral to normal homeostasis and to the response to 
injury, and their biologic activities and synergistic actions continue to be 
elucidated. In physiological quantities, these polypeptides are beneficial via 
activities such as myeloproliferation, immunostimulation and 
readjustments of metabolic processes to provide substrates important in 
an effective host response to injury. However, an excessive production of 
some cytokines may induce an inappropriate and detrimental host 
response. There is a precedent for this sort of biological behaviour, in the 
ability of a wholesale release of prostaglandins to induce deleterious effects 
on circulatory dynamics (Fink MP et al., 1985) and pulmonary vascular 
resistance and function (Demling RH et al., 1985). Therefore future effort 
will be focused increasingly on the enhancement of beneficial cytokine 
responses and, on the other hand, the development of antagonists to 
endotoxin and cytokines for use during an aberrant cytokine response. 
This will apply not only to the management of trauma and sepsis, but also 
to malignancy and immune disorders. Some success using IL-1 receptor 
antagonists, anti-TNF and anti-endotoxin have already been reported. The 
development of ever improving monoclonal antibodies and molecular 
biological techniques are two of the reasons behind this explosion of 
interest in immunotherapy. However the cost of this research is 
enormous and it must be hoped that constant appraisal and rigorous peer 
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review of this research, by the "critical research mass", will prevent bad 
and inappropriate research from obscuring the potential benefits of this 
exciting new field. 
Thus, immuno-monitoring is in its infancy, while immunotherapy has 
moved on considerably from Coley's toxins. With the increased 
understanding of cytokines and other mediators elicited during the 
integrated host response, it is hoped that new treatments, perhaps 
representing modernised versions of Coley's toxins, will be able to arouse, 
enhance and modify the body's natural forces. These forces exist, the task 
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